Clinical Outcomes in Interstitial Lung Diseases : Measuring and improving quality of life by Van Manen, M.J.G. (Mirjam)
Clinical 
Outcomes 
 in Interstitial 
 Lung Diseases
Measuring 
and improving 
quality of life
C
lin
ical O
u
tco
m
es in
 In
terstitial Lu
n
g
 D
iseases 
M
easuring and im
proving quality of life 
 
 
 
M
irjam
 van
 M
an
en
Mirjam van Manen

Clinical Outcomes in Interstitial Lung Diseases
Measuring and improving quality of life
Mirjam Johanna Gerdina van Manen
The work described in this thesis was conducted at the Department of Respiratory Medicine, Eras-
mus MC, Rotterdam, the Netherlands
Clinical Outcomes in Interstital lung Disease
ISBN: 978-94-92683-87-8
Layout and printing: Optima Grafische Communicatie, Rotterdam, the Netherlands (www.ogc.nl)
Copyright holder pre-adapted cover image: Ralph Hutchings/Visuals Unlimited, Inc. 
All rights reserved. No part of this thesis may be reproduced, stored in a retrieval system of any 
nature, or transmitted in any form or by any means, without permission of the author, or when 
appropriate, of the publishers of the publications.
Copyright © M.J.G. van Manen, Rotterdam, the Netherlands
Clinical Outcomes in Interstitial Lung Diseases
Measuring and improving quality of life
Klinische uitkomsten in interstitiële longziekten
Meten en verbeteren van kwaliteit van leven
Proefschrift 
ter verkrijging van de graad van doctor aan de 
Erasmus Universiteit Rotterdam 
op gezag van de 
rector magnificus
Prof.dr. H.A.P. Pols
en volgens besluit van het College voor Promoties. 
De openbare verdediging zal plaatsvinden op
woensdag 20 september 2017 om 15:30 uur 
door
Mirjam Johanna Gerdina van Manen
geboren te Reeuwijk
ProMotiecoMMissie
Promotor  Prof.dr. H.C. Hoogsteden
Overige leden  Prof.dr. J.G.J.V. Aerts
   Prof.dr. E.F.C. van Rossum
   Prof.dr. C. Vancheri
copromotor  Dr. M.S. Wijsenbeek
TabLe Of COnTenTs
chapter 1 General introduction 9
Part 1 - Outcome measures in interstitial lung diseases
chapter 2 New insights on patient-reported outcome measures in  
idiopathic pulmonary fibrosis: only PROMises? 
Curr Opin Pulm Med. 2016 Sep;22(5):434-441 
29
chapter 3 Validation of the King’s Sarcoidosis Questionnaire (KSQ)  
in a Dutch sarcoidosis population 
Sarcoidosis Vasc Diffuse Lung Dis. 2016 Mar;33(1):75-82
45
chapter 4 Scalp hair cortisol and testosterone as objective biomarkers for 
psychological distress and fatigue in patients with sarcoidosis 
Under review
65
chapter 5 Clubbing in patients with fibrotic interstitial lung diseases 
Under review
81
Part 2 - Improving quality of life in interstitial lung diseases
chapter 6 Optimizing quality of life in patients with idiopathic  
pulmonary fibrosis 
Ther Adv Respir Dis. 2017 Mar;11(3):157-169 
99
chapter 7 Cough in idiopathic pulmonary fibrosis 
Eur Respir Rev. 2016 Sep;25(141):278-286 
119
chapter 8 Effect of pirfenidone on cough in patients with idiopathic 
pulmonary fibrosis
Adapted version in press in Eur Respir J
135
chapter 9 What patients with pulmonary fibrosis and their partners think:  
a live, educative survey in the Netherlands and Germany 
ERJ Open Res. 2017 Feb;3(1)
153
chapter 10 Patient and partner empowerment programme for idiopathic 
pulmonary fibrosis 
Eur Respir J. 2017 Apr;49(4)
173
chapter 11 General discussion 185
summary 207
samenvatting 215
About the author 225
PhD Portfolio 229
List of publications 235
Dankwoord 239


chapter 1
General introduction
“The real purpose of the scientific method is to make 
sure nature hasn’t misled you into thinking you know 
something you actually don’t know”
Robbert M. Pirsig
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GeneraL InTrODuCTIOn
Interstitial lung diseases
Interstitial lung diseases (ILDs) are also known as diffuse parenchymal lung diseases 
(DLPDs), and affect around 50 million people worldwide.1,2 DLPDs are characterized by 
alterations of the interstitium, but can also effect the alveoli, respiratory tract, pleura 
and blood vessels, and contain more than 200 diverse disorders.2 During the past de-
cades the classification of DLPDs has been a dynamic process with new insights driving 
adaptations.1,3-8 In this thesis, the most recent classification of 2013 is used.6 The DLPDs 
can roughly be divided in four groups (figure 1).1 The first group consists of DLPDs with 
a known cause, such as an underlying collagen vascular disease or environmental or 
drug related DLPD. The second group contains disorders of unknown cause, called the 
idiopathic interstitial pneumonia’s (IIPs). IIPs are a group of non-neoplastic disorders 
were the pulmonary parenchyma is affected by inflammation and/or fibrosis.1 The pres-
ence of crackles and/or finger clubbing is suggestive for fibrosis.1 IIPs are diagnosed 
based on clinical, radiological and pathological features, and can be subdivided in 
unclassifiable IIP’s, rare IIP’s and major IIP’s.6 The latter being the largest group, contain-
ing several heterogeneous disorders with the most common one idiopathic pulmonary 
fibrosis (IPF). The third group consist of other forms of DLPD such as lymphangioleio-
myomatosis, pulmonary Langerhans’ cell histiocytosis and eosinophilic pneumonia.1,2 
The fourth group of DPLD consists of granulomatous diseases, which are characterized 
by an accumulation of epithelioid macrophages, called granulomas. The most common 
granulomatous disease is sarcoidosis. This thesis will mainly focus on the most common 
ILDs: IPF and sarcoidosis.
Diffuse Parenchymal Lung Disease
Unclassifiable IIPs Major IIPs Rare IIPs
DPLD of known cause Idiopathic interstitial 
pneumonias
GranulomatousOther forms
IPF
Other
Sarcoidosis
Other
figure 1. Classification of interstitial lung diseases
DLPD, Diffuse parenchymal lung disease; IIPs, idiopathic interstitial pneumonias; IPF, idiopathic pulmonary fibrosis
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Idiopathic pulmonary fibrosis
Epidemiology
IPF is a progressive fibrotic lung disease of unknown cause. Estimated incidence of IPF in 
Europe and North America is about 3-9 cases per 100.000 per year.9 For the Netherlands 
this would mean between 500 and 1500 new cases yearly diagnosed. Patients are typi-
cally aged 60 years or older at diagnosis, and the disease is more common in men and 
in former smokers.5,10 
Pathogenesis
The exact pathogenesis of IPF is unknown. It is hypothesized that various exposures can 
cause repeated epithelial injury, which may lead to the activation of fibrotic cascades 
and abnormal wound healing, resulting in excessive collagen production that leads 
to scarring of the lung.11 Risk factors associated with the development of the disease 
include smoking, occupational exposure, chronic microaspiration, microbiome and 
genetic predisposition.12-14
Diagnosis
In IPF, chest auscultation can reveal fine basal end-inspiratory crackles, and around 25-
50% of patients develop digital clubbing.1,10,12 A restrictive pattern is generally found 
on pulmonary function tests and reduced oxygen transport measured by the transfer 
factor for carbon monoxide (TLCO).10 Though, normal pulmonary function does not 
exclude IPF. 
In the Netherlands, it is agreed that a diagnosis of IPF should be made in an experienced 
multidisciplinary team, with at least a pulmonologist, pathologist and radiologist. IPF is 
characterized by a histological and radiological pattern of usual interstitial pneumonia 
(UIP). A chest X-ray can reveal diffuse bilateral and reticular abnormalities, mainly at the 
periphery and lung bases.5 To diagnose IPF, a high-resolution computed tomography 
(HRCT) is needed. The HRCT scan is consistent with an UIP pattern when there is pre-
dominantly basal and subpleural reticulation, honeycombing with absence or presence 
of traction bronchiectasis, and absence of radiologic clues for other ILDs.5 Other causes 
of the UIP pattern, such as treatment-related lung damage and auto-immune disease, 
should be excluded.5 If the combination of the clinical picture and HRCT is inconclusive, 
a diagnostic biopsy of the lung tissue should be considered. In clinical practise, a biopsy 
is not always possible or desired by patients, and an experienced multidisciplinary team 
may decide on a “working diagnosis” of IPF, based on imaging, clinical characteristics 
and likelihood. 
Clinical course and symptoms
The main symptoms patients experience are progressive breathlessness, cough and fa-
tigue.15 Especially cough and fatigue are often difficult to treat. Eventually, the progres-
sive fibrosis results in hypoxemia and the use of supplemental oxygen in the majority of 
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patients. Though the disease course varies between patients, life expectancy is around 
3-5 years without treatment, which is worse than many forms of cancer.16-18 
Treatment
Currently, the only cure for IPF patients is lung transplantation. Unfortunately, only few 
patients are eligible due to generally older age of IPF patients and associated comor-
bidities. Nowadays, there are two drugs approved for treatment of IPF: pirfenidone and 
nintedanib. They slow down disease progression and prolong survival, but cannot cure 
the disease.19,20 Both drugs show a similar effect on slowing down lung function decline, 
but differ in their side-effect profile.19,20 
Quality of life
The progressive nature of the disease, reduced life expectancy, often high symptom 
burden, and limited treatment options have a major impact on patients with IPF. Sev-
eral studies show that quality of life (QoL) in patients with IPF and their caregivers is 
substantially decreased, and that there is a great need for adequate information, ILD 
specialist nurses, psychological support, access to treatment, and interventions aim-
ing at improving QoL.21-26 In the trials with the two anti-fibrotic drugs that significantly 
slowed down disease decline, no convincing effect on QoL was shown.19,20 This lack of 
effect of treatment may be because we are not able to measure the effect, as there is 
a paucity of well-developed and validated IPF-specific measures to capture symptoms 
and health-related QoL (HRQoL). Another reason might be that disease-specific thera-
pies may address the underlying pathophysiology, but they do not necessarily improve 
patient’s symptoms. Therefore, in addition to the disease-centered care, there is a need 
for a different and complementary approach to manage and measure symptoms.
sarcoidosis
Epidemiology
Sarcoidosis is a multisystem granulomatous disease with unknown etiology. The disease 
can affect various organs, but is most commonly seen in the lung (90%), skin, eyes, 
liver and peripheral lymph nodes.27 Sarcoidosis is usually diagnosed in patients aged 
25-50 years, but can also occur at older age, and is more frequent in women and in 
Afro-Caribbeans and African-Americans than in Caucasians or Asians.4,28-30 Incidence 
and prevalence rates differ between countries and ethnic groups, with worldwide an-
nual incidences ranging from 5-40 per 100.000, and an estimated prevalence in the 
Netherlands of 50 per 100.000.28,31,32 
Pathogenesis
The etiology of sarcoidosis still needs to be unraveled, but it seems that both genetic 
susceptibility and environmental factors play a part.33,34 An immunological response 
to infectious agents, such as mycobacteria and Propionibacterium might play a role, 
which results in an excessive T-cell response, characterized by enhanced Th1/Th17 cells, 
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and impaired functioning of immunosuppressive regulatory T-cells and possibly also of 
checkpoint inhibitors such as CTLA-4.35,36
Diagnosis
A diagnosis of sarcoidosis is established when histological (mostly non-caseating 
epithelioid cell) granulomas are present, clinico-radiological findings are consistent with 
sarcoidosis, and other causes of granulomatous inflammation and local sarcoid reaction 
are excluded.4,27 Physical examination can show skin lesions, ocular abnormalities and 
in some cases abnormalities on chest auscultation. Pulmonary function tests may reveal 
an obstructive or restrictive pattern, with or without a reduced diffusion capacity.4,27 
Hypercalcemia and hypercalciuria are present in 10-40% of sarcoidosis patients.31 
Clinical course and symptoms
Sarcoidosis has multiple manifestations, ranging from asymptomatic to life-threatening 
pulmonary fibrosis or cardiac disease.4,37 The disease can have an acute onset and re-
solve spontaneously or after treatment; or an insidious one with a chronic progressive 
course, and in a minority of patients permanent clinical symptoms.4,37,38 The majority of 
patients with sarcoidosis have a normal life expectancy, it is estimated that around 5% 
of patients will die of sarcoidosis.39-41 Symptoms in sarcoidosis are often non-specific 
and dependent on organ involvement and disease course.4,42 Most common symptoms 
are cough, dyspnoea, pain and fatigue.42-44 
Treatment
A large group of sarcoidosis patients will never require treatment.45,46 Treatment op-
tions for the others differ due to heterogeneity of disease, and are based on expected 
prognosis, organ involvement, impact, activity and severity of disease, and possible 
side-effects of treatments.47,48 No curative treatment is currently available for sarcoid-
osis. Corticosteroids are the mainstay of treatment, but also cytotoxic agents, such as 
methotrexate, and biologicals as infliximab and adalimumab are prescribed as second 
or third line therapy.48-52 
Quality of life
QoL is reduced in many patients with sarcoidosis.53,54 Disease-related symptoms are one 
of the factors contributing to the impaired QoL found in these patients. Depending on 
location and severity of disease, patients can experience a vast range of bothersome 
symptoms including cough, dyspnea, arthralgia, muscle pain, fever, eye problems, skin 
injury, sleep disturbances, headache, anorexia, dizziness, neurological pain, general 
weakness, cognitive failure, small-fiber neurological impairment and fatigue.29,32,53 Of 
these, chronic fatigue seems to have the greatest impact on QoL.55,56 Comorbidities 
and side-effects of treatment might also influence QoL in sarcoidosis patients.53,57,58 All 
the factors may influence mobility, social interaction, working capacity and activities 
of everyday life, which may induce psychological distress, and might be another factor 
contributing to the impaired QoL found in sarcoidosis patients.53 QoL in sarcoidosis is 
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difficult to measure, due to the multisystem and heterogeneous nature of the disease. 
Current sarcoidosis-specific measures for QoL do often not take into account the multi-
ple-organ involvement. QoL interventions in sarcoidosis are scarce and mostly focused 
on pulmonary rehabilitation.59,60 Comprehensive measures of sarcoidosis-specific QoL 
and interventions on improving QoL of patients with sarcoidosis are needed.
The past years, more attention has been paid in ILDs to the needs of patients, patient-
centered care and participation of patients in care. Also, studies have started to engage 
patients in the set-up and design of clinical trials, and patient-reported outcome mea-
sures (PROMs) are increasingly used as outcome measure.19,20,61,62 It is expected that in 
the coming years more emphasis will be placed on PROMs, not only in interventions 
aiming at improving QoL, but also in trials aiming at disease modification.
Outcome measures in interstitial lung diseases
Outcomes can be divided in four groups: 1. physiological outcomes, 2. physiological 
outcomes reported by patients, 3. patient-relevant outcomes, and 4. patient-driven out-
comes (figure 2). These outcomes are all considered patients-centered outcomes (PCOs), 
as they present medical outcomes that are important and specific to patients. The last 
three outcomes are also patient-reported outcomes (PROs), which are described as “Any 
report coming directly from the patient without interpretation by a third party about 
how they feel or function in relation to a health condition and given intervention.”63 
PROs can be measured with PROMs, which are usually questionnaires, mostly focus-
sing on QoL. The use of PROMs both in clinical trials and clinical practice has increased 
over the last years, and several ILD-specific PROMs have been developed. However, 
these PROMs have some limitations. Most ILD PROMs were original developed for other 
lung diseases, such as the St George’s Respiratory Questionnaire (SGRQ), which was 
originally developed for asthma and COPD.64 This can lead to irrelevant questions, and 
relevant topics might be lacking. Additionally, most PROMs are developed in English-
speaking countries, and are sometimes less appropriate for use by patients from other 
backgrounds. For example, an US developed questionnaire asks about dyspnea when 
mowing your lawn or washing your car, which is for a lot of patients around the world 
not a feasible scenario.65 
Physiological outcomes
In ILDs, most used physiological outcomes are pulmonary function parameters as FVC, 
TLCO and the 6-minute walk test. In the two landmark trials with pirfenidone and nint-
edanib for IPF, FVC has been used as primary endpoint, so FVC will likely be used in new 
drug trials.19,20 In sarcoidosis, physiological outcomes are dependent on organs affected. 
For example, distribution of lesions, lesions’ target area and volume are used in cutane-
ous sarcoidosis, while for pulmonary sarcoidosis lung function tests will be used.66-68 
Symptoms, such as fatigue, have shown to decrease QoL in patients with sarcoidosis 
and increase psychological distress.53,57,69 No objective physiological outcome currently 
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exists that can capture subjective outcomes of QoL, such as anxiety, depression and 
psychological distress.
Physiological outcomes reported by patients
Symptoms are physiological outcomes reported by patients, and are often scored with 
a 100-mm visual analogue scale (VAS). Although it is regularly known which symptoms 
are the most troublesome to patients, nowadays, many drug development programs 
do not evaluate these symptoms. Cough, breathlessness and fatigue are the three most 
bothersome symptoms in IPF according to a study by the Food and Drug Administra-
tion on the perspectives of patients with IPF regarding their disease and its impact.70 
Our studies focus on cough as there is currently, little knowledge about mechanisms, 
pathology and assessment of cough in IPF, and studies on effective treatments for cough 
in patients with IPF are scarce. 
Patient-relevant outcomes
Patient-relevant outcomes are measures of QoL, which may be referred to using terms 
as QoL, HRQoL and health status.71 QoL is defined by the World Health Organization 
as “an individual’s perception of their position in life in the context of the culture and 
value systems in which they live and in relation to their goals, expectations, standards 
and concerns. It is a broad ranging concept affected in a complex way by the person’s 
physical health, psychological state, personal beliefs, social relationships and their 
relationship to salient features of their environment.”72 HRQoL is the subset of QoL that 
is affected by health71,73, while health status is defined as: “the impact of disease on 
Physiological outcomes
Physiological outcomes 
reported by patients
Patient-relevant outcomes
Patient-driven outcomes
Patient-centered
Patient-reported
FVC
6MWT
Symptoms
VAS
HRQoL
PCORI
PESaM
figure 2. Study outcomes 
FVC, forced vital capacity; 6MWT, 6-minute walk test; VAS, visual analogue scale; HRQoL, health-related quality of life; PCORI, 
patient-centered outcome research institute, PESaM, patient experiences and satisfaction with medication questionnaire.
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patients’ physical, psychological and social functioning.”74 Although these terms repre-
sent different concepts, in daily care and research, they are often used synonymously.73 
QoL can be measured with questionnaires. There are different types of questionnaires; 
generic, disease-specific and symptom-specific questionnaires.75 Generic question-
naires are used to measure QoL independent of disease status and can be used in the 
general population, while disease-specific questionnaires are developed explicit for 
a certain disease or patient group.75 Symptom-specific questionnaires assess how a 
specific complaint, such as cough or dyspnoea, affects a patient’s wellbeing.65,76 (HR)
QoL measures often show poor correlation with physiological outcomes as pulmonary 
function testing.77,78 As previously described, QoL is impaired in both patients with IPF 
and sarcoidosis. In sarcoidosis, QoL has been a focus of research and an outcome of 
clinical trials for a long time.60,67,79,80 In IPF, research into QoL has gained more attention 
the past years.
Patient-driven outcomes
Patient-driven outcomes are outcomes that were developed and chosen together with 
patients. New initiatives also strive to engage patients not only in outcome develop-
ment, but also as a meaningful contribution throughout the whole research process. 
Patients are involved in topic selection for design and conduct of research, and engaged 
in dissemination of results. An example of such an initiative is the patient-centered 
outcomes research institute (PCORI), an American independent non-profit organization 
which focusses on improving clarity of data to enhance health decision making.81 By 
supporting studies on PCOs and involving patients, caregivers, clinicians, healthcare 
stakeholders and researchers in the process, they try to define what the best health-
care options are for individual patients.81 In the Netherlands, the patient experiences 
and satisfaction with medication (PESaM) questionnaire for patients with IPF is being 
developed together with patients, physicians, patient associations, and researchers.82
Improving quality of life in interstitial lung diseases
QoL has shown to be decreased in patients with ILDs, due to burdensome symptoms, 
the chronic and/or progressive nature of disease, and, for some ILDs, the poor life-
expectancy. However, little research has been done on how to optimize QoL of these 
patients. 
One of the symptoms with the most impact on QoL in patients with IPF is cough.15 
Patients often have a persistent and refractory chronic cough (≥8 weeks), which has 
major physical and psychological impact (figure 3). The cough is generally difficult to 
treat, and often not responsive to conventional anti-tussive therapies. Until now, there 
is no drug with a convincing effect on chronic cough in IPF. Since recent years, cough is 
increasingly used as endpoint in clinical pulmonary fibrosis trials, and IPF-related cough 
is regularly included as subgroup in chronic cough trials. In sarcoidosis, fatigue is one 
of the symptoms with the most impact on QoL and reported by 50-70% of patients.55,56 
The exact cause of fatigue is unknown, but different factors might play a role, such 
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as the underlying inflammatory disease process, comorbidities, sleeping problems, 
psychological distress and side-effects of treatments.57
Optimizing QoL requires information on patients’ needs and preferences in care. The 
past years, many initiatives have gained information on the needs of IPF patients. In 
a recent study of Bonella et al., 12 patient advocacy group representatives from nine 
European countries developed a European IPF patient charter on the care needs of IPF 
patients.25 Besides early and accurate diagnosis, equal access to care, a holistic approach 
to standardise IPF management, better access to palliative care and end-of-life care, this 
charter revealed a need for “comprehensive and high-quality information about IPF”.25 
Though other studies confirmed this information need, little is known about the best 
way to educate IPF patients on their disease. In sarcoidosis, well-established studies on 
needs and preferences in care are currently lacking. 
QoL interventions in ILDs are still scarce and mainly focused on pulmonary rehabilita-
tion.59,83-86 Recently, a study in 142 ILD patients (61 IPF, 22 asbestosis, 8 sarcoidosis, 
and 51 other ILDs) showed that an 8-week exercise training clinically improved 6MWT, 
Cough 
Vomiting
Urine 
incontinenceChest pain
Relationship Socialembarrassment
Depression/
Anxiety
Work Disruption dailyactivities
Sleep 
disturbance
Sore throat
Physical 
Psychological 
figure 3. Impact of chronic cough
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symptoms and HRQoL scores.87 Although patients with asbestosis and IPF benefited 
most of the training, short-term improvements were seen in all types of ILDs. Pulmonary 
rehabilitation improves muscle strength, exercise endurance and symptoms, and often 
contains additional disease education and support that can improve QoL.84,88 The effect 
of education and psychological support alone on patients’ QoL has rarely been studied 
in ILDs. Two initiatives in IPF were started directly aiming at patient education and sup-
port.86,89 A 6-weeks management-program for IPF patients and their partners resulted in 
significant deterioration of anxiety and HRQoL scores, even though all participants were 
positive about the program.86 The other program focussed on disease education, man-
agement of treatment and possible side-effects, and providing psychological support on 
how to cope with the disease, for patient starting on pirfenidone.89 Patients were really 
satisfied with the program, however, no control group was present and data on the 
effect of the program measured with QoL PROMs are not present.89 More research on 
interventions that improve QoL for patients with different ILDs is desperately needed.
Chapter 1
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Aims and outline of the thesis
Interstitial lung diseases have a major impact on QoL. Though awareness is rising on 
the importance of improving QoL in these patients, few trials incorporate QoL and good 
measures for QoL are scarce. The aim of this thesis was to measure and improve QoL 
in ILDs by generating better clinical outcome measures for QoL (part 1) and developing 
interventions focussed on improving QoL (part 2).
Part 1: Outcome measures in interstitial lung diseases
chapter 2 outlines the current knowledge and future prospects on PROMs in IPF.
chapter 3 describes the translation and validation of the Dutch King’s Sarcoidosis Ques-
tionnaire, a sarcoidosis-specific PROM. 
chapter 4 reports on a study analyzing the feasibility of scalp hair cortisol and testos-
terone as biomarker for psychological distress and fatigue in patients with sarcoidosis.
chapter 5 describes a study in patients with fibrotic ILDs, evaluating the agreement 
between different clubbing measuring methods, the prevalence of clubbing, and the 
relationship between clubbing, disease severity and QoL.
Part 2: Improving quality of life in interstitial lung diseases
chapter 6 reviews the recent insights on improving QoL for patients with IPF, and dis-
cusses challenges in the management of this devastating disease. Moreover, it proposes 
a new model for holistic care in IPF: the ABCDE of IPF care.
chapter 7 provides an overview of the latest insights into the pathophysiology of cough, 
methods to assess cough and developments in treatment of cough in IPF.
chapter 8 describes the results of an international multicenter study on the effect of 
pirfenidone on cough in patients with IPF.
chapter 9 reports on the needs of patients with pulmonary fibrosis and their partners, 
and the value of interactive interviewing as educational method. 
chapter 10 describes the effect of a newly developed multidisciplinary empowerment 
program on QoL in patients with IPF and their partners.
chapter 11 discusses the findings presented in this thesis.
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AbstrAct
Purpose of review 
In a chronic, progressive and ultimately fatal disease like idiopathic pulmonary fibrosis 
(IPF), the maintenance of patients´ quality of life should be regarded as a major aim of 
treatment. Although better knowledge and two antifibrotic drugs are now available in 
IPF, the individual response to treatment and its acceptance remain poorly explored. 
This review summarizes recent advances in research on patient-reported outcomes and 
their measures, indispensable instruments to investigate how patients feel and func-
tion, and how the disease impacts their lives. 
recent findings 
In IPF, there is a paucity of specific well-validated patient-reported outcome measures 
(PROMs). The use of generic PROMs in past IPF trials revealed a poor correlation of such 
questionnaires with established endpoints of treatment response. Several attempts 
are currently ongoing to develop specific IPF PROMs. The King’s Brief Interstitial Lung 
Disease health status questionnaire and the Tool to Assess Quality of Life in IPF are 
promising questionnaires developed by using institutional recommendations and are 
currently being validated in large cohorts.
summary 
Well-validated relevant PROMs can be employed for multiple purposes: as outcome 
measures for daily care or for driving therapeutic decisions, as efficacy endpoints in 
clinical trials, or as tools to collect useful data for healthcare policy makers in order to 
improve access and quality of care. 
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InTrODuCTIOn
Idiopathic pulmonary fibrosis (IPF) is a chronic progressive disease with a poor progno-
sis and a devastating impact on the lives of patients and their families.1 Although major 
progress has been made in gaining insights in the mechanism of disease and in the de-
velopment of two drugs that slow down disease progression,2,3 IPF still remains a deadly 
disease with a progressively impaired health-related quality of life (HRQOL).4-6 Shortness 
of breath, cough and fatigue are major factors influencing HRQOL in IPF patients.7-9 In a 
fatal progressive disease, prolonging life at an acceptable quality is what most people 
strive for. Although research can provide numbers on safety and efficacy of a drug, it 
remains challenging to quantify how a patient with IPF subjectively experiences a new 
treatment and benefits from the drugs. In fact, treatment success is also determined 
by patient factors such as expectations, experiences and motivations. Patient-reported 
outcomes (PROs) are therefore important as they attempt to reflect how patients feel 
and function, and how that impacts their lives. 
In IPF, there is a paucity of specific well-validated patient-reported outcome measures 
(PROMs). Recently the first steps in collaboration between patients and caregivers have 
resulted in better insights into the burden of disease, symptoms and unmet needs in 
care for IPF.4-6,10,11 However, good PROMs are needed, not only as outcome measures 
or even efficacy endpoints in clinical trials, but also for daily care, enabling patient and 
doctors to follow up the impact of treatment on patients’ lives and guide treatment 
choices. Furthermore, there is an increasing demand from the healthcare providers and 
policy makers to obtain insight in the patients’ perspectives and experiences during 
disease course and treatment, to monitor and improve care delivery. In this article, we 
look at recent insights in the use and development of PROMs and what promises these 
hold for care and research in IPF. 
PaTIenT-rePOrTeD OuTCOmes anD measures
PROs are defined as ‘Any report coming directly from the patient without interpretation 
by a third party about how they feel or function in relation to a health condition and 
given intervention’.12 PROs can be physiological outcomes reported by patients, for in-
stance cough severity measured by a visual analogue scale or a Medical Research Coun-
cil (MRC) dyspnea scale. PROMs can also be questionnaires reflecting what is relevant 
to patients. HRQOL questionnaires are mostly used as PROMs. They assess a person’s 
satisfaction with aspects of living that are affected by health and can be roughly divided 
in domain-specific, disease-specific and generic PROMs. Domain-specific PROMs are 
focused on a particular organ or symptom. Disease-specific PROMs are tailored to 
the impact and symptoms of a specific disease. Generic PROMs are developed for a 
total population, irrespective of the presence of disease, and reflect general aspects 
such as dependency, mobility and mood. Often different types of PROMs are used in 
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combination. The advantage of disease-specific PROMs is that they are more relevant 
to the patient and have a better face validity and credibility.13 Generic PROMs allow 
comparing between different conditions and with a general population. PROMs should 
be distinguished from patient-reported experience measures (PREMs) that capture 
patients’ experiences with healthcare or services.13 
use Of PaTIenT-rePOrTeD OuTCOme measures
Initially PROMs were developed for use in clinical trials. The use of PROMs is, however, 
much broader, which is increasingly acknowledged the past years (Fig. 1). Using PROMs 
in routine practice has shown to improve communication and shared decision-making 
between patients and care-providers, and improves patients’ satisfaction with care and 
potentially also outcome of care.14-16 Also, completing questionnaires will increase a 
feeling of being involved, which might be beneficial itself for health.17 In a research 
setting, PROs could not only function as outcome measure, but may also be used to 
support predictive modelling for researchers, enabling identification of subgroups of 
patients based on PRO scores that might benefit from a certain treatment.18,19 Possible 
practical advantages may be avoidance of observer bias and probably high completion 
rates. Clinicians are often hesitant to use PROMs in daily care because they consider 
PROMs 
Healthcare institutions 
 
 Benchmarking 
 Quality assessment and 
improvement 
Policy makers 
 
 Performance assessment 
 Valorization of 
implementations 
Research 
 
 Endpoints 
 Identification of subgroups of 
patients 
Society 
 
 Facilitate care choices 
 Information  
 
Daily care 
 
 Facilitate communication 
 Detect unrecognized problems 
 Guide treatment choice 
 Monitor treatment response 
figure 1. Possibilities of PROM use by different stakeholders. 
PROM, patient-reported outcome measurement.
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it time-consuming and doubt the additive value to the consultation. Patients are in 
general more positive to using PROMs on regular basis.15,20
DeveLOPmenT Of PaTIenT-rePOrTeD OuTCOme measures
As described above, well-developed PROMs can be used for a lot of purposes. However, 
clinicians and patients often lack the expertise, time and funding to develop good and 
broad PROMs. Many PROMs in the past have been developed in trial settings in sub-
groups of patients sponsored by industry.18,21 The Food and Drug administration (FDA) 
has made criteria about Guidance for Industry on qualification process for PROMs for 
drug development (Fig. 2).12 However, as the FDA states ‘This guidance does not address 
the use of PRO instruments for purposes beyond evaluation of claims made about a 
medical product in labeling’. The Patient-Centered Outcomes Research Institute (PCORI) 
developed a set of draft minimum standards for the development, selection and use of 
PROs data, incorporating existing guidance documents including the FDA guidance.12,22
DEVELOPMENT OF PATIENT-REPORTED
OUTCOME MEASURES
As described above, well-developed PROMs can be
used for a lot of purposes. However, clinicians and
patients often lack the expertise, time and funding
to develop good and broad PROMs. Many PROMs in
the past have been developed in trial settings in
subgroups of patients sponsored by industry
[18,21]. The Food and Drug administration (FDA)
has made criteria about Guidance for Industry on
qualification process for PROMs for drug develop-
ment (Fig. 2) [12]. However, as the FDA states ‘This
guidance does not address the use of PRO instru-
ments for purposes beyond evaluation of claims
made about a medical product in labeling’. The
Patient-Centered Outco es Research Institute
(PCORI) developed a set of draft minimum stand-
ards for the development, selection and use of PR s
data, incorporating existing guidance documents
including the FDA guidance [12,22].
PATIENT AS PARTNER IN CARE AND
RESEARCH
Collaboration between patients, patient advocacy
groups and healthcare providers has greatly
improved our knowledge on the impact of IPF on
patients and partners, and the need for improve-
ments [4–6,23]. A recent initiative of 11 European
IPF patient advocacy and interstitial lung disease
(ILD)-physicians identified five key themes of unmet
needs for IPF (Fig. 3). This patient–physician initiat-
ive underlines the inequalities in IPF care across
Europe and was presented at the European parlia-
ment to call to action for healthcare policy makers.
In the United States, the FDA conducted a meet-
ing with patients with IPF part of the agency’s
Patient-Focused Drug Development initiative, to
look at the patients’ perspectives on symptoms
and treatment approaches, important for the drug
development process. This meeting underscored
that there is a great need for better medication
and symptom relief, in particular shortness of
breath, severe cough and fatigue [7]. Understanding
what matters to patients is essential for patient-
centered care and research, but the next important
step is active patient involvement. For the 2015 IPF
clinical practice guideline, a patient representative
participated for the first time in the development
group and his contribution was greatly acknowl-
edged [1]. The PCORI aims to meaningfully involve
patients, caregivers, clinicians and other healthcare
stakeholders throughout the research process [24]
an provides guid nce doc ments. A unique project
in d termining domain a d outcome parameters in
onnect ve tissue disease-ILD and IPF demonstrated
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in relation to claim
Confirm conceptual framework with scoring rule
Assess score reliability, construct validity, and ability to
detect change
Finalize instrument content, formats, scoring, procedures
and training materials
Document measurement development
i.
v.
iv.
iii.
ii.
FIGURE 2. FDA guidance on the development of a PRO instrument for drug development. By permission of Oxford University
Press, USA. http://www.fda.gov/downloads/Drugs/.../Guidances/UCM193282.pdf. FDA, Food and Drug administration;
PRO, patient-reported outcome.
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figure 2. FDA guidance on the devel pment of a PRO instrument for drug development. 
By permission of Oxford University Press, USA. http://www.fda.gov/downloads/Drugs/.../Guidances/UCM193282.pdf. FDA, 
Food and Drug administration; PRO, patient-reported outcome.
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PaTIenT as ParTner In Care anD researCh
Collaboration between patients, patient advocacy groups and healthcare providers has 
greatly improved our knowledge on the impact of IPF on patients and partners, and the 
need for improvements.4-6,23 A recent initiative of 11 European IPF patient advocacy and 
interstitial lung disease (ILD)-physicians identified five key themes of unmet needs for 
IPF (Fig. 3). This patient-physician initiative underlines the inequalities in IPF care across 
Europe and was presented at the European parliament to call to action for healthcare 
policy makers. 
In the United States, the FDA conducted a meeting with patients with IPF as part of 
the agency’s Patient-Focused Drug Development initiative, to look at the patients’ 
perspectives on symptoms and treatment approaches, important for the drug develop-
ment process. This meeting underscored that there is a great need for better medica-
tion and symptom relief, in particular shortness of breath, severe cough and fatigue.7 
Understanding what matters to patients is essential for patient-centered care and 
research, but the next important step is active patient involvement. For the 2015 IPF 
clinical practice guideline, a patient representative participated for the first time in the 
development group and his contribution was greatly acknowledged.1 The PCORI aims to 
 
 
 
• Early and accurate diagnosis  
          by raising awareness of IPF and recognizing IPF as a chronic condition 
 
• Equal access to care 
          including medication and transplantation irrespective of age, by coordinating 
          timely and efficient drug approvals at a national level and revising the eligibility 
          criteria for lung transplantation 
 
• A holistic approach to standardise IPF management 
          by involving all aspects of support from early diagnosis to treatment and 
          rehabilitation including correct referral, access to multidisciplinary teams, lung 
          transplantation, emotional support, ambulatory and domiciliary services 
 
• Comprehensive and high quality information about IPF 
          including its treatment, transplant information and emotional care for both 
          patients and families 
 
•      Better access to palliative care and end-of-life care 
          with support for both patients and families 
European IPF Patient Charter 
figure 3. European Idiopathic Pulmonary Fibrosis Patient Charter: five key points.
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meaningfully involve patients, caregivers, clinicians and other healthcare stakeholders 
throughout the research process24 and provides guidance documents. A unique project 
in determining domains and outcomes parameters in connective tissue disease-ILD and 
IPF demonstrated the impact of patients’ involvement on the development of the core 
set of outcome parameters.25 To patients, cough was an essential parameter that should 
be included, whilst it did not come out of the Delphi survey of 254 medical experts. The 
same applied for the patient perspectives on dyspnea and HRQOL, which showed impor-
tant discordances between healthcare providers and patients. In the Netherlands, the 
National Pulmonary Foundation (Longfonds) together with patients, health economic 
experts, government representatives and physicians launched a project to develop a 
new PREM to better assess patients experience and satisfaction with expensive medica-
tion in rare diseases (PESaM-project). These examples of fruitful collaboration between 
patients and healthcare providers underline the necessity to proceed on this road.26
WhaT Is useD In IDIOPaThIC PuLmOnary fIbrOsIs?
We can learn from shared experiences of diseases such as chronic obstructive pulmo-
nary disease (COPD) and lung cancer that already have incorporated patient-centered 
care and have used PROMs much longer.14,27 IPF has inherent challenges such as the un-
predictable disease course and a mostly elderly population, often with co-morbidities, 
which may also influence HRQOL. In IPF, there has long been an absence of an IPF-specific 
measure. Mostly used were existing questionnaires that have been adapted from other 
populations and have subsequently been validated in IPF. For example, the St. George’s 
Respiratory Questionnaire (SGRQ) that was originally developed for COPD has been 
extensively used in IPF trials and its psychometric properties are well assessed.28 Only 
in the trials STEP-IPF (sildenafil) and INPULSIS 2 (nintedanib), some significant favorable 
changes in SGRQ were seen.2,29 Its activity domain appears the most sensitive to change 
in IPF.2 Although there is also a modified IPF version (SGRQ-I), the experience with this 
questionnaire is limited.30 The past years, PROMs also been developed and validated 
specifically in IPF. The King’s Brief Interstitial Lung Disease questionnaire (K-BILD) has 
been developed in a mixed ILD population including patients with IPF.31,32 It is short with 
15 questions and holds good psychometric properties, and is currently further validated 
in larger multicultural longitudinal cohorts. The other PROM is A Tool to Assess Quality 
of Life in IPF (ATAQ-IPF).33 The original version posed a burden on patients with 89 ques-
tions, but the version was reduced to 43 items and validated in the United Kingdom and 
the United States.34 However, longitudinal studies on the performance of the K-BILD 
and ATAQ-IPF over time are still lacking. A recent initiative studied the use of the NIH 
Patient-Reported Outcomes Measurement Information System (PROMIS) in IPF. PROMIS 
includes measures of self-reported health and HRQOL for a range of conditions.6 They 
found that almost all PROMIS domain scores significantly differed between groups of 
patients divided according to MRC score and that test-retest reliability was acceptable. 
Further psychometric validation of the PROMIS-29 is planned. 
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In IPF, several symptom-specific questionnaires have been used aiming at assessing dys-
pnea. Patient-reported dyspnea, measured by the MRC dyspnea scale, has been shown 
to be a predictor of disease progression and survival.35-37 For dyspnea, the University of 
California San Diego Shortness of Breath Questionnaire (UCSD)38 was used as secondary 
outcome in several clinical trials in IPF. Although in the ASCEND (pirfenidone) trial rate of 
forced vital capacity (FVC) decline was significantly reduced in the pirfenidone-treated 
group, no significant effect was found on the UCSD score.3
Although cough is one of the symptoms that matter most to patients, experience with 
cough PROMs in IPF is limited. The Leicester Cough Questionnaire was found to have a 
high correlation with objective cough frequency measurements and cough visual ana-
logue scales in IPF.39,40 The cough quality-of-life questionnaire has also been validated 
in IPF.41 Both questionnaires need further validation in IPF and are currently included in 
several trials in IPF (NCT02009293, NCT02502097, NCT01874223). It is intriguing that 
while fatigue is often a great concern in patients, to our knowledge no validated fatigue 
PROMs have been used or developed in IPF.
In IPF, PROM-use has mainly been focused on use in clinical trials and registries, though 
initiatives are taking place to use PROs in a broader sense. For example, in the United 
Kingdom, the National Institute for Health and Care Excellence developed quality stan-
dards incorporating PROMs as performance indicators for ILD specialist centers.42 In the 
Netherlands a conditional approval for reimbursement of antifibrotic drugs was granted 
by the government, requiring a national registry for IPF with physiological outcomes 
and PROs for all patients treated with antifibrotic medication.43
PaTIenT-rePOrTeD OuTCOmes In IDIOPaThIC PuLmOnary fIbrOsIs 
TrIaLs 
With FVC used as a primary endpoint in the trials of the two drugs that were approved 
for IPF, there is a strong precedent that new drug trials will also use change in FVC as 
endpoint.2,3,44 Even though a physiological endpoint as FVC reflects decline, it does not 
correlate well with HRQOL in IPF. For instance, K-BILD total and subdomains correlate 
only moderate with FVC (r=0.47) and transfer factor of the lung for carbon monoxide 
(TLCO) (r=0.50). For the SGRQ, this is even worse, FVC (r=-0.34), TLCO (r=-0.38).30,31 Also 
recently, Ley et al.45 showed that prediction models that work well for mortality in IPF 
correlate poorly with functional disease progression, measured with UCSD-SOBQ and 
6-minute walk tests. PROMs clearly capture another dimension of disease. All major 
trials in IPF have used PROMs as secondary outcome measures, but have failed to show 
a convincing signal (Table 1).2,3,29,46-54
We believe there are several potential reasons for this. The most obvious one being the 
paucity of well-developed and validated IPF-specific PROMs to capture symptoms and 
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burden of disease. Maybe we should also strive for easier straightforward questionnaires 
that remain close to the day-to-day consultations. Another explanation might be that 
while we all believe slowing down lung function decline is meaningful, it is the ques-
tion if this also applies to HRQOL. What is the value of a non-significant improvement 
or stabilization in HRQOL in a disease with a progressive decline? Minimal important 
difference (MID) is defined as ‘the smallest difference in score in the domain of interest 
which patients perceive as beneficial which would mandate, in the absence of trouble-
some side effects and excessive costs a change in patient’s (healthcare) management’.55 
Often the MID is not known or only determined in a small subgroup of patients. Also, 
it might be that disease-modifying treatments do not necessarily improve patients’ 
symptoms and different trial strategies are needed to improve symptoms and HRQOL. 
Table 1. Patient-reported outcome measurements used in trials over the past decade
trial treatment ProM outcome
Shionogi 46 Pirfenidone Hugh-Jones ns
CRQ ns 
IFIGENIA47 N-acetylcysteine SGRQ ns
Etanercept48 Etanercept SGRQ ns
MDI ns 
INSPIRE49 IFN-γ SGRQ ns
UCSD ns 
STEP-IPF29 Sildenafil SGRQ p=0.005
USCD p=0.006 
Borg ns 
SF-36 ns 
EQ-5D ns 
BUILD-350 Bosentan SF-36 ns
EQ-5D ns 
CAPACITY 1&251 Pirfenidone UCSD ns
BIBF-112052 Nintedanib SGRQ 150 mg bid, p=0.03
Ambrisentan53 Ambrisentan SGRQ ns
TDI ns 
SF-36 ns 
ASCEND3 Pirfenidone UCSD ns
PANTHER54 N-acetylcysteine SF-36 p=0.03*
EQ-5D ns 
SGRQ ns 
UCSD ns 
ICE-CAP p=0.01** 
INPULSIS2 Nintedanib SGRQ ns, INPULSIS2, p=0.02
* mental domain ** summary score
Hugh-Jones, Hugh-Jones Classification Score; CRQ, Chronic Respiratory Questionnaire; EQ-5D, EuroQol-5D; ICE-CAP, ICEpop 
CAPability measure; MDI, Mahler Dyspnea Index; ns, not significant; SF-36, Short-Form 36; SGRQ, St. George’s Respiratory 
Questionnaire; UCSD, the University of California San Diego shortness of breath questionnaire; Borg, Borg Dyspnea Index; 
TDI, Transient Dyspnea Index.
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Collaboration between patients, healthcare providers and researcher will be required 
to fuel advances in this field. 
WhICh PaTIenT-rePOrTeD OuTCOme measure shOuLD I ChOOse 
fOr my sTuDy? 
We believe that PROMs used to date in IPF have not been demonstrated to have the 
performance characteristics necessary to function as primary endpoints in IPF trials 
aimed at disease modification. However, in trials aimed at symptom relieve, palliation 
and improvement of HRQOL, PROMs could hold more prominent endpoint positions, 
depending on the hypothesis studied. Also, PROMs should be included as secondary 
or exploratory endpoints in other trials, not only to strive to capture what matters to 
patients, but also to further develop and validate the instruments in bigger and interna-
tional cohorts. The choice of PROM will depend on many factors.8 A PROM must meet 
certain basic psychometric criteria, especially if it serves as primary endpoint.12 The FDA 
has made guidance documents for the use of PROMs.12 But it is good to realize that 
validation is an ongoing process and if the choice of PROMs is only based on familiarity 
and convincing psychometric criteria, PROMs development in IPF will halt, so newer 
PROMs could well serve as exploratory or secondary endpoints. The intervention being 
studied should guide the decision on what domains and symptoms are outcomes of 
interest, for instance, does the investigator wish to assess the severity of cough or the 
impact on patient’s emotional wellbeing. Ideally, this choice should be dominated by 
the patients’ preferences. Also the design of the study, the comparator group and time 
span are of relevance. In general, the combination of a generic PROM and a disease or 
even symptom-specific measure is recommended.8 
ChaLLenGes In PaTIenT-rePOrTeD OuTCOmes
The approval of two drugs for IPF and the fast expansion of studies with promising new 
compounds, have had a positive effect on interest in PROM development.2,3 However, 
there is still a paucity of well-developed and validated IPF PROMs.4 One of the caveats is 
the lack of longitudinal data to support validity and assess minimal clinically important 
differences. Also, currently used scales are often very detailed with the belief that more 
is better. However, for an individual patient, it will be hard to remember what was 
scored the previous time, leading likely to changes in scores in every patient, complicat-
ing assessment of a meaningful change. Simple, easy to remember scales, like MRC, 
should be investigated more. Another limitation is that cultural differences are not tak-
ing into account; most PROMs are developed in United Kingdom or United States, while 
international collaboration is needed in IPF trials.30,31,33,38 PROMs should be linguistically 
validated for use in other countries, and it is essential to engage patient representatives 
from different countries and continents throughout the development and validations 
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process.12 One of the other challenges in a patient involvement is the burden this may 
pose on patients especially when disease advances and there is variation in fitness of 
the patient from day to day. This will require a flexibility of the team in planning and 
use of technologies to involve patients for whom travelling is too much. Also, partners 
and caregivers can not only help overcome practical difficulties, but are also an under 
recognized source of information.5 
fuTure PersPeCTIves
Findings from international registries will provide longitudinal PROM data from differ-
ent parts of the world in a real life non-selected IPF population.56-61 The collection of 
these data will allow for analysis of changes throughout disease course and hopefully 
guide determination of meaningful and feasible PRO parameters. New structures in 
organization of care, like the initiative of the European Committee to organize care 
for rare diseases in European Networks in close collaboration with patient advocacy 
groups, could facilitate the development and validation of multicultural and multilingual 
PROMs.62 New information and communication technologies can facilitate worldwide 
collaboration. Innovative systems that capture and use PROs are tested. Computerized 
adaptive testing is a system in which the number and choice of questions are adjusted 
according to the patient’s answers, in this way avoiding non-relevant questions and im-
proving relevance for the patient. The system is used by the NIH PROMIS initiative,63 but 
to our knowledge has not been used in IPF yet; it could be of value taking into account 
the heterogeneity of disease course and burden for patients. With increasing costs and 
hopefully new drugs, regulatory bodies will ask for proof of value for money. PROMs 
will play an important role in this, not only reflecting the patients’ experiences with 
new drugs, but also allowing for performance assessment, benchmarking and quality 
improvement. 
COnCLusIOn
The use of PROMs holds promises to support changes in how research is done and 
healthcare is delivered. Although the available tools to explore needs of IPF patients 
in terms of quality of life are poor, we are undoubtedly at the beginning of a new era. 
Patients-centered outcome measures focusing on symptoms, psychological and social 
wellbeing of our patients have the great potential to reveal new aspects to better un-
derstand the variable response to treatment and reduce interpretation biases in clinical 
trials. The next years are likely to bring new well-validated instruments, which will pro-
vide useful data to researchers, healthcare providers and policy makers to ameliorate 
quality and access to IPF care. Patients as partners in care and research are the promise 
for the future.
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AbstrAct
background 
The King’s Sarcoidosis Questionnaire (KSQ) is a brief questionnaire assessing health sta-
tus using five modules (General Health Status, Lung, Medication, Skin, Eyes) in patients 
with sarcoidosis. The KSQ was only validated in one English sarcoidosis cohort. 
Objective 
The aim of this study was to validate the KSQ in a Dutch sarcoidosis population.
Methods
The KSQ was translated according to international guidelines and tested in interviews 
with patients. Consecutive outpatients completed multiple questionnaires twice, two 
weeks apart. Construct validity, internal consistency and repeatability were determined.
results 
Of the 98 patients included 85 had lung, 22 skin and 24 eye disease. There was good 
construct validity of the KSQ General Health Status module against the World Health 
Organization Quality of Life-BREF questionnaire. The Medication module correlated 
weak to moderate with most questionnaires. The correlations with organ-specific ques-
tionnaires varied from strong for Eyes (r=0.75), Skin (r=-0.62) to moderate for Lung 
(r=-0.45 with MRC breathlessness scale). Internal consistency was good for all KSQ 
modules (Cronbach’s α 0.72-0.93). Intraclass correlation coefficients (0.70-0.90) and 
Bland-Altman plots showed good repeatability of the KSQ.
conclusion
The Dutch KSQ is the first translation of the English KSQ, validated in a Dutch sarcoidosis 
population.
47
Validation of the KSQ in a Dutch sarcoidosis population
ch
ap
te
r 3
InTrODuCTIOn
Sarcoidosis is a heterogeneous multisystem disease with different clinical phenotypes. 
Sarcoidosis manifests most commonly in the lungs, but can affect skin, eyes, lymphatic 
nodes and other organs as well.1 Health status is impaired in the majority of patients 
with sarcoidosis due to symptoms such as dyspnea, persistent cough, peripheral pain, 
fatigue and cognitive dysfunction, leading to limitations in activities, social isolation and 
depression.1-3 Therapy for sarcoidosis often leads to side effects impacting health sta-
tus.4,5 In recent years patient related outcome measures (PROMs) have gained increasing 
importance in clinical trials and health status is now a standard outcome measure.6 
Most studies evaluating health status used generic questionnaires such as the World 
Health Organization Quality of Life-BREF (WHOQOL-BREF) or the MOS 36-item Short 
Form Health Survey (SF-36), both non-disease specific questionnaires.7-12 Currently, no 
sarcoidosis specific instruments measuring health status in patients with sarcoidosis are 
available in Dutch. In 2012 the King’s Sarcoidosis Questionnaire (KSQ) was developed.13 
This self-administered measure for sarcoidosis covers different domains of health status; 
General Health Status (GHS), Lung (L), Medication (M), Skin (S) and Eyes (E). The aim of 
this study was to validate the KSQ in a Dutch sarcoidosis population.
meThODs
Translation validation
The KSQ was translated from English to Dutch according to a multi-step forward-back-
ward procedure, following international guidelines14-16 and was reviewed by sarcoidosis 
experts and the developers (online supplement 1). The relevance and applicability of 
the translated KSQ was tested using ten structured patient interviews.
Psychometric validation
Subjects
In July 2014 consecutive sarcoidosis outpatients of the pulmonary department of the 
Erasmus Medical Center were asked to participate. During the same period sarcoidosis 
outpatients of the ild care team, Hospital Gelderse Vallei were approached by email. 
Patients were excluded from the study if they were unable to understand question-
naires due to intellectual impairment or language barrier, when comorbidities that 
severely impact health status existed (such as malignancies, collagen vascular diseases 
and cardiac failure other than due to sarcoidosis) or when they had unstable disease as 
considered by the treating physician. If patients completed less than 85% of a question-
naire they were withdrawn from the study. Formal consultation with the Medical Ethical 
Committee of the Erasmus Medical Center learnt that, under the Dutch act for medical 
research involving human subjects (Wet Medisch Onderzoek), approval of this study by 
the Medical Ethical Committee is not required.
Chapter 3
48
Study procedure
All patients were asked to complete up to seven questionnaires (depending on organ in-
volvement) in addition to the KSQ: WHOQOL-BREF,7 Fatigue Assessment Scale (FAS),17 Small 
Fiber Neuropathy Screening List (SFNSL),18 Medical Research Council dyspnea scale (MRC 
dyspnea scale),19 Dermatology Life Quality Index (DLQI),20 National Eye Institute Visual Func-
tion Questionnaire (NEI-VFQ25)21 and Euroqol-5D-5 level (EQ-5D-5L).22 Online supplement 
2 shows the organ specific questionnaires and corresponding KSQ modules. Patients also 
completed two general health status measurements: Punum Ladders23 and Global Rating 
of Change-Quality of Life (GRC-QoL).24 Patients were asked to self-complete the question-
naires at home, two weeks apart.
Results of routinely measured pulmonary function outcomes were gathered from the 
medical records. The diagnosis of sarcoidosis was established when there was compat-
ible clinical behaviour and pathological or BAL confirmation, according to international 
guidelines.25 Patients were asked about their organ involvement during a short face to 
face interview or interview by telephone.
Statistical analysis 
Data are presented as mean values (± standard deviation). KSQ scores were calculated 
on a logit scale as this scale is more linear and has the potential to perform better at 
the extreme ends of health related QoL.26 The validity of the KSQ remains unchanged 
from the original format.27 Construct validity between the general and organ specific 
domains of KSQ and the corresponding questionnaires were determined using Pearson’s 
correlation coefficients. A correlation coefficient of < 0.30 is considered weak, 0.30 – 0.50 
moderate and > 0.50 strong.16 Cronbach’s α coefficient was used to determine the internal 
consistency of the reliability of the KSQ. A minimum of 0.70 is considered a good inter-
nal consistency. Bland-Altman plots and intraclass correlation coefficients were used to 
evaluate the repeatability at baseline and at two weeks, in patients with stable disease. 
To assess stable disease we used Punum ladders.23 Patients with ≥ 4 differences in Punum 
score were excluded in the repeatability analyses. The limits of agreement were calculated 
as mean ± 1.96 X SD of within-subject differences. Values of p < 0.05 were considered 
statistically significant. All data were analyzed with SPSS version 21.
resuLTs
Translation validation
A Dutch version of the KSQ, achieved after forward and backward translation, was ap-
proved by the KSQ developers. Following this approval, ten patient interviews with the 
Dutch version of the KSQ took place (step T3 online supplement 1). Discussion of these 
interview results with the KSQ developers did not necessitate any further adaptations 
of the translation and resulted in the final Dutch KSQ-version (online supplement 3).
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Psychometric validation
One hundred and four consecutive outpatients in the Erasmus Medical Center were 
evaluated for participation, 89 were interested and 54 participated in this study. At the 
same time 117 patients of the ild care team, Hospital Gelderse Vallei were approached 
by email, 60 patients responded and 44 were recruited. Reasons for exclusion were: 
clinical instability (15), comorbidity that severely impacted quality of life (14), no PA/
BAL confirmation (9), not able to read or write Dutch (5) or other reasons (8) (not willing 
to participate, not reachable by telephone or by email, participating in another study). 
Thus in total 98 patients were included. Eighty-eight (90%) of them completed week 
zero and 83 (85%) week two (figure 1).
Demographics
Table 1 shows the demographics of the patients included. Patients with two or more 
organs involved showed a significantly worse health status than patients with single-
organ disease: mean (SEM) KSQ GHS score 53(1.6) versus 68(3.7); mean difference 15; 
95% Confidence Interval (CI) 7-23; p = 0.001. No significant difference was found be-
tween the KSQ GHS score for females compared with males: mean (SEM) 54 (2.5) versus 
60 (2.3); mean difference 5; 95% CI 1-12, p = 0.115. Patients with more complaints of 
fatigue (FAS score ≥ 22) have a significantly worse health status (mean (SEM) KSQ GHS 
Consecutive outpatients 
asked to participate 
Erasmus Medical Center 
104 
Consecutive outpatients 
approached by email  
Hospital Gelderse Vallei  
117 
 
Exclusion 
51 
  
Inclusion 
98 
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88 
Week 2 
83 
16 
Not able to read or write Dutch    5 
54 
Clinical instable   15 
Comorbidity that severly impact QoL  14 
Sarcoidosis not PA/BAL confirmed    9 
Other     8 
Responders 
60 
Interested in 
participating  
89 
35 44 
Reasons of  
exclusion 
Drop out 
10 
Lost to  
follow-up 
5 
figure 1. Study design
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52(1.5)), than those with lower FAS scores (mean (SEM) 76(3.2); mean difference KSQ 
GHS -24; 95% CI -30 to -17, p = 0.000).
Construct validity
The correlations between the KSQ GHS domain and all generic questionnaires (WHOQOL-
BREF and EQ-5D-5L) were strong (r= 0.50 – 0.84). KSQ organ modules combined with 
the GHS module all showed a moderate to strong correlation with the WHOQOL-BREF 
and EQ-5D-5L (r= 0.44 – 0.85). The Medication module showed a weak to moderate 
correlation with the generic questionnaires (r= 0.26 – 0.47) (Table 2).
All KSQ modules correlated moderately to strongly with the FAS. The relationship be-
tween the KSQ organ-specific modules and their corresponding organ-specific question-
naires was also moderate to strong. The Lung module was weakly correlated with the 
FVC% predicted (r= 0.24) (Table 2).
table 1. Patient demographics
All patients
Organ involvement
Lung Skin Eyes
Number 88 85 22 24
Age, years, mean (SD) 52 (11) 51 (11) 52 (11) 52 (13)
Women, n (%) 36 (41) 35 (41) 10 (46) 11 (46)
Ethnicity, n (%)
Caucasian 70 (80) 67 (79) 17 (77) 16 (67)
Afro-American 2 (2) 2 (2) - -
Surinamese-Hindi 13 (15) 13 (15) 4 (18) 5 (21)
Morrocan 2 (2) 2 (2) 1 (5) 2 (8)
Unknown 1 (1) 1 (1) - 1 (4)
Smoking status, n (%)
Current 3 (3) 3 (4) - 1 (4)
Ex 15 (17) 15 (18) 5 (23) 8 (33)
Never 64 (73) 61 (72) 15 (68) 12 (50)
Unknown 6 (7) 6 (7) 2 (9) 3 (13)
Time since diagnosis, years, mean (SD) 8.0 (8.8) 8.1 (8.9) 7.4 (10.5) 8.4 (11.2)
Organs involved, n (%)
Lungs 85 (97)
Skin 22 (25)
Eyes 24 (27)
Small nerve fibers 26 (30)
FVC % predicted, mean (SD), [n] 92 (20) [84] 91 (20) [81]
FEV1/FVC ratio % predicted, mean, [n] 76 (13) [74] 76 (13) [72]
TLCOc % predicted, mean (SD) , [n] 81 (21) [73] 81 (21) [70]
TLC % predicted, mean (SD) , [n] 86 (18) [57] 86 (18) [56]
FVC, forced vital capacity; FEV1, forced expiratory volume in 1 s; TLCO, diffusing capacity of the lung for carbon monoxide, 
corrected for hemoglobin level; TLC, total lung capacity as % predicted.
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Reliability
All domains of the KSQ had good internal consistency, Cronbach α; 0.90 (GHS), 0.91 
(Lung), 0.72 (Medication), 0.84 (Skin), and 0.93 (Eyes). With regard to the repeatability 
(test-retest) 83 patients (lung n= 80, skin n= 20 and eyes n= 22) completed the KSQ twice. 
The following intraclass correlations were found: GHS 0.85, Lung 0.74, Medication 0.70, 
Skin 0.77, Eyes 0.90, suggesting a good reliability. Twelve patients in the GHS and 13 
patients in the Lung module groups were excluded from the analysis for repeatability, 
because they did not show stability in their Punum scores. The Bland-Altman plots in 
figure 2 and 3 show the repeatability of the KSQ GHS and Lung module, respectively. 
Both plots have a few outliers (outside the 95% of limits of agreement). We found a 
mean difference between the first and second measurement of 2.20 in the KSQ GHS 
module and 2.45 in the Lung module.
DIsCussIOn
The Dutch KSQ is the first health status questionnaire for sarcoidosis in the Netherlands. 
It is also the first non-English validation of the questionnaire. The KSQ is simple to ad-
Mean KSQ GHS score over 2 weeks
100806040
Di
ffe
re
nc
e 
in
 K
SQ
 G
HS
 s
co
re
s 
ov
er
 2
 w
ee
ks
40
20
0
-20
-40
2.20
17.44
-13.03
Page 1
figure 2. Bland Altman plot of repeatability of King’s Sarcoidosis Questionnaire General Health Status module. 
Solid line represents mean difference and dashed lines represent 95% limits of agreement
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minister, adaptable to individual organ involvement and shown to be a valid and reliable 
health status measurement in Dutch patients with sarcoidosis.
PROMs are becoming more important in clinical trials and daily care.6 Health status 
is nowadays a standard outcome measure. Most sarcoidosis studies use non-disease 
specific questionnaires such as the WHOQOL-BREF and the SF-36.10-12 The KSQ is a 
self-administered sarcoidosis specific instrument. The KSQ questionnaire was originally 
developed in the UK and was not available in languages other than English. The avail-
ability of the KSQ in other languages could facilitate international collaboration aiming at 
measuring, comparing and improving health status in patients with sarcoidosis, which is 
often severely affected. During translation in Dutch and the patient interviews no major 
cultural difference was noted and the questionnaire was considered comprehensible 
and relevant by Dutch patients.
The patient demographics of the current Dutch study population were in line with the 
original study, though there were slightly more Caucasians in our study and lung func-
tion was less severely affected.13 Quality of life was worse in females similar to Patel et 
al. but in contrast did not reach statistical significance.13,28 
Mean KSQ Lung score over 2 weeks
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figure 3. Bland Altman plot of repeatability of King’s Sarcoidosis Questionnaire Lung module. 
Solid line represents mean difference and dashed lines represent 95% limits of agreement
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The following domains of health status are covered in the KSQ: General Health Status, 
Lung, Medication, Skin and Eyes. Construct validity of the organ-specific questionnaires 
with their corresponding modules is similar to the development paper.13 The KSQ Lung 
module showed a weaker correlation with the MRC. In the original article from Patel et 
al. the MRC dyspnea scale as well as the St. George Respiratory Questionnaire (SGRQ) 
was used. They found a Pearson’s correlation of -0.58 for the MRC dyspnea scale and 
-0.85 for the SGRQ. It therefore seems that the MRC dyspnea scale is a less reliable tool 
to assess construct validity in this population. We did not include the SGRQ, because 
of the high number of questionnaires patients had to complete for validation and we 
feared this would lead to ‘questionnaire fatigue’. Moreover, the SGRQ is a disease-
specific questionnaire developed for chronic obstructive pulmonary disease, with 50 
items and no questions about skin or eye involvement.
We found a difference in study population between Patel et al. and ours; our popula-
tion had less patients with a severe impairment of the lungs, which is shown in the 
difference in TLCOc% predicted (63 vs. 81 in our group).13 This could also explain the 
weaker correlation found between the Lung module and FVC% predicted (r= 0.24). To 
date, this lack of correlation between health status questionnaires and lung function 
has often been reported in other pulmonary diseases as well.29 This underlines the idea 
that health status questionnaires measure different aspects of disease severity and 
therefore are a very important additional outcome measures. When combined with the 
KSQ GHS module all organ-specific KSQ modules showed a better correlation with the 
generic questionnaires. This supports the use of organ-specific modules in combination 
with the GHS module.
Fatigue is a major problem in patients with sarcoidosis with an important impact on 
health status.30 This was reflected by a strong correlation between the FAS and GHS. 
This confirms that the KSQ also captures the health status caused by fatigue.13 Our re-
sults are in line with other studies showing the major effect of fatigue on the wellbeing 
of patients.30 
Small fiber neuropathy related symptoms, which are disabling and difficult to control, 
can also significantly reduce health status.31 We chose to include the SFNSL question-
naire to evaluate if the KSQ also captures this problem as this had not been evaluated 
before. Strong correlations with the SFNSL were found by combining the KSQ GHS and 
the organ-specific KSQ modules. This suggests the KSQ captures the small fiber neu-
ropathy related influences on health status.
In line with Patel et al. findings, weak to moderate correlations were found between the 
optional Medication module and almost all questionnaires.13 Therapy for sarcoidosis, 
as for instance corticosteroids, often causes burdensome side effects. It is tempting to 
speculate that these side effects may have affected health status more than the symp-
toms of sarcoidosis. In both Patel et al. and the present study the Medication module 
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does not contribute much. Longitudinal studies are needed with changes in medication 
to see if the KSQ captures influences of medication on health status.
According to the study of Patel and colleagues, we found that the KSQ has a good inter-
nal consistency.13 Reliability was also assessed with Bland-Altman plots showing good 
repeatability (test-retest) in measurements.
At the time of this study, the Sarcoidosis Health Status Questionnaire (SHQ) was the only 
alternative sarcoidosis health status questionnaire.32 In our view this 29-item instru-
ment, developed in 2001, has some important limitations. It contains only few organ-
specific questions, has not been validated for eye and skin disease and can, therefore, 
not be tailored to individual clinical phenotypes. Furthermore, the SHQ is mostly longer 
than the KSQ, because most patients do not have to fill in all the organ-specific KSQ 
modules. Recently, Judson et al. validated a new patient reported outcome measure, 
the Sarcoidosis Assessment Tool (SAT).31,33 The SAT was constructed in a similar way as 
the KSQ and also consists of organ-specific modules. With 51 questions it is consider-
ably longer than the KSQ. The SAT was validated in an interventional study giving the 
advantage that the MCID has been calculated.5 However, to our knowledge repeatability 
has not yet fully been assessed making it difficult to conclude if a difference in scores 
indicates a low repeatability or a true change in health status. It would be valuable to 
compare the different sarcoidosis questionnaires prospectively.
In sarcoidosis any organ can be involved and it remains unclear if the KSQ will also cap-
ture the impact of more rare forms of sarcoidosis on health status. Another limitation of 
our study is the lack of follow-up after two weeks. Responsiveness of the questionnaire 
can thereby not be assessed. Further research, through longitudinal studies in larger 
patient cohorts, is warranted to determine the responsiveness, the influence of rarer 
disease forms and the value of the Medication module.
In conclusion, the Dutch KSQ is the first translation of the English KSQ, validated in a 
Dutch sarcoidosis population.
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suPPLemenTaL
Forward translation 
Dutch King’s sarcoidosis health status questionnaire (D-KSQ) : T3 
Patient interviews  
• 10 patiënts (Dutch native speakers)  
• Different ages, sexes, stages of severity and level of education 
• Evaluate (face to face) T3 with a structured questionnaire 
Dutch King’s sarcoidosis health status questionnaire (D-KSQ) : T4 
Discuss results patient interviews with KSQ 
developers and experts 
King’s sarcoidosis questionnaire (KSQ) : BT12 
T4 (D-KSQ) validated 
King’s sarcoidosis questionnaire (KSQ) 
Forward translation by a translational agency 
and a Dutch native speaker 
Dutch King’s sarcoidosis health status questionnaires (D-KSQ’s) : T1 + T2 
Evaluation by pneumonologists 
Dutch King’s sarcoidosis health status questionnaire (D-KSQ) : T12 
Backward translation by native speakers 
King’s sarcoidosis questionnaires (KSQ’s) : BT1 + BT2 
Evaluation and approval KSQ developers 
Online supplement 1. Translation procedure
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online supplement 2. Depending on their organs affected patients will be asked to complete specific ques-
tionnaires
Questionnaire KSQ (GHS 
+ M)
KSQ (L) KSQ (S) KSQ (E) MRC DLQI NEI-VFQ25
Organ(s) affected
Lung X X X
Skin X X X
Eyes X X X
Lung, Skin X X X X X
Lung, Eyes X X X X X
Skin, Eyes X X X X X
Lung, Skin, Eyes X X X X X X X
KSQ, King’s Sarcoidosis Questionnaire; GHS, General Health Status; M, Medication; L, Lung; E, Eyes; MRC, Medical Research 
Council; DLQI, Dermatology Life Quality Index; NEIVFQ-25, National Eye Institute Visual Function Questionnaire-25
.
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Online supplement 3. The Dutch King’s Sarcoidosis Questionnaire
The KSQ is protected by copyright, King's College Hospital, U.K 
Online Supplem nt 3 - T e Dutch King's Sarcoido is Questionnaire 
King’s Sarcoïdose Vragenlijst (KSQ) 
Invuldatum: ………………………………………………….. 
Het doel van deze vragenlijst is het bepalen van de invloed van sarcoïdose op 
verschillende aspecten van uw leven. Lees elke vraag zorgvuldig door en 
omcirkel het antwoord dat het meest op u van toepassing is. Beantwoord ALLE 
vragen zo eerlijk mogelijk. Deze vragenlijst is vertrouwelijk. Alle vragen hebben 
betrekking op de manier waarop SARCOIDOSE uw gezondheid heeft beïnvloed. 
ALGEMENE GEZONDHEIDSTOESTAND 
In de laatste 2 weken … De hele 
tijd 
Het grootste 
deel van de 
tijd 
Een flink 
deel van de 
tijd 
Een deel 
van de 
tijd 
Een klein 
deel van 
de tijd 
Heel 
zelden 
Helemaal 
niet 
1 Heb ik me gefrustreerd gevoeld 1 2 3 4 5 6 7 
2 Heb ik moeite gehad me te 
concentreren 
1 2 3 4 5 6 7 
3 Heb ik onvoldoende motivatie 
gehad 
1 2 3 4 5 6 7 
4 Heb ik me moe gevoeld 1 2 3 4 5 6 7 
5 Heb ik me zorgen gemaakt 1 2 3 4 5 6 7 
6 Heb ik last of pijn in mijn 
spieren/gewrichten gehad 
1 2 3 4 5 6 7 
7 Heb ik me geschaamd 1 2 3 4 5 6 7 
8 Heb ik me zorgen gemaakt over 
mijn gewicht 
1 2 3 4 5 6 7 
9 Heb ik me zorgen gemaakt over 1 2 3 4 5 6 7 
mijn sarcoïdose 
In de laatste 2 weken … Zeer 
sterk 
Behoorlijk 
sterk 
Matig sterk Enigszins Weinig Zeer 
weinig 
Niet 
10 Heeft vermoeidheid mij 1 2 3 4 5 6 7 
gehinderd bij mijn normale 
sociale activiteiten, zoals 
uitgaan met vrienden of familie 
Zie volgende pagina 
The KSQ is protected by copyright, King’s College Hospital, U.K.
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The KSQ is protected by copyright, King's College Hospital, U.K 
LONG 
 
 
 
 In de laatste 2 weken … De hele 
tijd 
Het grootste 
deel van de 
tijd 
Een flink 
deel van 
de tijd 
Een deel 
van de 
tijd 
Een klein 
deel van de 
tijd 
Heel 
zelden 
Helemaal 
niet 
11 Heb ik pijn/ongemak gehad 
door het hoesten 
1 2 3 4 5 6 7 
12 Ben ik buiten adem geraakt 
als ik de trap op klom of een 
flauwe helling op liep 
1 2 3 4 5 6 7 
13 Heb ik diep moeten 
ademhalen, ook bekend als 
“snakken naar adem” 
1 2 3 4 5 6 7 
14 Heb ik me benauwd op de 
borst gevoeld 
1 2 3 4 5 6 7 
15 Heb ik perioden van 
benauwdheid gehad 
1 2 3 4 5 6 7 
16 Heb ik last gehad van pijn op 
de borst 
1 2 3 4 5 6 7 
 
 
 
 
 
MEDICATIE 
 
 
Gebruikt u medicatie voor uw sarcoïdose? 
 
JA O                           NEE O (ga naar het volgende onderdeel) 
 
 
 In de laatste 2 weken … Zeer 
sterk 
Behoorlijk 
sterk 
Matig 
sterk 
Enigszins Weinig Zeer 
weinig 
Niet 
17 Heb ik me zorgen gemaakt 
over bijwerkingen van mijn 
medicijnen 
1 2 3 4 5 6 7 
18 Heb ik me slechter gevoeld 
door mijn medicijnen voor 
sarcoïdose 
1 2 3 4 5 6 7 
19 Ben ik aangekomen door mijn 
medicijnen voor sarcoïdose 
1 2 3 4 5 6 7 
 
 
 
 
 
 
 
 
 
Zie volgende pagina 
The KSQ is protected by copyright, King’s College Hospital, U.K.
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The KSQ is protected by copyright, King's College Hospital, U.K 
HUID 
 
 
 
In de laatste 2 weken … Zeer 
sterk 
Behoorlijk 
sterk 
Matig 
sterk 
Enigszins Weinig Zeer 
weinig 
Niet 
20 Heb ik last gehad van mijn 
huidproblemen 
1 2 3 4 5 6 7 
21 Heb ik me zorgen gemaakt 1 2 3 4 5 6 7 
 over veranderingen in de 
kleur van mijn 
huidafwijkingen 
       
In de laatste 2 weken … De hele 
tijd 
Het grootste 
deel van de 
tijd 
Een flink 
deel van 
de tijd 
Een deel 
van de 
tijd 
Een klein 
deel van de 
tijd 
Heel 
zelden 
Helemaal 
niet 
22 Heb ik mij geschaamd 1 2 3 4 5 6 7 
 vanwege mijn huid        
 
 
 
 
 
OGEN 
 
 
 
 In de laatste 2 weken … De hele 
tijd 
Het grootste 
deel van de 
tijd 
Een flink 
deel van 
de tijd 
Een deel 
van de 
tijd 
Een klein 
deel van de 
tijd 
Heel 
zelden 
Helemaal 
niet 
23 Heb ik droge ogen gehad 1 2 3 4 5 6 7 
24 Heb ik problemen gehad met 
fel licht 
1 2 3 4 5 6 7 
25 Zijn mijn ogen rood geweest 1 2 3 4 5 6 7 
26 Heb ik pijn in of rond mijn 
ogen gehad 
1 2 3 4 5 6 7 
27 Heb ik moeite gehad met 1 2 3 4 5 6 7 
 lezen        
 In de laatste 2 weken … Zeer 
sterk 
Behoorlijk 
sterk 
Matig 
sterk 
Enigszins Weinig Zeer 
weinig 
Niet 
28 Heb ik last gehad van wazig 
zien 
1 2 3 4 5 6 7 
29 Heb ik me zorgen gemaakt 
over mijn gezichtsvermogen 
1 2 3 4 5 6 7 
 
 
 
Einde vragenlijst 
The KSQ is protected by copyright, King’s College Hospital, U.K.
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objective biomarkers for psychological 
distress and fatigue in patients with 
sarcoidosis
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AbstrAct
background
Patients with sarcoidosis often experience fatigue and psychological distress, but little 
is known about the etiology of these conditions. While serum and saliva cortisol levels 
are used to monitor acute stress, scalp hair analysis is a new method enabling mea-
surement of long-term steroid levels. We investigated whether scalp hair cortisol and 
testosterone levels differ between sarcoidosis patients both with and without fatigue 
and general population controls. Additionally, we studied if these hormones could serve 
as objective biomarkers for psychological distress in sarcoidosis.
Methods
We measured hair steroid levels using liquid chromatography-tandem mass spectrom-
etry in glucocorticoid naïve sarcoidosis patients. Patients completed the Perceived 
Stress Scale, Fatigue Assessment Scale, Hospital Anxiety and Depression Scale and Short 
Form 36 (SF-36). Hair steroid levels from 293 participants of the Lifelines cohort study 
served as controls.
results
Thirty-two patients (14 males) were included. Hair cortisol concentrations were sig-
nificantly higher in sarcoidosis patients than in general population controls (mean 6.6 
versus 2.7 pg/mg, p<0.001). No differences were found in hair cortisol and testosterone 
levels between fatigued and non-fatigued sarcoidosis patients. Hair cortisol of sarcoid-
osis patients correlated significantly with anxiety (r=0.47, p=0.01), depression (r=0.46, 
p=0.01), and SF-36 mental domain (r=-0.38, p=0.03), but not with fatigue. 
conclusions
Patients with sarcoidosis have chronically higher levels of the stress hormone cortisol 
than the normal population. Hair cortisol levels were positively related to subjective 
measures of psychological distress, but not fatigue. Our study shows that hair cortisol is 
a promising non-invasive biomarker for psychological distress in patients with sarcoid-
osis.
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baCKGrOunD
Sarcoidosis is a multi-organ disease of unknown etiology, characterized by non-caseating 
granulomas, which commonly occur in the lymph nodes, lungs, skin and eyes.1 In patients 
with sarcoidosis, fatigue and psychological distress are frequently reported problems.2-5 
Fatigue has been reported in 50-70% of the sarcoidosis patients.3 Even when sarcoidosis 
is in clinical remission, fatigue may persist chronically and cause impaired quality of life 
(QoL) and reduced socio-economical participation.6 The exact mechanism for chronic 
fatigue in sarcoidosis is currently unknown.
Stress might be one of the factors contributing to the onset of fatigue. Chronic fatigue 
in sarcoidosis patients has been associated with increased levels of perceived stress 
and psychological stressors such as depression and anxiety.4-6 Psychological and physical 
stressors lead to activation of the hypothalamus-pituitary-adrenal axis, resulting in an 
increase in circulating levels of the stress hormone cortisol.7 Cortisol, in turn, influences 
a wide range of bodily functions including metabolism, behavior and immunity.7 Stress 
can be assessed subjectively using validated questionnaires, but cortisol levels can also 
be used as a biomarker for stress.8,9 Systemic inflammation in chronic diseases has been 
associated with fatigue, and may affect cortisol levels as well.10,11 While stress and in-
flammation are both associated with increased levels of cortisol, there are also studies 
that show evidence of hypocortisolism in relation to chronic fatigue,12,13 thereby leaving 
the relationship between cortisol and fatigue in sarcoidosis unclear.
In male patients with sarcoidosis, another potential factor contributing to fatigue may 
be hypogonadism, with its consequent low levels of testosterone. Serum testosterone 
has shown to be significantly decreased in patients with chronic lung disease,14,15 and 
has also been inversely related to fatigue in patients with advanced cancer and ob-
structive sleep apnea.15,16 In a study of 30 patients with sarcoidosis, almost half of the 
patients had lower circulating testosterone levels than healthy controls; however, this 
study did not assess the relationship with fatigue.17 
Both cortisol and testosterone are commonly measured in blood, urine, or saliva. 
However, these tests reflect only short-term exposure, and levels of cortisol and testos-
terone can greatly fluctuate within and across days.7,18 Moreover, the tests themselves 
can induce stress and increase cortisol levels.19 
In this study, we use a relatively novel method: scalp hair analysis to measure long-term 
cortisol, cortisone, and testosterone levels. This method has been validated in other – 
non pulmonary - diseases and allows a retrospective measurement of the endogenous 
production of these hormones over months of time, based on an average hair growth 
of approximately 1 cm per month.20 Previous studies have shown that hair cortisol can 
serve as a biomarker for chronic stress.9,21 
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To the best of our knowledge, no studies have investigated hair steroid biomarkers, 
such as cortisol, cortisone and testosterone, in sarcoidosis. This non-invasive method 
could potentially give new insights into the mechanism of fatigue and psychological 
distress in sarcoidosis. Moreover, it may be used as a screening and follow-up tool to 
objectively measure fatigue and psychological distress as an alternative to the currently 
used subjective patient-reported outcome measures. 
In this explorative study, we aimed to investigate whether scalp hair cortisol, cortisone, 
and testosterone levels differ between sarcoidosis patients both with and without 
fatigue and general population controls. Additionally, we studied if these scalp hair 
steroid levels could serve as an objective biomarker for psychological distress, fatigue 
and/or other clinical outcomes in patients with sarcoidosis. 
meThODs
study design and population
We conducted a prospective observational study. Sarcoidosis patients were recruited 
during their regular follow-ups at the outpatient clinic of the pulmonary department 
of the Erasmus University Medical Center, Rotterdam, the Netherlands, from June till 
December 2014. Patients aged 18 or older were included if they had been diagnosed 
with sarcoidosis according to the latest ATS/ERS/WASOG statement on sarcoidosis,1 and 
if they had sufficient knowledge of the Dutch language. We aimed to include 20 patients 
with fatigue and 10 without fatigue. Fatigue was defined as a score of 22 or higher 
on the Fatigue Assessment Scale (FAS).22 Other causes of fatigue had to be excluded 
or, in the case of contributing comorbidities (e.g. obstructive sleep apnea syndrome, 
hypothyroidism or anemia), optimally treated. Patients were excluded if they had a hair 
length of less than 1 cm, had used systemic and/or inhalation steroids in the last year, 
or had taken methylphenidate less than 1 month before the study. Scalp hair steroid 
levels of participants of the Dutch population-based Lifelines cohort study were used 
as general population controls.23,24 Formal consultation with the Medical Ethical Com-
mittee of the Erasmus Medical Center affirmed that, under the Dutch act for medical 
research involving human subjects (Wet Medisch Onderzoek), approval of this study 
by the Medical Ethical Committee was not required (MEC-2014-206). All patients gave 
written informed consent. 
Procedures
Hair sample collection and processing
In each subject, a small hair sample of approximately 150 hairs was cut from the pos-
terior vertex as close to the scalp as possible using small scissors. Hair samples were 
taped on paper and stored in envelopes at room temperature. The hair samples of all 
patients were analyzed in one batch at the diagnostic endocrine laboratory of the in-
ternal medicine department of the Erasmus MC, Rotterdam. For analyses, hair samples 
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were divided in segments of 1 cm, weighed, washed, and steroids were extracted with 
methanol. Subsequently, hair cortisol, cortisone, and testosterone were analyzed with 
liquid chromatography-tandem mass spectrometry (LC-MS/MS) (figure 1). A detailed 
description on scalp hair analysis is available in a previous publication by Noppe and de 
Rijke et al.25
Questionnaires
Patients filled in the FAS at the outpatient clinic. Other questionnaires were completed 
at home as soon as possible, but within a maximum of two weeks from the clinic visit. 
The 10-item FAS measures fatigue and has been well-validated in patients with sar-
coidosis.3,26 Scores range from 10 to 50, with higher scores indicating more fatigue, 
a FAS score of ≥22 is considered as significant fatigue.27 Subjective health status was 
evaluated with standardized self-reported generic instruments, the Euroqol-5D 5-level 
(EQ5D5L), and the 36-item medical outcomes short form 36 (SF-36), with higher scores 
representing better health status.28 The King’s Sarcoidosis Questionnaire (KSQ) was used 
to measure disease-specific health status and consists of five modules: General health 
status, Lung, Medication, Skin, and Eye.29,30 All domain scores range from 0 to 100, with 
a higher score representing a better disease-specific health status.29 The 14-item Per-
ceived Stress Scale (PSS) is a broad score to assess a person’s perception of stress, with a 
higher score indicating a higher perceived stress.8 The Hospital Anxiety and Depression 
Scale (HADS) has a 7-item anxiety and a 7-item depression domain. The scores for both 
domains range from 0-21, with a cut-off point of 8 for depression or anxiety.31
Clinical parameters
Weight, height and waist circumference were measured during the visit. The results 
of routinely measured pulmonary function outcomes (forced vital capacity (FVC) and 
transfer factor for carbon monoxide corrected for hemoglobin (TLCOc)) were used when 
available. 
Collection Sample preparation Extraction Analysis
1. Cut sample of interest 
    (e.g. 3 cm = 3 months)
Methanol
Hair sample
LC-MS/MS
2. Weigh sample
Hair is cut as close to the scalp as 
possible, at the posterior vertex
012345 cm
side of 
scalp
figure 1. Scalp hair analysis: hair sample collection, pre-treatment and analysis
LC-MS/MS, liquid chromatography-tandem mass spectrometry. Modified from20 with permission from the publisher.
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outcomes
The primary outcome was the differences between scalp hair steroid levels of sarcoid-
osis patients both with and without fatigue and general population controls. Secondary 
outcomes were relationships between scalp hair steroid levels, fatigue and psychologi-
cal distress scores, and clinical parameters. 
statistical analysis
Data is presented as median (range) when not stated differently. Scalp hair steroid levels 
are presented as geometric mean (95% confidence interval, CI) and expressed in pg/
mg; data was log-transformed to achieve normal distribution. To determine differences 
in characteristics of sarcoidosis patients with and without fatigue, we used a Mann-
Whitney U test for continuous variables and Fisher’s exact test for binomial variables. 
Hair steroid levels were compared between the two groups of sarcoidosis patients using 
independent sample t-tests. Analysis of (co)variance (AN[C]OVA) was used to compare 
hair cortisol and testosterone levels of sarcoidosis patients with general population 
controls, corrected for age and gender. Mann Whitney U tests were used for analyzing 
differences in questionnaire scores of patients with and without fatigue. Correlations 
between hair steroid levels, questionnaire scores and clinical parameters were assessed 
using Pearson’s correlation coefficients. All statistical analyses were performed using 
SPSS version 21.0 (IBM, Armonk, NY). A p-value of <0.05 was considered statistically 
significant. 
resuLTs
Of the 36 patients screened for the study, 32 were included. Patients were excluded for 
the following reasons: incomplete questionnaires (2), not enough hair for hair sample 
(1), and psychiatric problems (1). Based on the FAS score, 23 of the 32 sarcoidosis 
patients had significant fatigue. There were no significant differences in patients’ char-
acteristics between the fatigued and non-fatigued groups of patients (table 1). 
Hair steroid levels
Scalp hair cortisol and cortisone levels were detected in all sarcoidosis patients, and 
testosterone levels in 13 of the 14 male patients with sarcoidosis. In the population-
based controls from the Lifelines study cohort, there were 293 participants with scalp 
hair steroid samples (262 had both cortisol and cortisone levels available, 4 only cortisol 
level, and 27 only cortisone). In 62 male participants, testosterone levels were also 
available. Hair steroid levels in the sarcoidosis patients with fatigue did not significantly 
differ from those of sarcoidosis patients without fatigue (figure 2). Scalp hair cortisol 
and cortisone concentrations of the total group of sarcoidosis patients were signifi-
cantly higher than those of the general population controls (hair cortisol: mean 6.6 
(95% CI 5.1-8.4) versus 2.7 (95% CI 2.5-2.9) pg/mg, p<0.001, hair cortisone: mean 18.0 
(95% CI 15.2-21.2) versus 8.3 (95% CI 7.9-8.8) pg/mg, p<0.001) (figure 3). No significant 
71
Scalp hair cortisol and testosterone in sarcoidosis
ch
ap
te
r 4
differences in testosterone levels were found between male patients with sarcoidosis 
and male general population controls (mean 1.0 (95% CI 0.7-1.3) pg/mg versus 1.0 (95% 
CI 0.9-1.2) pg/mg, p=0.78) (figure 3). Cortisol correlated significantly with cortisone 
(r=0.72, p<0.001), but not with testosterone (r=0.38, p=0.20); neither did cortisone 
correlate with testosterone (r=0.26, p=0.39).
Psychological distress and fatigue questionnaires
Mean questionnaires scores are shown in table 2. Sarcoidosis patients with fatigue 
had significantly higher stress, anxiety, depression and lower quality of life scores than 
sarcoidosis patients without fatigue (table 2). 
A significant positive correlation was found between scalp hair cortisol levels and 
anxiety (r= 0.47, p=0.01) and depressive symptoms (r=0.46, p=0.01) (table 3). Addition-
ally, higher hair cortisol levels significantly correlated with lower mental health scores 
measured by the SF-36 (r=-0.38, p=0.03), indicating worse health status (table 3). There 
was a trend observed between hair cortisol levels and the PSS (r=0.31, p=0.09), but no 
correlation existed with the FAS (r=0.14, p=0.45) (table 3). For scalp hair testosterone 
levels, in male sarcoidosis patients, no significant correlations were found with any of 
the psychological distress and fatigue scores. Figure 4 shows an interaction network 
between hair steroid levels, psychological distress and fatigue scores, and pulmonary 
function tests in the total group of sarcoidosis patients.
table 1. Characteristics of the groups of sarcoidosis patients
all patients 
[n = 32]
fatigue 
[n = 23]
non-fatigue 
[n = 9]
p-value* 
Fatigue severity 32 (10-46) 33 (22-46) 16 (10-21) <0.001
Age 47 (31-66) 45 (31-64) 55 (36-66) 0.15
Women 18 (56%) 13 (57%) 5 (56%) 1.00
Ethnicity 0.69#
Caucasian 23 (72%) 17 (74%) 6 (67%)
Moroccan 3 (9%) 3 (13%) 0 (0%)
Surinamese Hindi 6 (19%) 3 (13%) 3 (33%)
BMI, kg/m2 26 (20-39) 26 (20-39) 29 (23-36) 0.21
Waist circumference 93 (65-116) 91 (65-116) 95 (84-104) 0.48
Time since diagnosis, y 5 (0-24) 4 (0-24) 6 (0-18) 0.82
FVC % predicted 105 (55-123) 103 (81-123) 106 (55-121) 0.95
TLCOc % predicted 88 (50-162) 89 (50-131) 86 (60-162) 0.82
Data are presented as median (range) or n (%). BMI, body mass index; FVC, forced vital capacity; TLCOc transfer factor for 
carbon monoxide corrected for hemoglobin. 
* Mann-Whitney U test was used for continuous variables and Fisher’s exact test for binomial variables to compare fatigue 
and non-fatigue sarcoidosis patients 
# Caucasian versus other
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Clinical parameters
Scalp hair cortisol and cortisone did not correlate with clinical parameters. However, 
testosterone showed a significant positive correlation with weight (r=0.69, p=0.01), 
and a significant inverse correlation with waist circumference (r=-0.69, p=0.01) and FVC 
(r=-0.76, p=0.02). 
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Sarcoidosis patients [n=32]
General population controls [n=293]
p<0.001
p<0.001
p=0.78
figure 3. Hair cortisol, cortisone and testosterone levels in patients with sarcoidosis and general population 
controls23,24
* measured in 13 male sarcoidosis patients and in 62 male general population controls. Data are shown as geometric mean 
(95% CI), and corrected for age and gender. General Linear model – Univariate (ANCOVA) was used for analysis.
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figure 2. Hair cortisol, cortisone and testosterone levels in sarcoidosis patients with and without fatigue
* measured in 10 male sarcoidosis patients with fatigue and in 4 male patients without fatigue. Data are shown as geometric 
mean (95% CI). Independent sample t-test was used for analysis.
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DIsCussIOn
This study is the first to assess the feasibility of scalp hair steroid levels as a biomarker 
for psychological distress and fatigue in patients with sarcoidosis. Hair cortisol and 
cortisone levels were significantly higher in sarcoidosis patients than in general popu-
lation controls. Hair cortisol levels were positively related to subjective measures of 
psychological distress. No differences were found in scalp hair steroid levels between 
sarcoidosis patients with and without fatigue.
In the current study, instead of the more conventional methods such as serum, urine 
or saliva measurements, we used scalp hair analysis to determine steroid levels. This 
method has several advantages. First, scalp hair analysis enables long-term steroid 
level determination as opposed to all methods using body fluids that only represent 
table 2. Questionnaire scores of patients with sarcoidosis
Questionnaire total 
[n=32]
fatigue
[n=23]
non-fatigue
[n=9]
p-value*
FAS 32 (10-46) 33 (22-46) 16 (10-21) <0.001
PSS 26 (4-55) 29 (4-55) 14 (9-28) <0.001
HADS anxiety 6 (0-19) 7 (0-19) 1 (0-2) <0.001
HADS depression 6 (0-21) 8 (0-21) 0 (0-5) <0.001
EQ5D5L 0.7 (-0.1-1.0) 0.7 (-0.1-0.9) 1.0 (0.6-1.0) <0.001
SF-36 mental health 64 (36-75) 64 (36-75) 64 (60-64) 0.71
SF-36 general health 62 (30-87) 62 (47-87) 57 (30-77) 0.26
KSQ GHS 58 (2-100) 53 (2-83) 98 (75-100) <0.001
Data are shown as median (range). * Mann-Whitney U was used for comparing questionnaire scores in fatigue and non-
fatigue patients with sarcoidosis. FAS, Fatigue Assessment Scale; PSS, Perceived Stress Scale; HADS, Hospital Anxiety and 
Depression Scale; EQ5D5L, Euroqol-5D 5-level; SF-36, Short Form-36; KSQ, King’s Sarcoidosis Questionnaire; GHS, General 
Health Status domain
table 3. Correlations between scalp hair cortisol and cortisone and psychological distress and fatigue scores 
in all patients with sarcoidosis (n=32)
Questionnaires Cortisol Cortisone
FAS 0.14 -0.01
PSS 0.31# <-0.01
HADS anxiety 0.47** 0.14
HADS depression 0.46** 0.18
EQ5D5L -0.26 0.03
SF-36 mental health -0.38* -0.05
SF-36 general health -0.28 -0.18
KSQ GHS -0.25 -0.04
Pearson correlations, data are presented as R. FAS, Fatigue Assessment Scale; PSS, Perceived Stress Scale; HADS, Hospital 
Anxiety and Depression Scale; EQ5D5L, Euroqol-5D 5-level; SF-36, Short Form-36; KSQ, King’s Sarcoidosis Questionnaire; 
GHS, General Health Status domain
# p≥0.05 and <0.10, * p<0.05 and >0.01, ** p≤0.01
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a momentarily steroid level and which can be influenced by acute stress, the diurnal 
rhythm, or pulsatile secretion of steroid hormones.7,18,20 A recent study has shown that 
hair cortisol measurement provides a reliable measure of long-term integrated free 
cortisol production. It demonstrated that hair cortisol levels correlated well with 30-day 
average salivary cortisol area-under-the curve based on 3 samples collected during the 
day.32 Second, scalp hair samples are easy to collect and store at room temperature.33 
In contrast, measuring steroid levels in body fluids, especially at multiple time-points, 
is invasive for patients, labour-intensive, and depends on patient instruction and coop-
eration.20 Also, the measurement itself, as with blood sampling, can induce stress and 
thereby influence results.19 Third, hair strings can be divided into segments of one or 
more centimeters to create retrospective timelines. In this way, scalp hair steroids could 
potentially be used in future trials to objectively measure the effect of interventions on 
psychological distress using only one or a few hair strings, thereby allowing easy data 
collection on a large scale.
Pearson correlation
0.30-0.50
0.50-0.70
>0.70
SF-36
GH
PSS
EQ5D5L
Cortisone
HADS 
depression
HADS 
anxiety
KSQ 
GHS
SF-36
 MH
FAS
Test
 
TLCOc
Cortisol
 
FVC
figure 4. Interaction network showing all significant correlations between hair steroid levels, psychological 
distress and fatigue scores, and pulmonary function tests in sarcoidosis patients (n=32).
Each node of the network corresponds to a questionnaire score, and its size is proportional to the % of the total score of the 
questionnaire. Two nodes are linked if they significantly correlate, the wider the string the better the correlation. EQ5D5L; 
Euroqol-5D 5-level; FAS, Fatigue Assessment Scale; SF-36, Short Form-36; MH, mental health domain; GH, general health 
domain; KSQ; King’s Sarcoidosis Questionnaire; GHS, General Health Status domain; HADS, Hospital Anxiety and Depression 
Scale; PSS, Perceived Stress Scale; TLCOc, transfer factor for carbon monoxide corrected for hemoglobin; FVC, forced vital 
capacity; Test, testosterone.
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Interestingly, hair cortisol and cortisone levels were significantly higher in patients with 
sarcoidosis than in the general population controls. Hair cortisol has previously been 
associated with both physical and mental health status and was found to be increased 
in patients with various diseases such as obesity, post-traumatic stress syndrome, and 
cardiovascular diseases, and was also associated with extreme exercise, shift work, life 
events and chronic pain.20,21,34 Cortisol is the active form of glucocorticoid and can be 
converted into cortisone, which has almost no biological activity.35 The balance between 
cortisol and cortisone makes it possible to regulate cortisol levels. In our study, cortisol 
and cortisone showed good correlations and were both increased. This makes a mecha-
nistic cause in the conversion or balance between cortisol and cortisone in sarcoidosis 
patients unlikely as the underlying mechanism for the higher cortisol levels found.
Scalp hair steroid levels did not differ between sarcoidosis patients with and without 
fatigue. Korenromp et al. reported that, in a principal component analyses, serum ACTH 
and cortisol were significantly lower in patients with sarcoidosis-related fatigue than 
in patients without fatigue.12 However, their baseline cortisol analysis showed no dif-
ference between fatigued and non-fatigued patients, which is in line with our findings. 
Different assessment methods can complicate comparisons between studies. Koren-
romp et al., for example, measured cortisol in blood serum, a momentarily measure of 
cortisol, while in our study, cortisol was analysed in scalp hair representing long-term 
cortisol levels. As previously shown by Sauve et al., hair cortisol levels are not affected 
by diurnal variations or acute stress, and serum cortisol levels do not seem to correlate 
well with scalp hair cortisol levels.36
Hair testosterone levels in men with sarcoidosis did not differ from those of the general 
population controls. This is contrary to findings of Spruit et al. which showed significantly 
lower serum testosterone levels in male sarcoidosis patients than in healthy controls.17 
This variance could be due to differences in measuring methods since hair testosterone 
is a long-term measure, whereas serum testosterone is a time-point measure. But the 
small sample size (13 testosterone samples) of our study might have also played a role 
in the findings. Nevertheless, both our study and the study of Spruit et al. found no 
correlation between psychological wellbeing scores and testosterone levels. We can 
therefore only conclude that the clinical relevance of testosterone levels in sarcoidosis 
is not yet clear, and ideally a larger cohort should be studied. 
Currently, tools to measure fatigue and psychological distress in sarcoidosis are limited 
to subjective patient-reported outcome measures (PROMs). PROMs often comprise 
many questions, which may complicate use in clinical practice. Not only can complet-
ing PROMs be time consuming, but patients may also struggle to remember what 
they answered the previous time. This can lead to variations in scores and difficulties 
to evaluate a meaningful change. Previous studies have shown that scalp hair cortisol 
can serve as a biological marker for chronic stress.9,21 In our study, scalp hair cortisol 
levels, indeed, positively correlated with psychological distress scores of depression 
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and anxiety. A trend was found in the correlation with perceived stress scores. These 
findings are in line with previous studies.33,37 The underlying mechanism of the positive 
correlation between scalp hair cortisol levels and psychological distress in sarcoidosis 
patients could be bi-directional. Hence, sarcoidosis-associated inflammation may cause 
increased cortisol levels, and increased cortisol levels can lead to psychological distress. 
Studies in Cushing patients suggested a similar relationship.38 On the other hand, having 
such a disease as sarcoidosis might also directly cause psychological distress, resulting 
in higher cortisol levels. We found that while stress scores differed significantly between 
fatigue and non-fatigue patients, no differences in cortisol levels were found. This might 
indicate that psychological stress is not the predominant underlying mechanism driving 
the increase in cortisol levels found in sarcoidosis patients.
Little is known about the etiology of fatigue in sarcoidosis. Fatigue is presumably 
multifactorial, and might be related to aspects in pathogenesis, comorbidities, and 
medication.2,3 In the current study, no relationship could be found between cortisol 
and testosterone levels and fatigue. This is in line with clinical experience that, in 
sarcoidosis-associated fatigue, steroids treatment is often futile, or might even result in 
side-effects causing further deterioration. As can been seen in figure 4, fatigue is closely 
related to quality of life, anxiety, depression and stress scores, which, in turn, are also 
strongly interrelated. This underlines the major impact fatigue has on patients’ lives and 
the need for studies to advance knowledge on its etiology and for effective treatment 
interventions for fatigue in sarcoidosis. Figure 4 also shows that scalp hair cortisol is 
the only objective clinical parameter correlating with subjective scores of psychologi-
cal distress. No correlation is found between questionnaires and pulmonary function 
parameters. This is in line with previous findings that pulmonary function tests do not 
correlate with subjective questionnaire scores as they capture another dimension of 
disease.29,30 Testosterone levels showed a correlation with FVC in sarcoidosis patients; 
however, sample size was limited and too small to draw conclusions about the clinical 
significance of this finding.
Our study has some limitations. Only patients without steroid use were included, 
whereas in daily practice, both systemic and topical corticosteroids are used by a fair 
number of patients with sarcoidosis. Previous studies have shown that endogenous 
cortisol production can be suppressed by exogenous corticosteroids.39 In children with 
asthma using inhalation corticosteroid, serum and scalp hair cortisol levels were found 
to be lower than in healthy controls.40 Likewise, studies in healthy adults showed sig-
nificantly lower hair cortisol levels in participants using systemic corticosteroids than in 
non-users.24,33 It needs to be studied if scalp hair cortisol analysis can be used to assess 
compliance and dosing of corticosteroid treatment in sarcoidosis. Currently, hair analysis 
can only be done on scalp hair, and the method is not validated for other types of bodily 
hair, thereby excluding patients with very short or no scalp hair. Another limitation is 
the small sample size, which might explain the lack of differences found in hair steroid 
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levels in fatigued and non-fatigued patients. Nevertheless, hair steroid levels of the total 
group of patients differed significantly from those of the general population controls. 
COnCLusIOns
Patients with sarcoidosis have significantly higher levels of scalp hair cortisol and 
cortisone than the general population controls. Scalp hair steroids levels did not differ 
in sarcoidosis patients with and without fatigue. Increased hair cortisol in sarcoidosis 
patients was associated with increased psychological distress, assessed by question-
naires. In male sarcoidosis patients, no significant correlations were found between 
hair testosterone and scores of psychological distress and fatigue. This study suggests 
that scalp hair cortisol analysis is a feasible, non-invasive biomarker for psychological 
distress, but not fatigue, in patients with sarcoidosis.
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AbstrAct
background
Clubbing is associated with poor prognosis and considered typical in idiopathic pulmo-
nary fibrosis (IPF), but is also seen in other fibrotic interstitial lung diseases (ILDs). Little 
is known about the exact prevalence, clinical meaning, and the best method to assess 
clubbing in these ILDs. We aimed to evaluate the agreement between different club-
bing assessment methods in patients with fibrotic ILDs. Additionally, we assessed the 
prevalence of clubbing in different fibrotic ILDs, and related clubbing to disease severity 
and quality of life.
Methods
Consecutive outpatients with fibrotic ILDs of two tertiary referral centers were included. 
Clubbing was assessed with the phalangeal depth ratio, the digital index, the Schamroth 
sign test, and by the treating physicians and investigator.
results
We included 153 patients (100 men), mean age 65 (range 33-88), mean FVC 79% (25-
145%), mean TLCOc 50% (16-104%). Kappa values between clubbing assessment meth-
ods ranged from -0.47 – 0.68. Prevalence of clubbing ranged from 7-42% in the total 
group of patients and 7-52% in IPF, depending on assessment method used. Clubbing 
did not correlate with FVC or TLCOc (p>0.2) or with quality of life scores. 
conclusion
Clubbing was present in 7-42% of our fibrotic ILD cohort, and showed no correlation 
with disease severity. Although considered an important clinical feature, assessment 
methods for clubbing showed no to poor agreement. Further studies are needed to 
gain more insight into measuring clubbing reliably, and the possible prognostic value 
and evolution of clubbing.
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InTrODuCTIOn
Interstitial lung diseases (ILDs), also known as diffuse parenchymal lung diseases, 
contain a variety of disease affecting the pulmonary interstitium or alveoli.1,2 A signifi-
cant proportion of these diseases is characterized by progressive pulmonary fibrosis. 
The most common form is idiopathic pulmonary fibrosis (IPF), a deadly disease with 
a median survival of 3-5 years without treatment.3 Patients with pulmonary fibrosis 
experience symptoms of breathlessness, cough and fatigue.4 Physical examination often 
reveals fine bibasilar inspiratory crackles and finger clubbing.5 Clubbing is a deformation 
of the nail base, resulting in a swollen and sponginess, convex distal phalanx, with loss of 
the nail-fold angle.6,7 Severe clubbing can be bothersome and painful for patients. The 
exact underlying mechanism of clubbing is unknown; though it has been hypothesized 
that dysfunction of fragmentations of megakaryocytes into platelets in the lungs plays 
a role.8
In most studies the presence of clubbing is assessed by the treating physicians.5,9,10However, 
many other methods have been described to measure clubbing, such as the digital 
index, phalangeal depth ratio and the Schamroth sign test.11-13 Little is known about the 
best method to quantify clubbing in fibrotic ILDs.
Digital clubbing is thought to be present in approximately 50 percent of patients with IPF 
and has been associated with poor prognosis of disease.5,14 Yet, there is little knowledge 
on prevalence, and clinical meaning of clubbing in other fibrotic lung diseases, such as 
underlying collagen vascular disease (CVD) and chronic hypersensitivity pneumonitis 
(CHP). Currently, it is increasingly acknowledged that IPF and other fibrotic ILDs share 
common features and might also benefit from the same treatments. To our knowledge 
no good studies have been performed to look at clubbing and associated patients char-
acteristics in these diseases.
The purpose of this study was to evaluate agreement between different clubbing as-
sessment methods in patients with fibrotic ILDs. Secondary, we assessed the prevalence 
of clubbing in different fibrotic ILDs, and the relationship between clubbing, disease 
severity and quality of life.
meThODs
study design and population
This study is a prospective, consecutive, cohort study at the outpatient clinic of the 
pulmonary department of the Erasmus MC, Rotterdam and the St. Antonius hospital, 
Nieuwegein. Patients were included from May till December 2016, when having pul-
monary fibrosis, defined as: “the presence of reticulation and traction bronchiolectasis 
or traction bronchiectasis, with or without honeycombing” and one of the following 
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diagnoses: IPF, underlying CVD, CHP, fibrosing pulmonary sarcoidosis, unclassifiable 
pulmonary fibrosis (PF), or other fibrotic ILDs. The study was approved by the local 
medical ethical commission of both centers (METC 2016-214) and all patients com-
pleted informed consent.
outcomes
The primary outcome was the agreement between different clubbing assessment 
methods in patients with fibrotic ILDs. Secondary outcomes were the prevalence of 
clubbing in these patients, and the relationship between clubbing and disease severity 
(measured by pulmonary function tests) and quality of life (QoL). 
Measurements
Clubbing was measured at the outpatient clinic using the digital index, phalangeal depth 
ratio and Schamroth sign test, and rated at sight by the treating physician and investiga-
tor (figure 1).
Digital index 
            
Phalangeal depth ratio 
              
Schamroth sign test 
      
 
A B 
DIP 
C D 
E F 
NB 
DPD IPD DPD IPD 
figure 1. Clubbing measuring methods
A Measuring circumference of NB  b Measuring circumference of DIP
c Normal finger with DPD<IPD  D Clubbed finger with DPD>IPD 
e Diamond-shaped window: negative  f No diamond-shaped window: positive
NB, nail bed; DIP, distal interphalangeal joint; DPD, distal phalangeal depth; IPD, interphalangeal depth. Digital index = NB:DIP 
ratios for all 10 fingers. Phalangeal depth ratio = DPD:IPD ratio.
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Digital Index
The digital index was calculated by measuring the nailbed (NB) to the distal interphalan-
geal (DIP) ratio for each finger (figure 1).11 A total score of the ten ratios above 10.2 is 
consistent with clubbing and a score ≤10.2 is considered normal.6,11
Phalangeal depth ratio
The phalangeal depth ratio is the ratio of the distal phalangeal depth (DPD) to the inter-
phalangeal depth (IPD) (figure 1).6,12 The ratio was measured with a digital caliper (150 
mm) and determined for both index fingers. A ratio above 1.0 is indicative for clubbing.7
Schamroth sign test
For the Schamroth sign test, patients were asked to put the dorsal part of their nails of 
both index fingers together (figure 1). In patients without clubbing, a diamond shaped 
window is seen. The test is positive when this window disappears.6,13
At sight
Before starting the clubbing measurements, the treating physicians and investigator 
were asked to rate the patients’ clubbing as present or not. They were blinded for each 
other’s results.
Questionnaires
Patients completed several questionnaires at home, shortly after the visit. The 15-item 
King’s Brief Interstitial Lung Disease health status questionnaire (K-BILD) is a vali-
dated, self-completed health status questionnaire with three domains: psychological, 
breathlessness and activities and chest symptoms.15 Scores range from 0-100, with a 
higher score indicating a better health status.15 The Euroqol-5D-5 level (EQ-5D-5L) is 
a self-administered generic measure of health-related QoL, and defines health in 5 
dimensions: mobility, self-care, usual activities, pain and discomfort and anxiety and 
depression.16 A higher score indicates better health-related QoL. The 5-item ICEpop 
CAPability measure for Older people (ICECAP-O) assesses capability in elderly people 
and focuses on five conceptual attributes of QoL: attachment, security, role, enjoyment 
and control.17 The 15-item Groningen frailty indicator (GFI) is a short, self-administered 
screening questionnaire. It contains questions about psychological and physical frailty.18 
A 100 mm visual analogue scale (VAS) was used to assess cough, breathlessness, fatigue 
and general wellbeing.
Physiological measures
Results of routinely measured pulmonary function tests, forced vital capacity (FVC), 
forced expiratory volume in the first second (FEV1) and the transfer factor for carbon 
monoxide corrected for haemoglobin (TLCOc)), were used when available.
Chapter 5
86
statistical analysis
Data is presented as mean (range) when not stated differently. To assess differences in 
demographics and questionnaire scores between patients with IPF and other diagno-
sis, we used an independent sample t-test for continuous variables and a Chi-Square 
test for categorical variables. The level of agreement between the different clubbing 
measuring methods was analyzed using Cohen’s kappa.19 Prevalences of clubbing were 
calculated as frequencies. Independent sample t-tests were used to compare clubbing 
measuring method, questionnaire and disease severity scores in patients with and 
without clubbing. Pearson correlation coefficients were used to assess the relationship 
between clubbing measuring methods, pulmonary function tests and questionnaire 
scores. SPSS version 21.0 was used for all statistical analysis. A p-value of <0.05 was 
considered statistically significant.
resuLTs
Of the 167 patients approached for the study, 153 patients were included. Fourteen 
patients declined because they were not interested (5), too busy (8) or had difficulties 
understanding the questionnaires (1). Demographics are shown in table 1. The group 
“others” contains 19 (12%) underlying CVD, 12 (8%) CHP, 15 (10%) fibrosing pulmonary 
sarcoidosis, 17 (11%) unclassifiable pulmonary fibrosis, and 22 (14%) various fibrotic 
ILDs. A list of the various fibrotic ILDs can be found in supplementary table 1. In most 
patients, the dominant hand was right (right: 137 (90%), left: 10 (7%), no preference: 5 
(3%) and unknown 1 (1%)). 
Questionnaire scores are shown in table 2, and were missing in 16 patients (10%). 
No significant differences were found in questionnaire scores between IPF and other 
diseases, except for the K-BILD psychological (IPF: mean 50 (range 22-76), others: mean 
57 (range 22-100), p<0.01) and total domain (IPF: mean 53 (range 27-72) others: mean 
57 (range 34-91), p=0.04).
For the digital index the mean score was 9.72 (range 8.74-10.47, SD 0.31), for the pha-
langeal depth ratio left 0.97 (range 0.75-1.18, SD 0.07) and the phalangeal depth ratio 
right 0.96 (range 0.60-1.20, SD 0.08). Cohen’s kappa values showed no to weak agree-
ment on the presence of clubbing between the different clubbing methods, except for 
a moderate agreement between clubbing ratings of the physician and the investigator 
(0.62) (table 3).
Table 4 shows the prevalence of clubbing in fibrotic ILDs analyzed with the different 
clubbing measurement methods. Prevalences range from 7-42% in the total group of pa-
tients and 7-52% in patients with IPF. Interestingly the digital index and Schamroth sign 
test showed much lower prevalences in the total group of patients than the phalangeal 
depth ratio and ratings of the physician and investigator (7-8% versus 31-42%) (table 4).
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In supplementary table 2 questionnaire and pulmonary function test scores are shown 
for patients with and without clubbing according to the different clubbing measuring 
methods. TLCOc and, dependent on clubbing measuring method used, FVC were signifi-
cantly lower in patients with clubbing than in those without clubbing. Yet, no correlation 
was found between pulmonary function tests and clubbing, measured with the digital 
index and phalangeal depth ratio (supplementary table 3). Pearson correlations ranged 
from -0.02 to -0.10 between TLCOc and the different clubbing measures. Questionnaire 
scores showed no to poor correlations with clubbing (supplementary table 3).
table 1. Demographics
Patients 
(n=153)
IPf
(n=68)
others 
(n=85)
p-value#
Age (years) 65 [33-88] 69 [47-86] 62 [33-88] <0.001
Male 100 (65) 55 (81) 45 (53) <0.001
BMI 27 [19-42] 27 [20-39] 28 [19-42] 0.32
Smoking status <0.01*
Former 98 (64) 53 (78) 45 (53)
Never 48 (31) 13 (19) 35 (41)
Current 7 (5) 2 (3) 5 (6)
Pack years 23 (18) 26 [1-85] 20 [0-64] 0.05
Comorbidity 0.84**
Pulmonary hypertension 6 (4) 4 (6) 2 (2)
Cardiac 27 (18) 16 (24) 11 (13)
Gastro-intestinal 2 (1) 0 (0) 2 (2)
Thyroid 2 (1) 0 (0) 2 (2)
Other 20 (13) 8 (12) 12 (14)
Medication 0.69***
Nintedanib 17 (11) 17 (25) 0 (0)
Pirfenidone 25 (16) 23 (34) 2 (2)
Other 69 (45) 14 (21) 55 (65)
None 48 (31) 20 (29) 28 (33)
Lung function parameters
FVC % predicted 79 [25-145] 78 [37-130] 79 [25-145] 0.78
FEV1 % predicted 77 [25-152] 79 [40-120] 76 [25-152] 0.44
TLCOc % predicted 50 [16-104] 46 [16-104] 55 [18-95] <0.01
Data are presented as n (%) or mean [range]. IPF, idiopathic pulmonary fibrosis; FVC, forced vital capacity; FEV1, forced expi-
ratory volume in the first second; TLCOc, transfer factor for carbon monoxide corrected for hemoglobin. #IPF versus others, 
analyzed with an independent sample t-test for continuous variables and a Chi-Square test for categorical variables * never 
versus former/current smoker ** comorbidity versus no comorbidity *** medication versus no medication
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DIsCussIOn
Digital clubbing is considered typical in IPF and has been associated with poor prognosis 
of disease. Yet, there is little knowledge on prevalence and clinical meaning of clubbing 
in other fibrotic lung diseases. This is the first study to assess multiple methods for mea-
suring clubbing in a large fibrotic ILD cohort. Agreement between the different clubbing 
measuring methods was poor to moderate. Prevalence of clubbing ranged from 7-42% 
in the fibrotic ILD cohort and from 7-52% in patients with IPF. Clubbing did not correlate 
with disease severity or quality of life scores.
table 2. Questionnaire and pulmonary function test scores for the total group of patients and patients with 
idiopathic pulmonary fibrosis
Questionnaires Total group
(n=137)
IPf
(n=62)
others
(n=75)
P-value*
K-BILD psych 54 (22-100) 50 (22-76) 57 (32-100) <0.01
K-BILD BA 41 (0-100) 38 (0-80) 43 (0-100) 0.10
K-BILD chest 68 (17-100) 69 (32-100) 68 (17-100) 0.51
K-BILD total 55 (27-91) 53 (27-72) 57 (34-91) 0.04
EQ-5D-5L VAS 65 (20-100) 63 (20-100) 66 (20-100) 0.40
EQ-5D-5L index value 0.8 (-0.01-1.0) 0.7 (-0.01-1.0) 0.8 (0.2-1.0) 0.37
VAS cough 40 (0-100) 43 (0-92) 38 (0-100) 0.46
VAS breathlessness 48 (0-98) 51 (8-98) 46 (0-97) 0.38
VAS fatigue 49 (0-98) 52 (3-97) 46 (0-98) 0.41
VAS general health 41 (0-99) 44 (0-97) 39 (0-99) 0.41
GFI 3.7 (0-11) 4.0 (0-10) 3.5 (0-11) 0.45
ICECAP-O 0.8 (0.3-1.0) 0.8 (0.3-1.0) 0.8 (0.4-1.0) 0.31
Data is presented as mean (range). * Independent sample t-test: IPF versus others
K-BILD, King’s Brief Interstitial Lung Disease health status questionnaire; psych, psychological domain; BA, breath and ac-
tivities domain; EQ-5D-5L, euroqol-5D-5L; VAS, visual analogue scale; GFI, Groningen frailty indicator; ICECAP-O, ICEpop 
CAPability measure for Older people.
A higher score indicates better quality of life
A higher score indicates worse cough, breathlessness, fatigue, frailty and capability
table 3. Cohen’s kappa values of agreement for different clubbing measuring methods 
Digital index Phalangeal depth ratio schamroth sign at sight
Left Right Physician 
PDR – right 0.20 0.68
PDR – left 0.21
Schamroth sign test 0.02 0.01 -0.07
Physician -0.12 -0.30 -0.25 -0.07
Investigator -0.11 -0.47 -0.40 -0.12 0.62
Presence of clubbing is rated as yes or no, with a cut-off for digital index of ≥10.2 and for the phalangeal depth ratio of 
>1.0 indicating clubbing. IPF, idiopathic pulmonary fibrosis; CVD, collagen vascular disease, CHP, chronic hypersensitivity 
pneumonitis; PF, pulmonary fibrosis; ILDs, interstitial lung diseases
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etiology of clubbing
The exact cause of clubbing is unknown, though several theories have been proposed. 
The most plausible seems to be the “platelet” theory, which is supported by outcomes 
of various studies.8,20-23 In this theory, clubbing is explained by a dysfunction of the 
fragmentation of megakaryocytes into platelets in the lungs. Normally, megakaryocytes 
enter the pulmonary circulation and are fragmented into platelets when going through 
the small calibre vessels of the pulmonary capillary bed.21 Alterations of the lungs or 
systemic circulation, as caused by for instance lung tumours, pulmonary fibrosis or 
right-to-left intracardiac shunts, can cause entire or large fragments of megakaryocytes 
to enter the systemic circulation instead of the pulmonary circulation.8,24 The mega-
karyocytes become impacted in the distal limbs circulation and release platelet-derived 
growth factor (PDGF) and vascular endothelial growth factor (VEGF).23 The occlusion 
of the capillaries leads to a hypoxic environment which further promotes PDGF and 
VEGF release. PDGF and VEGF promote growth, vascular hyperplasia and permeability, 
oedema, chemotaxis, connective tissue changes and proliferation of fibroblasts and 
osteoblasts, characteristic for clubbing.
Clubbing measuring methods
In daily practice clubbing is assessed at sight, however changes are often subtle and 
presence of clubbing can be debated in those situations. Several more objective meth-
ods have been proposed to assess clubbing, but no “gold standard” exist. In the current 
study, clubbing was measured with the digital index, phalangeal depth ratio and Scham-
roth sign test, and rated at sight by the treating physician and investigator. Although 
clubbing is considered an important clinical feature, assessment methods for clubbing 
showed no to poor agreement in the current study. Only kappa values of agreement 
(0.62) for the physician and investigator were moderate (table 3), which corresponds 
with findings from previous studies, where kappa-values ranged from 0.39 to 0.90.6 
Apparently, the physician and investigator recognize something on sight that current 
measuring methods fail to detect. The poor agreement found between the clubbing 
table 4. Prevalence of clubbing in fibrotic ILDs according to the different clubbing measurements
N (%)
Digital
index
Phalangeal
depth ratio
schamroth
sign
at sight
≥10.2 Left Right Positive Physician Investigator
Total group 10 (7) 50 (33) 47 (31) 12 (8) 63 (41) 64 (42)
IPF 5 (7) 21 (31) 19 (28) 6 (9) 35 (52) 27 (40)
Underlying CVD 1 (5) 3 (16) 3 (16) 2 (11) 7 (37) 8 (42)
CHP 0 (0) 6 (50) 5 (42) 1 (8) 5 (42) 6 (50)
Fibrosing pulmonary sarcoïdose 0 (0) 4 (27) 3 (20) 0 (0) 3 (20) 5 (33)
Unclassifiable PF 0 (0) 6 (35) 7 (41) 1 (6) 6 (35) 8 (47)
Various fibrotic ILDs 4 (18) 10 (46) 10 (46) 2 (9) 7 (32) 10 (46)
IPF, idiopathic pulmonary fibrosis; CVD, collagen vascular disease, CHP, chronic hypersensitivity pneumonitis; PF, pulmonary 
fibrosis; ILDs, interstitial lung diseases
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methods was surprising. We assessed both hands, as it might be that circulation differs 
in the dominant hand, but found no differences in clubbing. When using the phalangeal 
depth ratio’s, a mean of 0.97 (SD 0.07) for the left index finger and 0.96 (SD 0.08) for the 
right was found, which corresponds with previous studies in COPD and bronchogenic 
carcinoma, and is higher than scores found in healthy subjects.6 
Prevalence of clubbing
The poor agreement between the assessment methods leads to clubbing prevalences 
ranging from 7-42% in the total group of patients and 7-52% for IPF in our study. Previous 
literature also showed varieties of clubbing prevalences in fibrotic ILDs (table 5), which 
may be partly due to different assessment methods, though most of the assessments 
were done by a physician or investigator. The lower percentage of clubbing found with 
the Schamroth sign test and digital index compared to the phalangeal depth ratio and 
ratings at sight, suggest that these methods assess only the more severe clubbing. As 
there is no “gold standard” to assess clubbing, caution should be placed on putting too 
much emphasis on the diagnostic supportive role of the presence or absence of clubbing.
Clubbing, disease severity and quality of life
In previous studies in IPF, clubbing was found to have a prognostic implication.5,14 If 
this hold true for other fibrotic ILDs remains unclear to our knowledge. We found that 
TLCOc was significantly lower in patients with IPF than in patients with other fibrotic 
ILDs, and in patients with than without clubbing. However, symptoms and general QoL 
scores did not differ between patient with and without clubbing and, strikingly, also not 
between IPF and other fibrotic ILDs. Only the K-BILD psychological domain and total 
scores were significantly worse in patients with IPF, but they did not reach a minimal 
important difference (8 points).37 This is in contrast to a previous study of Wapenaar et 
al. that showed a more impaired QoL in patients with IPF.38 It might be explained by less 
difference found in lung function between our groups than in other studies. 
table 5. Clubbing frequencies in previous literature
Percentages of clubbing measuring method
IPF 13-73 15,9,14,25-31
Underlying CVD Unknown
CHP 23-54 110,32
Fibrosing pulmonary sarcoïdose 4-6 19,33
Unclassifiable PF Unknown
Various fibrotic ILDs
Asbestosis 32-43 134, 235,36
NSIP 18-20 19,25
1. Observed by the physician or investigator as present or absent
2. Estimated if hyponychial angle was ≥195°
IPF, idiopathic pulmonary fibrosis; CVD, collagen vascular disease, CHP, chronic hypersensitivity pneumonitis; PF, pulmonary 
fibrosis; ILDs, interstitial lung diseases; NSIP, non-specific interstitial pneumonia
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anti-fibrotic drugs
The clinical behaviour of clubbing is dependent on the underlying disease. In patients 
receiving a lung transplant, clubbing completely disappears after some time.39,40 The 
same phenomenon has been observed in patients with clubbing associated with inflam-
matory bowel disease that were successfully treated.41,43 If clubbing could be stabilised 
or reversed by successfully treating pulmonary fibrosis is not known. Neither is known 
if the underlying hypothesized pathway of clubbing itself could be influenced by anti-
fibrotic treatment. One of the anti-fibrotic drugs, nintedanib, is a tyrosine-kinase inhibi-
tor, that targets, among others the platelet derived growth factor receptor (PDGFR) and 
slows down lung function decline.44 As the PDGF likely plays a role in the pathogenesis 
of clubbing,42 nintedanib may hold properties to influence clubbing. If the presence 
of clubbing might be associated with a different phenotype of disease or a different 
response to therapy is unknown. Though the idea of clubbing being a potential easy 
physical marker of response to anti-fibrotic therapy is attractive, we first need to be able 
to assess and quantify clubbing in a reliable way. 
COnCLusIOn
Although clubbing is considered an important clinical feature in IPF and has been as-
sociated with poor prognosis, different methods to assess clubbing showed no to poor 
agreement. The prevalence of clubbing in fibrotic ILDs ranged from 7-42%. Further stud-
ies are needed to gain more insight into measuring clubbing reliably, and the possible 
prognostic value and evolution of clubbing.
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supplementary table 1. Various fibrotic interstitial lung diseases
Diagnoses n (%)
Non-specific interstitial pneumonia 5 (3)
Interstitial pneumonia with autoimmune features 3 (2)
Desquamative interstial pneumonia 3 (2)
Pleuroparenchymal fibroelastosis 2 (1)
Drug induced 1 (1)
Antisynthetase syndrome 1 (1)
Cryptogenic organizing pneumonia 1 (1)
Mixed dust pneumoconiosis 1 (1)
Follicular bronchiolitis 1 (1)
Hermansky Pudlak syndrome 1 (1)
Rheumatoid arthritis 1 (1)
ILD, exact diagnosis not yet known 1 (1)
ILD, interstitial lung disease
supplementary table 3. Correlations between clubbing measurements and questionnaire scores and lung 
function parameters
Digital index Phalangeal depth ratio
Left index finger Right index finger
K-BILD psych 0.12 0.04 0.04
K-BILD BA 0.11 <-0.01 0.05 
K-BILD chest 0.02 -0.10 -0.09 
K-BILD total 0.11 0.021 0.04
EQ-5D-5L VAS 0.19* <0.01 0.03
EQ-5D-5L index value 0.15 <-0.01 0.03
VAS cough -0.09 -0.12 -0.13
VAS breathlessness -0.14 -0.01 -0.05 
VAS fatigue -0.23** -0.13 -0.13 
VAS general health -0.07 -0.02 0.04 
GFI -0.06 0.03 -0.03 
ICECAP-O 0.22* 0.12 0.14
FVC % predicted <-0.01 -0.08 -0.07 
FEV1 % predicted 0.12 <-0.01 -0.06
TLCOc % predicted -0.10 -0.09 -0.02
* p<0.05 and ≥0.01, ** p<0.01
K-BILD, King’s Brief Interstitial Lung Disease health status questionnaire; psych, psychological domain; BA, breath and ac-
tivities domain; EQ-5D-5L, euroqol-5D-5L; VAS, visual analogue scale; GFI, Groningen frailty indicator; ICECAP-O, ICEpop 
CAPability measure for Older people; FVC, forced vital capacity; FEV1, forced expiratory volume in the first second; TLCOc, 
transfer factor for carbon monoxide corrected for hemoglobine
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AbstrAct
Idiopathic pulmonary fibrosis (IPF) is a devastating, progressive and ultimately fatal lung 
disease. The combination of poor prognosis, uncertainty of disease course and severe 
symptom burden heavily impacts patients’ and their families’ quality of life. Though 
new antifibrotic drugs have been shown to decrease disease progression, the effect 
on health-related quality of life (HRQOL) has not been convincingly demonstrated. In 
a relentless disease such as IPF, striving to optimize HRQOL should complement the 
endeavour to prolong life. Unfortunately, there is a paucity of interventions improving 
symptoms and functionality for patients with IPF, and research focusing on symptom 
improvement, and assessing and optimizing HRQOL, is limited. 
This review summarizes the most recent insights into measuring and improving quality 
of life for patients with IPF, and discusses challenges in the management of this devas-
tating disease. Moreover, we postulate a new model for continuous care in IPF – ‘the 
ABCDE of IPF care’: assessing patients’ needs; backing patients by giving information 
and support; delivering comfort care by focusing on treating symptoms and taking into 
account Comorbidities; striving to prolong life by Disease modification; helping and 
preparing patients and their caregivers for the eventual end-of-life events that are likely 
to occur. 
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InTrODuCTIOn
Idiopathic pulmonary fibrosis (IPF) is a devastating, progressive, fibrotic lung disease. 
IPF is characterized by irreversible loss of lung function, ultimately resulting in most pa-
tients dying from respiratory failure within 3-5 years. The most common symptoms are 
dry cough, dyspnoea and fatigue.1 Though the disease course may vary among patients 
and many patients experience periods of relative stability, disease progression and 
worsening of symptoms are inevitable for the majority of patients.2,3 The combination 
of poor prognosis, uncertainty of disease course and severe symptom burden heavily 
impacts quality of life (QOL) both for patients and family members.1,4,5 Recently, knowl-
edge on the pathogenesis of the disease has improved and has led to the development 
of two antifibrotic drugs that slow down disease progression as measured by decline 
in pulmonary function. Though these drugs are major steps forward for patients, IPF 
still remains a devastating and deadly disease. It is encouraging that multiple new 
compounds are currently investigated in clinical trials, aiming at modifying the disease 
course. The majority of these trials are focused on disease modification measured by 
physiological parameters, such as lung function. However, in many patients with IPF, 
there is no clear correlation between physiological parameters and patient-reported 
outcome measures (PROMs), such as health-related QOL (HRQOL) scores, that strive 
to reflect how a patient feels or functions. In a relentless disease as IPF, striving to 
optimize HRQOL should complement the endeavour to prolong life. There is a paucity 
of interventions that convincingly improve symptoms and functionality for patient with 
IPF. This review summarizes the most recent insights into measuring and improving QOL 
in patients with IPF and postulates an ABCDE of IPF care to facilitate a systematic and 
comprehensive approach to care for patients with IPF. 
heaLTh-reLaTeD QuaLITy Of LIfe In IPf PaTIenTs
Health-related quality of life refers to a person’s satisfaction with aspects of life that 
may be affected by health.6 As clinicians, we focus primarily on HRQOL since QOL is also 
determined by such aspects of life as freedom, quality of environment and financial 
situation. Nevertheless, with a relentless disease as IPF, almost all aspects of life can 
become health-related.6 Patients with IPF report an impaired HRQOL.1 Symptoms as 
dyspnoea, decreased mobility and cough are often important determinants of HRQOL.7,8 
HRQOL is generally assessed by PROMs.9 Often, there is a poor correlation between 
physiological assessments of disease severity by pulmonary function testing and patient 
reported outcomes of HRQOL and symptoms.10 Drugs that may modify the disease by 
slowing down the pace of lung function decline, do not convincingly improve patients’ 
overall symptoms or HRQOL.11,12 Therefore, complementary disease management strat-
egies are needed to improve HRQOL. 
Chapter 6
102
unmeT neeDs Of IPf PaTIenTs anD CareGIvers
Several recent initiatives have examined the needs of patients with IPF and their 
relatives.1,5,13-18 Though identifying patient-specific needs is crucial in the individual 
treatment relationship between a patient and care provider, it should be recognized 
that many basic conditions for IPF care are still frequently unmet. An initiative by 11 
European patient advocacy groups for pulmonary fibrosis identified five key themes 
of unmet needs: 1) better diagnosis, 2) better access to different treatment forms, 
3) availability of emotional support, 4) improved information resources, and 5) equal 
availability of palliative and end-of-life care.18 The European IPF Patients Charter was 
developed based on these outcomes (http://www.ipfcharter.org/call-to-action/). 
An interesting study by Overgaard and colleagues not only looked at the the unmet needs 
of patients with IPF, but also included family caregivers.5 They studied patients’ and 
caregivers’ experiences of living with IPF using extensive interviews of patients and their 
caregivers. In total, 25 patients and 24 family caregivers participated in the study. The 
main findings of their study showed a need for stepwise information and disclosure, and 
awareness of differences in reactions and wishes between patients and family caregivers.
A study by Russell and colleagues underscores the previous studies, pointing out a need 
for better diagnosis of IPF, access to high-quality information on IPF, and emotional sup-
port for both patients and family caregivers.19 Additionally, they found a need for better 
access to interstitial lung disease (ILD) specialist nurses, and highlighted the meaningful 
position of physicians and ILD specialist nurses as main contact persons for patients. 
Sampson et al. looked at the care needs of IPF patients and their carers in different 
phases of disease course.17 Carers was defined as ‘a person of the patient’s choice who 
contributed most to their care or, in the early stages of disease, provided emotional 
support’. Their study shows that although patients and carers had adequate knowledge 
of the overall prognosis of IPF, it was difficult for them to translate this knowledge 
regarding their own disease course and the corresponding psychological and physical 
treatment possibilities. It also recommended that patients and carers needed a differ-
ent approach to evaluating IPF in clinic, and that physicians should focus not only on 
lung function parameters, but also on overall health status, self-management, nutrition 
and explanation of disease progression. 
An under recognized problem, but with great impact on QOL, is the presence of sexual 
dysfunction in some patients with IPF. Erectile dysfunction has been associated with 
chronic obstructive pulmonary disease (COPD) and was reported to be a common 
problem in ILD.20,21
As a part of the US Food and Drug Administration’s (FDA) patient-focused drug develop-
ment program, a meeting was conducted with patients to examine their perspectives in 
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treatment approaches. This meeting underscored the need for better medication and 
symptom relief, in particular for shortness of breath, severe cough and fatigue.8
Numerous other studies have evaluated the unmet needs of patients with IPF and 
their family caregivers.13,14,16,22 All confirm the above-mentioned needs, and show the 
importance of holistic complementary care, focused on optimizing QOL in patients with 
IPF and their family caregivers. 
PaTIenT-rePOrTeD OuTCOme measures
A variety of tools are used to assess the impact of disease on QOL in IPF; however, there 
is a paucity of specific well-validated PROMs and a lack of consensus on which tools to 
use for care and research.9,23 Patient-reported outcomes (PROs) are defined as ‘any re-
port coming directly from the patient without interpretation by a third party about how 
they feel or function in relation to a health condition and given intervention’.24 The most 
commonly used PROMs in IPF are questionnaires originally developed to assess HRQOL 
in other chronic (respiratory) diseases. These questionnaires have been modified and 
revalidated for the IPF population. Two of these questionnaires often used in IPF stud-
ies are the Saint George Respiratory Questionnaire (SGRQ) and the Medical Outcomes 
Study 36-item short-form health survey (SF-36).25,26 Both are well validated and have 
proven to possess validity in assessing HRQOL in IPF.27,28 Despite these qualities, they 
have failed to convincingly show changes in HRQOL in the major IPF trials. The SGRQ has 
only shown some significant positive changes in the STEP-IPF trial (using sildenafil) and 
the INPULSIS 2 trial (using nintedanib). 
Since a few years, disease-specific PROMs have been developed and validated in IPF 
patients. A modified IPF version of the SGRQ (SGRQ-I) was created by statistical analysis 
(Rasch analysis) of the SGRQ data of a clinical trial in IPF.29 The SGRQ-I holds validity and 
reliability comparable with the original SGRQ,29 but the experience with the questionnaire 
is limited. The King’s Brief Interstitial Lung Disease health status questionnaire (K-BILD) was 
developed in a population of 124 patients with mixed ILD’s and 49 patients with IPF.10,30 
The questionnaire is short (15 questions) and holds good psychometric properties. A Tool 
to Assess Quality of Life in IPF (ATAQ-IPF) was developed in a group of 95 IPF patients.31 
The questionnaire contains 43 items and is validated in the UK and the US.32 Longitudinal 
studies on the performance of the K-BILD and ATAQ-IPF are currently underway.
In addition, regarding IPF several symptom-specific questionnaires have been used. 
The most commonly used is the University of California San Diego Shortness of Breath 
Questionnaire (UCSD), which assesses dyspnoea.33 One of the IPF trials using the USCD 
was the ASCEND trial (using pirfenidone). Though patients in this trial experienced a 
significant reduction in their decline of lung function, no effect in UCSD scores was 
found.11 The Medical Research Council dyspnoea scale was found to be predictive of 
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disease progression, but its value to assess response to interventions in IPF is unclear.34 
The same limitation applies for other dyspnoea scoring tools, such as the Borg Rat-
ing of Perceived Exertion Scale and the Baseline Dyspnoea Index.35,36 Though by some 
estimates, over 80% of IPF patient’s experience cough, PROMs on cough in IPF are 
limited. Both the Leicester Cough Questionnaire (LCQ) and the Cough Quality of Life 
Questionnaire have been evaluated in IPF, but need further longitudinal validation.37,38 
Visual analogue scales are also used to assess the severity, frequency and impact of 
cough.39 LCQ and cough-VAS show correlation with objective cough counts.40,41 Though 
fatigue is often a problem in IPF, to our knowledge, no validated fatigue PROMs exist 
for IPF. Anxiety and depression are estimated to be present in around 25% of patients 
with IPF and are important to recognize.4,42 Although no IPF specific tools exist to screen 
for anxiety and depression, in general practice common tools such as Hospital Anxiety 
and Depression Scale and the Centre for Epidemiologic Studies Depression are often 
used.42,43 It is important to realize that though PROMs were initially mostly developed 
for use in clinical trials, their use is much broader. Using PROMs in routine care can im-
prove communication, detect unrecognized needs and problems, and serve as outcome 
measures for interventions.44-46
OPTImIzInG QuaLITy Of LIfe
Symptoms, perceptions and reactions all interact, and together they influence HRQOL 
for patients with IPF (Figure 1). This interacting balance wheel of symptoms, perception 
and reaction varies among patients, but also often changes within individual patients 
during the disease course (Figure1). 
A synchronized comprehensive management strategy is vital to match patients’ needs 
throughout the disease course.47 Below, we focus on interventions and treatments that 
may have a positive effect on HRQOL in IPF. To facilitate a systematic and comprehensive 
approach to IPF care, we postulate to use an ‘ABCDE of IPF care’ (Figure 2). 
assess patients’ needs and values
At time of diagnosis, careful discussion of preferences and needs of care should com-
mence, allowing the patient and family caregivers time and space to cope with the 
diagnosis and information given. Not only will individual patients have different needs 
and preferences, the success of therapies and interventions will also depend on patient 
factors such as expectations, experiences and motivations. Continuous reassessment 
of the individual patient’s wishes and adaptation of interventions is crucial. Good col-
laboration between patients and health care providers is the foundation for good care. 
Both need to trust and respect one another. The patient is obliged to inform the health 
care provider correctly, while the health carer is committed to provide the best care 
possible for this patient. Lee and colleagues elegantly modelled this patient-provider 
relationship as the foundation of care of the IPF patient.47 Family caregivers should be 
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involved from the onset of the disease and supported as they are the main support for 
the patient.5,48
backing patients
Education is one of the crucial factors that empowers patients to make realistic choices 
and to play an active role in their care. The need for information is universal for pa-
tients with IPF and their families, and is iterated in all initiatives on identifying patient 
needs.5,18,19 Nowadays, many patients diagnosed with IPF and their relatives turn to 
online sources of health information. Fisher and colleagues showed that these online 
sources are frequently of poor quality, outdated, or not available in the patients‘ native 
language.49 In daily practise, clinicians and ILD specialist nurses play a central role in pro-
viding information and guiding patients to sources of information and support. Though 
information is such a crucial factor, research on best practices of educating patients and 
partners is scarce. Some recent studies underlined that information should be gradu-
ally paced, and dyssynchrony between patient and partners in coping with the disease 
should be taken into account.5,50 
Over the last several years, support groups for patients with IPF have expanded (http://
www.pulmonaryfibrosis.org/life-with-pf/support-groups). Support groups can decrease 
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figure 1. Balance wheel of symptoms, perception and reaction in patients with idiopathic pulmonary fibrosis.
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anxiety and depression, are helpful in educating patients and family caregivers, and can 
improve wellbeing.51 In oncology, support groups have shown their merits in improving 
QOL.52,53 In IPF, unfortunately, only few studies have looked at the effect of support 
groups on the QOL of patients and family caregivers. Lindell and colleagues found that 
a 6-week disease-management program, surprisingly, decreased HRQOL and increased 
anxiety scores in IPF patients.54 Nevertheless, stress scores declined in their partners, 
and all participants found participation beneficial. Contrary to the study of Lindell and 
colleagues, unpublished data shows that a 3-week multidisciplinary patient and partner 
empowerment program for IPF (PPEPP) improved QOL.55 Patient advocacy groups can 
also play a role in providing information, support and contact with other patients to 
share experiences. Besides this, patients should be advised on preventative measures. 
Although no convincing evidence exists on the benefits of vaccination in IPF, influenza 
and pneumococcal vaccinations are generally advised. If patients still smoke they should 
be strongly encouraged to quit smoking. 
Trials remain crucial to advancing mechanistic insights and stimulating the develop-
ment of better therapies and intervention aimed at disease modification and improving 
HRQOL in IPF. A national survey of pulmonary fibrosis patients and family caregivers 
presented at the PFF Summit 2015 showed that healthcare providers discussed the 
trials that were currently being conducted with only 55% of their patients (http://
www.viddler.com/v/197d1e49). Collaboration between patients, family caregivers and 
researchers is essential to advance care in IPF. Moreover, information about ongoing 
research projects and registries should be made available to enable patients to make 
choices on possible participation in clinical trials and registries. 
Comorbidities and Comfort care
Adequate symptom relief is another crucial aspect in optimizing the QOL of patients and 
family caregivers.47 IPF is a disease with a high symptom burden for patients. Symptoms 
often escalate due to the progressive nature of IPF. In patients with IPF comorbidities 
are frequent and may importantly contribute to symptom burden and QOL.56 Identi-
fication and treatment of comorbidities may improve QOL and potentially influences 
prognosis.57 In the next section, we will review measures that may positively influence 
the most common symptoms patients with IPF experience; dyspnoea, cough, fatigue/
deconditioning and depression/anxiety.8 
Dyspnoea
Dyspnoea is defined by the American Thoracic Society (ATS) as ‘a subjective experience 
of breathing discomfort that consists of qualitatively distinct sensations that vary in 
intensity’.58 Almost all patients with IPF experience progressive dyspnoea, resulting in a 
major impact on their QOL; living with breathlessness impacts all aspects of daily life. 
Anxiety and avoidance of exertion lead to deterioration of functional impairment and 
social limitations.59 Dyspnoea and change in dyspnoea is also an independent predictor 
of survival34,60,61 and has a complex pathophysiology. Possibly, numerous factors – such 
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as mechanics related to the disease as well as psychological and neurological factors – 
play a role.58 Hence, it is useful to understand that hypoxemia does not always result in 
dyspnoea sensations in patients with IPF. 
Data on managing IPF-related dyspnoea is scarce. It is important to first rule out co-
morbidities, such as pulmonary hypertension, cardiac disease, muscle weakness, sleep 
disorders and psychosocial factors. Although antifibrotic therapies have a disease modi-
fying effect and slow down decline in lung function, they do not reduce dyspnoea. There 
are a few small scale studies suggesting a beneficial effect of supplemental oxygen on 
dyspnoea and exercise capacity in patients with IPF.62-64 However, supplemental oxygen 
can also decrease patients’ QOL as it may restrict daily activities, can be expensive, and 
makes the disease more visible.65 Some patients regard the initiation of oxygen therapy 
as a negative landmark in their disease and, as such, often try to postpone start-up. To 
increase acceptability, compliance and efficacy of supplemental oxygen, careful atten-
tion should be paid to the delivery system (e.g. pulse versus continuous, portable versus 
home-based). 
Pulmonary rehabilitation is widely used to improve exercise capacity in patients with 
chronic disease. In IPF, pulmonary rehabilitation programmes have also been shown 
to improve dyspnoea, QOL, physical activity and body composition.66-68 Unfortunately, 
improvements seem to decrease after finishing the program. Therefore, patients should 
be encouraged to attend a pulmonary rehabilitation maintenance programme, which 
may prolong the positive effect of participating. 
There is a lack of good quality studies on the effect of opioids on dyspnoea symptoms in 
patients with IPF. The few existing studies show systemic opioids may have a favourable 
effect on patients’ experience of dyspnoea.69 As opioids are often seen as end-of-life 
care and may also have unfavourable side effects, such as constipation and sleepiness, 
conscientious explanation on their use and anticipation of side effects is recommended. 
Colman and colleagues demonstrated in a small study that opioids can also be safely 
prescribed to those patients with ILD on the waiting list for lung transplants.70 In a co-
hort of 38 patients taking chronic opioids for their dyspnoea, there was no respiratory 
depression and no clinically important opioid toxicity. Furthermore, they observed a 
trend toward increased exertion during exercise sessions with opioids versus pre-
opioids. ATS, for example, recommends opioids as a treatment option for patients with 
chronic respiratory disease, but also, advises discussing drug choice and dosing with 
patient and family caregivers beforehand.71
There are some indications that sildenafil might decrease dyspnoea and improve QOL 
in patients with IPF.72 However, debate on this exists and more research is needed.73 A 
simple intervention that might be beneficial for patients with IPF is the use of a hand-
held fan. Booth and colleagues studied the feasibility of this fan in patients with chronic 
refractory breathlessness and found a decrease of symptoms in half of the patients.74
109
Optimizing quality of life in patients with IPF
ch
ap
te
r 6
Cough
No reliable data are available on the prevalence of cough in IPF. Almost 80% of patients 
with IPF experience some chronic cough, but the number of patients with severe dis-
abling cough may be lower.12,75 Nevertheless, cough is an invalidating symptom that 
can evoke spells of severe breathlessness and anxiety and may greatly impact patient’s 
social participation. Cough in IPF has been associated with disease progression.75 The 
exact underlying mechanism of cough in IPF patients is unknown, but is most probably 
‘multifactorial’ and driven by mechanical, biochemical and neurosensory changes, with 
an important role for comorbidities as well.76-78 
In the treatment of chronic cough in IPF, it is important to first exclude and treat un-
derlying co-morbidities. Frequent comorbidities are gastro-esophageal reflux disease, 
obstructive sleep apnoea (OSA), chronic sinusitis, emphysema, lung cancer, infection 
and COPD associated chronic bronchitis. Angiotensin-converting-enzyme inhibitors can 
also cause chronic cough directly after starting the medication, or even months later.79 
IPF-related cough is frequently refractory to antitussive therapy, and the management 
of cough in IPF often consists of trying different treatment approaches and can thus 
be frustrating for both patients and clinicians. Low dose steroids are regularly tried for 
cough in IPF though there is little data to support their effect.76 Considering the potential 
side effects and the fact that steroids as primary treatment for IPF have been associated 
with worse outcome, risk and benefits should be carefully balanced. In other respiratory 
diseases, opioids have been shown to decrease cough, although such evidence is absent 
in IPF data. Thalidomide has been shown to decrease cough in a small 24-week double 
blind study.39 As only 20% of screened patients completed the study and thalidomide 
has a severe side effect profile, we would not recommend it as routine treatment. Re-
cent findings suggest that the antifibrotic drug pirfenidone might have a positive effect 
on cough.80 As for nintedanib, its effect on cough is still unknown. While there are no 
convincing data on over-the-counter cough suppressants in IPF, some patients do report 
relieve with these agents and the risks of trying them are negligible. 
Fatigue and deconditioning
Many patients with IPF experience fatigue. The aetiology is multifactorial with factors 
such as deconditioning, reduction of skeletal muscle strength, cough, dyspnoea and 
hypoxemia likely to contribute. Additionally, comorbidities and psychological factors 
may play a role. Fatigue leads to fewer daily physical activities, resulting in a further 
decrease in exercise tolerance and muscle strength, which, in turn, increases the level 
of dependency and immobility, negatively affecting HRQOL and social participation. To 
objectively measure exercise capacity, a 6-minute walk test or cycle ergometry can be 
done.81
In the treatment of fatigue and deconditioning, it is again important to rule out comor-
bidities such as cardiac disease, depression and OSA. Referral to pulmonary rehabilita-
tion is, as for dyspnoea, recommended as treatment for fatigue and deconditioning 
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in IPF patients. Treatment is difficult, as patients find it hard to exercise due to their 
fatigue and dyspnoea. A decrease in exercise then provokes a downward spiral where 
muscle strength declines and leads to even less exercise.82 Early referral is advised as 
patients probably benefit most when there they are still able to exercise at full power.83 
In addition, oxygen supplementation can be given when hypoxemia limits exercise ca-
pacity; however, the exact benefits of oxygen therapy for fatigue in IPF patients are still 
unclear.64 The effects of pharmacological therapy for fatigue symptoms in IPF patients 
is unknown.47
Anxiety and depression
In general, patients with chronic diseases are more susceptible to such symptoms as 
anxiety and depression. Also, many patients with IPF and their partners experience 
these symptoms.48,84 In ILDs, percentages vary from 7% to 49 % for clinical meaning-
ful depression, and 9% to 12% for clinical meaningful anxiety.4,43,85,86 There is a known 
relationship between anxiety and breathlessness in other chronic diseases.87,88 Breath-
lessness causes anxiety, as patients panic when they cannot breathe and fear the next 
attack. But anxiety can, on the other hand, increase the perception of breathlessness.59 
It is stressful for family caregivers that they cannot help their loved ones during these 
attacks.22 Coughing can increase feelings of anxiety as it induces breathlessness as well. 
IPF patients also experience anxiety and depression due to the side effects of medica-
tion and the uncertainty about the disease course in the context of a poor prognosis. 
Depression and anxiety are not only essential in predicting the QOL for ILD patients, 
but can also aggravate breathlessness.42,84 Therefore, screening for depression and 
other underlying symptoms that can increase psychological stress and may decrease 
the patients QOL, is needed.42
In the treatment of anxiety and depression, it is important to look at comorbidities 
such as OSA, fatigue and polypharmacy. Again, referral to pulmonary rehabilitation can 
be beneficial.13,89 A valuable addition to pulmonary rehabilitation might be cognitive 
behavioural therapy (CBT).90 CBT focuses on the relationship between thoughts, emo-
tions, physical symptoms and behaviour, and enables people to cope with their nega-
tive thoughts.91 CBT has been shown to decrease anxiety and depression symptoms in 
patients with COPD and might be beneficial for all chronic physical diseases.42,91,92 In 
addition, ILD specialist nurses can play an important role in managing such symptoms 
as depression and anxiety. Since they are readily accessible and closely involved in the 
patient’s disease path, it is easier for patients to talk to ILD specialists about their con-
cerns and problems than doing so during their short visits to the doctor. Support groups 
can also help patients with their emotional struggles and are important for educating 
patients and their family caregivers.51 The effect of pharmacologic treatment for anxiety 
and depression, such as anti-depressant medication, has not been studied in IPF; thus, 
the need to use such treatment should be considered thoroughly for each patient.
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Disease-modifying treatment
The availability of two antifibrotic drugs with confirmed positive treatment effects 
has significantly changed the course of the disease and the hopes for patients.11,12 
Unfortunately, neither of these drugs cures IPF or completely halts disease progression, 
and lung transplantation remains the only curative treatment for the small minority 
of patients who are eligible for this major intervention. Although neither antifibrotic 
drug has convincingly demonstrated a positive effect on HRQOL, there is no evidence 
of negative reactions from side effects. It might well be that better tools are needed to 
detect changes in HRQOL. On the other hand, we should also consider the meaning of 
nonsignificant changes or stabilization of HRQOL for patients suffering from a disease 
that remains progressive. Furthermore, it might well be that disease modifying agents 
do not necessarily improve a patient’s HRQOL. Since HRQOL is determined by many 
aspects of life and disease, it is evident that complementary treatment strategies are 
needed. 
In the era before the availability of antifibrotic drugs, treatment goals gradually shifted 
during the course of the disease from more disease-centered management to more 
palliative measures.47 Currently, this shift is less obvious as even when lung function 
declines, the effect of the antifibrotic drugs may still be present.93 Furthermore, these 
drugs may prevent the development of acute exacerbation12,94-96 and thereby protect 
the patient from a sudden decline in HRQOL or even death. In clinical practice, reassess-
ing patients’ wishes and expectations, as well as incorporating the balance between 
efficacy and the burden of side effects, will guide decisions on discontinuation of anti-
fibrotic treatments. 
end-of-life care
Despite the fact that IPF has a prognosis worse than most malignancies,97 end-of-life 
care is far less developed in this area of medicine than in oncology. Experiences from 
oncology have taught us that early palliative care improves the QOL and the mood of 
patients with metastatic lung cancer, and this, in turn, has resulted in less aggressive 
care and better survival.98 There are a few issues that complicate end-of-life care in 
IPF. The disease is rare and relatively unknown to patients and the community. In 
qualitative interviews, patients and their relatives frequently rated their situation worse 
than patients with cancer. They perceived that in cancer everybody understands the 
seriousness of the disease and patients with cancer have “help coming from every di-
rection”.17 Another factor is the variable course of disease in IPF, in which sudden acute 
exacerbations can occur and prognosis is often unpredictable. Additionally, the timing 
of discussing end-of-life issues is difficult and should be tailored to the patients’ needs 
and wishes. There can also be dyssynchrony between patient and partners in wishing 
for information on this issue. Interactive questioning of patients in the Netherlands and 
Germany established that the majority of patients and partners prefer talking about the 
end-of-life early in the disease course, though we acknowledge that cultural differences 
may exist.48 It is useful, however, to realize that discussing end-of-life may be anxiety 
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provoking and can have a negative impact on HRQOL.54 Sampson and colleagues found 
that patients with IPF clearly understand their prognosis but struggle to understand 
how their disease will progress.17 Explaining the course of the disease, what to expect 
in the last phase, and palliative options may enable patients and families to make deci-
sions in line with their values. In a recent study, only 13.7% were referred to palliative 
care services,99 indicating that the use of palliative care teams is underutilised at the 
moment. Alternatively, Bajwah et al. showed that interdisciplinary community care 
conferences improved symptoms and QOL.100
Data from patients with other terminal diseases suggest that the majority of patients 
would prefer to die at home.101 Lindell and colleagues showed that in a US cohort of 
patients more than half of the patients died in hospital, a third on the ICU, and the re-
maining patients died in a hospice.99 European experiences showed that more patients 
died at home compared with the US study, but still the majority died in the hospital.102 
Hospital admission for respiratory-related causes in IPF is associated with high in-hospital 
mortality.103 The limited options and devastating outcomes of hospital admission in the 
end-stage of the disease should be discussed with patients in an early phase to enable 
them to make decisions on limitations of care and allow them to choose the place of dy-
ing. At the patient’s request – if this is legally possible in the country where the patient 
is seeking treatment – different options of dying should also be discussed. Currently, 
worldwide, euthanasia has been legalized under strict conditions in a few countries.104 
In these countries, patients should be able to receive information on euthanasia. It is 
important to also discuss a ‘do not resuscitate’ code and a ‘do not intubate’ code with 
patients and family to avoid medical futility or unwanted interventions. 
COnCLusIOn
In a relentless disease such as IPF, striving to optimize HRQOL should complement the 
endeavour to prolong life. As symptoms, perceptions and reactions interact and may 
change, a synchronized comprehensive management strategy is vital to match patients’ 
needs throughout the disease course. To do so, we propose the ABCDE of IPF care: 
Assess patients’ needs; give information and support to Back patients; deliver Comfort 
care by focusing on treating symptoms also taking into account Comorbidities; strive to 
prolong life by Disease modification; and help and prepare patient and family for the 
End-of-life. To optimize quality of life for patients with IPF, we need to provide patient-
centered care that is comprehensive and not mainly focused on disease modification 
therapies. 
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Cough in idiopathic pulmonary fibrosis
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AbstrAct
Many patients with idiopathic pulmonary fibrosis (IPF) complain of chronic refractory 
cough. Chronic cough is a distressing and disabling symptom with a major impact on 
quality of life. During recent years, progress has been made in gaining insight in the 
pathogenesis of cough in IPF, which is most probably “multifactorial” and influenced 
by mechanical, biochemical and neurosensory changes, with an important role for 
comorbidities as well. Clinical trials of cough treatment in IPF are emerging, and cough 
is increasingly included as a secondary endpoint in trials assessing new compounds for 
IPF. It is important that such studies include adequate end-points to assess cough both 
objectively and subjectively. This article summarizes the latest insights into chronic 
cough in IPF. It describes the different theories regarding the pathophysiology of cough, 
reviews the different methods to assess cough and deals with recent and future devel-
opments in the treatment of cough in IPF.
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InTrODuCTIOn
Idiopathic pulmonary fibrosis (IPF) is a progressive lung disease of unknown cause with a 
median-survival of 3-5 years after diagnosis.1 Treatment of IPF aims at slowing or stopping 
the disease progression, increasing survival, reducing symptoms and improving quality of life 
(QoL).2 Currently, two anti-fibrotic drugs are available that slow down disease progression.3,4 
In a small minority of patients lung transplantation is an option which can increase survival 
and improve QoL. Alleviating symptoms and improving QoL in IPF is often a major challenge 
to treating clinicians. Patients report that the symptoms that have the greatest impact on 
daily life are cough, shortness of breath and fatigue or malaise.2 Chronic cough in IPF is not 
only often refractory, but is also an independent predictor of disease progression.5 Better 
understanding of the underlying mechanism(s) causing cough in IPF and better treatments 
are clearly needed. This review summarizes the latest insights on chronic cough in IPF.
CharaCTerIsTICs anD DemOGraPhICs Of ChrOnIC COuGh
Chronic cough is defined as a cough lasting for at least 8 weeks. In the general population 
it has a prevalence of 9 to 33% in the USA and Europe.6 It is a frequent reason for seek-
ing medical advice, with a high number of medical consultations.7 The most important 
risk factor for chronic cough is cigarette smoking. Prevalence of chronic cough is three 
times higher in chronic smokers as in never- or ex-smokers.6
No reliable data on the prevalence of cough in IPF exist. Some studies report that 
up to 80% of patients experience chronic cough;5,8 however, lower numbers are also 
reported.4 This may be attributed to method of reporting and the definition of cough 
used (any cough versus disabling cough). When cough is present in IPF, it is severe and 
difficult to treat.8 Cough is mostly nonproductive and dry, although some patients expe-
rience non-purulent sputum production, possibly related to traction bronchiectasis in 
advanced IPF or concomitant chronic obstructive pulmonary disease (COPD). The urge 
to cough cannot be relieved by coughing.9 
Cough frequency is high in patients with IPF, with median (range) 24-h cough counts vary-
ing from 226 (36-946) to 520 (117-1493) depending on the population studied.10,11 The 
cough frequency in IPF is similar to patients with chronic cough presenting to a cough 
specialist clinic, and higher than in patients with asthma or COPD (asthma median (range) 
24-h cough rate 62.4 (0-341), COPD ex-smokers 117.6 (range 14.4-648)).10,12 Strikingly, 
IPF patients experience more cough symptoms during daytime (median hourly cough 
rate 14.6 during the day versus 1.9 during the night), analogous with COPD and asthma 
patients.10,12 Chronic cough in IPF is not related to age or gender, and is more common in 
“advanced” disease and in never-smokers,5,10 the latter in contrast to chronic cough in the 
general population.6 There is no clear explanation why IPF patients without a history of 
smoking cough more, but this may be related to the phenotype of IPF.13
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effeCT On The PaTIenT
In general, chronic cough can impact severely on different aspects of life.14 Problems 
with sleeping, raucous vocal sounds and musculoskeletal pain of the chest can occur.9 
Chronic cough can cause relationship difficulties, avoidance of public areas, decreased 
social interaction and work-related problems affecting physical, mental and social 
health.14,15 In IPF, the limited studies about cough and QoL also show that cough is a 
very disabling and distressing symptom impacting QoL.9,10 Some patients also experi-
ence cough-related urinary incontinence with dramatic impact on QoL.16 Moreover, 
the social impact of chronic cough in IPF further compounds limited exercise ability, 
reduced walking distance and the need to use supplemental oxygen. 
PaThOPhysIOLOGy Of ChrOnIC COuGh
A detailed overview of the pathophysiology of cough is beyond the scope of this review; 
however, a summary of the mechanisms that may play a role in cough in IPF17 is shown 
in figure 1. Imbalance between stimuli and responses results in increased coughing. Mi-
nor stimuli such as laughing, talking, smoke, perfume and temperature changes already 
induce a cough reflex.6,18 This has also been named cough hypersensitivity syndrome 
and can occur in patients with and without pulmonary disease.19
No reliable data on the prevalence of cough in IPF exist. Some studies report that up to 80% of patients
experience chronic cough [5, 8]; however, lower numbers are also reported [4]. This may be attributed to
method of reporting and the definition of cough used (any cough versus disabling cough). When cough is
present in IPF, it is severe and difficult to treat [8]. The cough is mostly nonproductive and dry, although
some patients experience nonpurulent sputum production, possibly related to traction bronchiectasis in
advanced IPF or concomitant chronic obstructive pulmonary disease (COPD). The urge to cough cannot
be relieved by coughing [9].
Cough frequency is high in patients with IPF, with median (range) 24-h cough counts varying from 226
(36–946) to 520 (117–1493) depending on the population studied [10, 11]. The cough frequency in IPF is
similar to patients with chronic cough presenting to a cough specialist clinic, and higher than in patients
with asthma or COPD (asthma median (range) 24-h cough rate 62.4 (0–341), COPD ex-smokers 117.6
(range 14.4–648)) [10, 12]. Strikingly, IPF patients experience more cough symptoms during daytime
(median hourly cough r te 14.6 during t e day versus 1.9 during the night), analogous with COPD an
asthma patients [10, 12]. Chronic cough in IPF is not related to age or gender, and is more common in
“advanced” disease and in never-smokers [5, 10], the latter is in contrast to chronic cough in the general
population [6]. There is no clear explanation why IPF patients without a history of smoking cough more,
but this may be related to the phe otype of IPF [13].
Effect on the patient
In general, chronic cough can impact severely on different aspects of life [14]. Problems with sleeping,
raucous vocal sounds and musculoskeletal pain of the chest can occur [9]. Chronic cough can cause
relationship difficulties, avoidance of public areas, decreased social interaction and work-related problems
affecting physical, mental and social health [14, 15]. In IPF, the limited studies about cough and QoL also
show that cough is a very disabling and distressing symptom impacting QoL [9, 10]. Some patients also
experience cough-related urinary incontinence with a dramatic impact on QoL [16]. Moreover, the social
impact of chronic cough in IPF further compounds limited exercise ability, reduced walking distance and
the need to use supplemental oxygen.
Pathophysiology of chronic cough
A detailed overview of the pathophysiology of cough is beyond the scope of this review; however, a
summary of the mechanisms that may play a r le in cough in IPF [17] is shown in figure 1. Imbal nce
between stimuli and responses results in increased coughing. Minor stimuli such as laughing, talking,
smoke, perfume and temperature changes already induce a cough reflex [6, 18]. This is also known as
cough hypersensitivity syndrome and can occur in patients with and without pulmonary disease [19].
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FIGURE 1 Pathophysiology of cough. TRPV1: transient receptor potential vanilloid 1; TRPA1: transient receptor
potential ankyrin 1; RAR: rapidly adapting receptor; SAR: slowly adapting receptor. Reproduced from [17] with
permission from the publisher.
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figure 1. Pathophysiology of cough.
TRPV1: transient receptor potential vanilloid 1; TRPA1: transient receptor potential ankyrin 1; RAR: rapidly adapting receptor; 
SAR: slowly adapting receptor. Reproduced from17 with permission from the publisher.
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The cough reflex has an afferent pathway, with sensory nerve fibres of the vagus nerve 
located in the ciliated epithelium of the upper airways and cardiac and oesophageal 
branches from the diaphragm.20 These afferent impulses go to the brain stem and 
cortical center, which are important in regulating the cough response. In response this 
activates the efferent motor pathway of the cough reflex, by sending impulses via the 
vagus, phrenic, and spinal motor nerves to the diaphragm, abdominal wall and muscles, 
resulting in cough.17,18,20
The afferent part of the cough reflex involves at least three broad classes of nerves: 
C-fibres, rapidly adapting receptors (RARs) and slowly adapting receptors (SARs).20 1) 
C-fibres are sensitive to thermal and chemical stimulation, such as capsaicin, citric acid 
and hypertonic saline. TRPV1 and TRPA1 are C-fibre receptors that are very responsive 
to chemicals.20,21 2) RARs are rapidly responsive to mechanical stimulation, such as 
changes in, for example, diameter, length, and compliance of the airways. RARs are also 
sensitive to changes in PH and osmolality but relatively insensitive to other chemical 
stimulation.22,23 3) SARs are highly sensitive to mechanical forces and are thought to be 
the afferent fibres involved in the Hering-Breuer reflex, which terminates inspiration 
and initiates expiration when the lungs are adequately inflated.20
Recently it has also been recognized that neuroplasticity, whereby nerves switch phe-
notype, can occur in different disease processes.24 Voluntary cough and the sensation of 
an urge to cough have their origin in the cerebral cortex.18
PaThOPhysIOLOGy Of COuGh In IPf 
The pathophysiology of chronic cough in IPF is still unknown and is complicated by the 
frequent confounding comorbidities in this population. Different concepts of the pos-
sible mechanisms of cough in IPF have been proposed.25
There is some evidence that the cough reflex sensitivity in patients with IPF is in-
creased,8,26 suggesting an upregulation of sensory fibres in the lungs.8,26 However, the 
studies assessing cough sensitivity were performed before the publication of the cur-
rent international guidelines for the diagnosis of IPF in 2011.1 Assuming that increased 
cough reflex sensitivity may play a role in at least part of the IPF population, the ques-
tion remains what causes this enhanced sensitivity. 
A possible explanation could be that mechanical distortion of the lung, caused by the 
fibrosis, directly influences nerve fibres. As RARs and SARs are sensitive to mechanical 
changes they could be influenced in sensitivity or quantity by the traction forces of the 
fibrosis.22,25 Nerves that inhibit cough might also be destroyed due to fibrosis.22 This 
corresponds with the finding of increased cough reflex sensitivity by mechanical stimu-
lation of the chest wall in IPF patients, compared with controls. An increased sensitivity 
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was especially found following low frequency stimulation of the posterior basal lung 
base, the area where lung fibrosis in IPF is typically most extensive.22 This mechanism 
may also explain the observation that cough seemed to be more frequent in advanced 
IPF, although in another study this correlation was not found.5,10 Moreover, this is in 
line with clinical findings that patients often report starting to cough when talking or 
not being able to stop coughing once they start. The transmission of vibration caused 
by talking or even coughing itself might lead to increased mechanical stimulation of the 
sensory receptors, perpetuating a cycle of more cough and more vibration.27
Another explanation of enhanced cough sensitivity could be the higher levels of neu-
rotrophins that have been found in the sputum of patients with IPF than in controls.8,25 
Neurotrophins induce the survival and development of different subgroups of sensory 
neurones and can also cause increased capsaicin sensitivity, enhancing cough reflex.8,25,26 
Immunohistochemical studies have shown that non-neuronal cell types, such as bron-
chial and alveolar epithelial cells, mesenchymal cells, lymphocytes and macrophages 
can express neurotrophins.28 In patients with idiopathic interstitial pneumonias, an 
increased expression of neurotrophins in the lung was shown, suggesting that they may 
potentially modulate sensory nerve proliferation and neuroplasticity.29 Immunoblots 
revealed more neurotrophin expression in IPF/usual interstitial pneumonia than in 
nonspecific interstitial pneumonia and respiratory bronchiolitis-associated interstitial 
lung disease.29 The underlying drivers of increased neurotrophin expression in IPF are 
unknown, although in other diseases inflammation is related to increased neurotrophin 
expression.30
Interestingly, cough is an independent predictor of disease progression and the amount 
of coughing is not clearly related to the pulmonary function measurements.10 Leslie31 
suggested that recurrent stretch injury caused by pressure changes during breathing 
may explain why fibrosis in IPF typically commences at the peripheral basal part of 
the lung. Leslie31 argues that in these areas the traction forces and alveolar collapse 
are greatest, leading to sheer stress, lung injury and activation of fibrotic cascades. By 
analogy, mechanical ventilation in IPF can be a risk factor for acute exacerbations of 
the pulmonary fibrosis.32 If pressure differences play a role in the pathogenesis of IPF, 
it could be speculated that the pressure differences caused by cough might influence 
disease behavior itself. One could hypothesise that cough is not only a symptom, but 
may also contribute to enhance activation of profibrotic mechanisms and disease wors-
ening in IPF.
Furthermore, cough could be evoked centrally through cortical influences. The urge to 
cough, induced by capsaicin inhalation, activates many areas of the cerebral cortex.33 
Administration of a placebo prior to capsaicin testing can decrease activity in several 
brain regions.34 This suggests that expectations of treatment can influence central pro-
cessing of peripheral sensory input.34 Suppression of cough by cortical influences could 
also explain why IPF patients cough less during their sleep.
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COmOrbIDITIes InfLuenCInG COuGh
In patients with IPF, a number of potential causes of chronic cough must be excluded 
before chronic cough may be considered directly linked to the underlying disease. In at 
least half of the patient comorbidities may play a role (table 1).35 
Gastro-oesophageal reflux disease (GORD) is highly prevalent in IPF, yet classical symp-
toms are often absent.37,38 GORD associated microaspiration of acid and non-acid reflux 
in the airway is thought to induce epithelial damage and may cause fibrosis.45 Traction 
caused by lung fibrosis also can result in a weakened lower esophageal sphincter, leading 
to gastro-oesophageal reflux and microaspiration.38,46 Cough receptors could be directly 
stimulated through aspiration of gastric secretion in the larynx and the upper airways.6 
Moreover, the presence of acid in the distal oesophagus may induce cough, probably 
through an oesophageal-tracheobronchial reflex.47 Disappointingly, a study of Kilduff 
et al. showed no improvement of cough by anti-acid treatments, but a paradoxical in-
crease in non-acid reflux. It might well be that non-acid reflux is influencing cough more 
than acidic reflux.48 Unfortunately, cough itself may also increase trans-diaphragmatic 
pressure and promote GORD.47
Obstructive sleep apnea (OSA) is common in IPF.39 OSA itself, with intermittent hypox-
aemia may promote profibrotic mechanisms.49 In the general population, chronic cough 
is more prevalent in OSA and can be improved by treatment with continuous positive 
airway pressure (CPAP).50 A complicating factor is that obstruction of the upper airway 
in OSA could increase a trans-diaphragmatic pressure differential promoting GORD.51,52 
GORD, on the other hand, may promote OSA, through microaspiration of gastric sub-
stance, creating an inflammatory reaction blocking the airway.53 GORD, chronic cough 
and, as recently shown, IPF can be improved by treatment of OSA.49,51 Figure 2 shows 
the interplay between IPF, GORD, OSA and cough. Further research is needed to disen-
tangle these interactions. 
table 1. Comorbidities influencing cough in idiopathic pulmonary fibrosis (IPF)
Comorbidity frequency in IPf (%) reference(s)
GORD 21 – 94 [36-38]
OSA 59 – 88# [38-40]
Emphysema 30 – 55 [41]
ACE inhibitor use 9 – 15 [5, 42]
Chronic sinusitis/ UACS 17 – 34 [5, 42, 43]
Lung cancer 4.4 – 16 [41, 44]
Infection 11 – 20 [3]
GORD: gastro-oesophageal reflux disease; OSA: obstructive sleep apnoea; ACE: angiotensin converting enzyme; UACS: up-
per airway cough syndrome. #: with high mean body mass index of 28-32 kg·m-2.
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Additional comorbidities not directly linked to IPF should also be evaluated, especially 
cardiovascular comorbidity and associated treatment. Left heart disease and the use 
of beta-blockers are possible causes of chronic cough. Angiotensin converting enzyme 
(ACE) inhibitor as a cause of chronic cough should always be checked. ACE inhibitors can 
cause enhanced cough receptor sensitivity leading to cough just after taking the drugs, 
but also even months later. Symptoms can improve days after drug removal, but can 
take longer to disappear completely.6 In the work-up of cough in IPF, infections, chronic 
sinusitis, COPD-associated chronic bronchitis and pulmonary malignancies should also 
be excluded. 
By analogy with chronic cough, we would recommend the visual analogue scale to measure the severity of
IPF related cough in a clinical setting, as it is fast and easy to use [60]. When designing a clinical trial,
validated subjective as well a objective cough outcome measures should be incorporated.
Treatment of cough in IPF
In clinical practice, cough in IPF is a major challenge for the treating physician and patient, as it is often
refractory. The first step in the management of chronic cough in IPF consists of addressing possible
comorbidities as described in table 1.
Conventional anti-tussive therapy is often not be eficial [8]. Oral corticosteroids have been shown to
improve cough symptoms in IPF patients in one small nonrandomised study [8], and low doses of
prednisone are sometimes tried in daily practice to relieve cough, and later are slowly tapered if beneficial.
However, no effect on QoL and survival was found and possible side-effects should be taken into
consideration. Although opiates are recommended in the palliative setting, their effect has not been proven
in IPF [1, 27]. Caution is warranted as opiates may influence the protective mechanism of cough, but
might be a useful option for palliation of severe cough in patients with advanced IPF. With respect to
GORD, no good evidence on the work-up and treatment of GORD-related cough in IPF exists, while the
effect of proton pump inhibitors on cough is debated [48, 61].
A 24 week single centre double-blind cross-over study with thalidomide for treatment of cough showed a
positive effect on QoL measured with the Cough Quality of Life Questionnaire. However, only 20% of the
screened subjects completed the study and the potential side-effects of thalidomide can be severe [43].
Thalidomide has anti-inflammatory and anti-angiogenic effects, similar to currently used anti-fibrotic
drugs. Its side-effect profile with dizziness and neuropathy suggests that it might also have effects on
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FIGURE 2 Interactions between idiopathic pulmonary fibrosis (IPF), gastro-oesophageal reflux disease (GORD),
obstructive sleep apnoea (OSA) and cough. 1: traction leading to a weaker lower oesophageal sphincter tonus [45];
2: microaspiration inducing epithelial damage [38, 46]; 3: restriction inducing instability of the upper airway [39];
4: intermitted hypoxaemia promoting profibrotic mechanisms [49]; 5: increased cough reflex sensitivity [22–31];
6: pressure causing stretch injury and activation of fibrotic mechanisms [31]; 7: microaspiration causing an
inflammatory reaction blocking the airway [53]; 8: obstruction increasing trans-diaphragmatic pressure [51, 52];
9: aspiration directly and acid reflux indirectly stimulate the cough reflex [6, 47]; 10: cough increasing
trans-diaphragmatic pressure [47]; 11: less central inhibition and inflammation increasing cough reflex
sensitivity [54].
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figure 2. Interactions between idiopathic pulmonary fibrosis (IPF), gastro-oesophageal reflux disease (GORD), 
obstructive sleep apnoea (OSA) and cough.
1: traction lea ing to a weaker l wer oesophageal sphincter tonus45; 2: microaspir tion inducing epithelial damage38, 46; 3: 
restriction indu ing i stability of the upper airway39; 4: intermitted hypoxaemia promoting profibrotic mechanisms49; 5: in-
creased cough reflex sensitivity22–31; 6: pressure causing stretch injury and activation of fibrotic mechanisms31; 7: microaspira-
tion causing an inflammatory reaction blocking the airway53; 8: obstruction increasing trans-diaphragmatic pressure51, 52; 9: 
aspiration directly and acid reflux indirectly stimulate the cough reflex6, 47; 10: cough increasing trans-diaphragmatic pres-
sure47; 11: less central inhibition and inflammation increasing cough reflex sensitivity54.
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assessmenT Of COuGh In IPf 
In recent years, many tools have been developed to assess different aspects of cough; 
subjectively with cough questionnaires or visual assessment scales, and objectively using 
cough recorders and cough challenge tests. All these instruments have been developed 
table 2. Cough measurements in idiopathic pulmonary fibrosis (IPF) patients
Cough measurement 
tool
Description validation studies 
and mCID
advantages Disadvantages
Subjective
Visual Analogue 
Scale56
100 mm scale 
with extremes no 
cough to worst 
possible cough 
severity
Not validated in IPF Easy to use
Repeatable 
Responsive
Not validated in 
IPF or chronic 
cough
Cough Quality-of-Life 
Questionnaire57
28-item cough-
specific quality-of-
life questionnaire 
with six domains
Validated in IPF 
(n=23) 
MCID in IPF: change 
of five points on a 
28-112 scale57
Comprehensive 
questionnaire
Reliable
Valid instrument 
for assessing 
impact of cough
Need more stud-
ies in IPF: MCID 
evaluated with 
a retrospective 
anchor scale
Leicester Cough 
Questionnaire15
19-item self-
administered 
chronic cough 
quality-of-life 
questionnaire with 
three domains
Evaluated in IPF:
high correlation 
found with cough 
visual analogue scale, 
cough symptom score 
and objective cough 
frequency in IPF10,22
MCID in chronic 
cough: 1.3
High reliability
Valid instrument 
for assessing 
impact of cough 
Ability to detect 
a response to 
change
Need more studies 
in IPF: MCID evalu-
ated in chronic 
cough 
Objective 
Cough challenge 
test58
Measurement of 
cough reflex sensi-
tivity by inhalation 
of nebulised tus-
sive agents (most 
common citric 
acid or capsaicin)
Not validated in IPF
No MCID
Standardized meth-
odology published 
by ERS14
Useful for testing 
effect of new 
cough therapies 
on cough reflex 
sensitivity and for 
obtaining mecha-
nistic insights 
Doesn’t measure 
efficacy of therapy 
or predict re-
sponse in patients
Limited availability
Cough monitor59 Microphone and 
recording device 
measuring cough 
in a pre-specified 
time slot
Validated cough 
monitors for chronic 
cough
High correlation 
found with subjective 
cough measure-
ments10
Measures cough 
frequency ac-
curately
Currently limited 
to research and 
trails 
Benefit in routine 
clinic is not clear 
MCID: minimal clinically important difference; ERS: European Respiratory Society.
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for chronic cough in a general population and are reviewed elsewhere.55 Experience and 
validation of these tools in patients with IPF are limited (table 2 provides an overview). 
By analogy with chronic cough, we would recommend the visual analogue scale to mea-
sure the severity of IPF related cough in a clinical setting, as it is fast and easy to use.60 
When designing a clinical trial, validated subjective as well as objective cough outcome 
measures should be incorporated. 
TreaTmenT Of COuGh In IPf
In clinical practice, cough in IPF is a major challenge for the treating physician and pa-
tient, as it is often refractory. The first step in the management of chronic cough in IPF 
consists in addressing possible comorbidities as described in table 1. 
Conventional anti-tussive therapy is often not beneficial.8 Oral corticosteroids have been 
shown to improve cough symptoms in IPF patients in one small nonrandomised study,8 
and low doses of prednisone are sometimes tried in daily practice to relieve cough, and 
later slowly tapered if beneficial. However, no effect on QoL and survival was found and 
possible side-effects should be taken into consideration. Although opiates are recom-
mended in the palliative setting, their effect has not been proven in IPF.1,27 Caution is 
warranted as opiates may influence the protective mechanism of cough, but might be a 
useful option for palliation of severe cough in patients with advanced IPF. With respect 
to GORD, no good evidence on the work-up and treatment of GORD-related cough in IPF 
exists, whilst the effect of proton pump inhibitors on cough is debated.48,61
A 24 week single center double-blind cross-over study with thalidomide for treat-
ment of cough showed a positive effect on QoL measured with the Cough Quality of 
Life Questionnaire. However, only 20% of the screened subjects completed the study 
and the potential side-effects of thalidomide can be severe.43 Thalidomide has anti-
inflammatory and anti-angiogenic effects, similar to currently used anti-fibrotic drugs. 
Its side-effect profile with dizziness and neuropathy suggest that it might also have 
effects on sensory nerves. Although these results advocate the need for further inves-
tigations, thalidomide should not be considered a routine treatment of cough in IPF, 
even as a second-line therapy, until further evaluation of the benefit/risk ratio has been 
undertaken. 
The majority of IPF patients are treated with one of the two new anti-fibrotic drugs, 
pirfenidone or nintedanib.62 Although the effect of these drugs on cough has not yet 
been evaluated, there are some indications of a possible effect on cough. Azuma et 
al.63 showed, in a subgroup analysis of the phase three trial in Japan, that pirfenidone 
seemed to reduce cough in patients with an forced vital capacity >70% and arterial 
oxygen saturation measured by pulse oximetry <90% predicted. Using a nonvalidated 
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cough score, a Dutch group also observed a reduction in cough with pirfenidone use.64 
In a guinea pig model, the capsaicin-induced cough reflex sensitivity was inhibited by 
pirfenidone in a dose-dependent manner.65 This effect was accompanied by a reduction 
of bronchoalveolar lavage mediators promoting cough sensitivity.65 No data currently 
exist on the effect of nintedanib on cough.
fuTure TrIaLs
Progress has been made in the treatment of “general” chronic cough. A combination of 
pregabalin and speech therapy has been found to improve cough and QoL more than 
speech therapy alone.66 Gabapentin, a neuromodulator, was shown to improve cough 
severity, cough frequency and QoL of patients with chronic cough.67 Physiotherapy 
aimed at suppressing cough improved sleep and cough frequency.68 Very recently AF-
219, a P2X3 receptor antagonist, showed very promising phase two results in chronic 
cough.69 
Many trials in IPF are emerging that assess the effect of these treatments or other novel 
medications on cough as either a primary or exploratory end-point, illustrating the need 
for better cough treatment in patients with IPF. Amongst these trials are studies on pir-
fenidone, AF-219, azithromycin, PA101, GSK2126458, laparoscopic anti-reflux surgery, 
supplemental oxygen, omeprazole and cognitive behavioral therapy (clinicaltrials.gov; 
searched using the terms “cough” and “IPF”; date last accessed: August 17, 2015).
COnCLusIOn
Chronic cough in IPF is a major problem for patients and treating physicians. The patho-
genesis of cough is most likely “multifactorial” and influenced by mechanical, biochemi-
cal and neurosensory changes. Comorbidities also have an important role, in particular 
GORD. While progress has been made in gaining insight into the pathogenesis of cough 
in IPF, more research is needed to find effective therapies. Clinical trials of cough treat-
ment in IPF have only recently started, with either compounds developed for “general” 
chronic cough or new compounds in development for IPF, which are also evaluated 
for their potential effect on cough. It is crucial that validated cough measurements are 
included in these trials. Hopefully these new studies will ultimately lead to adequate 
treatment of cough, thereby improving quality of life in patients with IPF. 
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AbstrAct
background
In patients with idiopathic pulmonary fibrosis (IPF), cough is a major unmet treatment 
need and independent predictor of disease progression. Clinical observations suggested 
that pirfenidone, an anti-fibrotic drug, decreased cough. We aimed to objectively assess 
the effect of pirfenidone on cough in patients with IPF.
Methods
In this multicenter, prospective, observational study, patients with IPF and a cough visual 
analogue scale (VAS) ≥40mm, about to start on pirfenidone, were recruited from four 
European centers. The primary endpoint was change in 24-h objective cough counts 
at 12 weeks compared to baseline, measured with the validated ambulatory Leicester 
Cough Monitor. Secondary endpoints included changes in subjective cough-related 
quality of life measured with the Leicester Cough Questionnaire (LCQ), cough severity 
with VAS, and quality of life with King’s Brief Interstitial Lung Disease questionnaire.
results
Of 46 patients screened for the study, 43 were included. Pirfenidone decreased ob-
jective 24-h cough by 34% (95% confidence interval (CI) -48 – -15; p=0.002) over 12 
weeks. Subjective measurements were consistent; LCQ scores improved by 2.0 points, 
(CI 1.0-3.0; p<0.001), cough VAS improved by 19 mm (CI -28 – -10); p<0.0001) and urge-
to-cough VAS improved by 18 mm (CI -26 – -10; p<0.0001). There were no significant 
changes in other quality of life scores.
conclusions
In patients with idiopathic pulmonary fibrosis suffering from cough, pirfenidone re-
duced objective 24-h cough counts and improved subjective measures of cough. The 
magnitude of these changes was clinically meaningful to patients.
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InTrODuCTIOn
Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive lung disease with a median 
survival of 3-5 years. One of the most disabling symptoms reported by patients with IPF 
is cough.1-3 A recent study reported that IPF patients cough on average 226 times per 
24-hours (range 36-946).4 Cough not only has a major impact on IPF patients’ quality of 
life (QoL), but is also an independent predictor of disease progression.2,4,5
In patients with IPF, cough is often non-responsive to anti-tussive therapy.6 Studies on 
cough in IPF are scarce and have unfortunately not yet resulted in effective treatments. 
Recently, pirfenidone, an anti-fibrotic drug which reduces disease decline measured by 
the forced vital capacity (FVC),7 was approved for treatment of IPF. Several observations 
have suggested that pirfenidone might decrease cough. Pirfenidone seemed to reduce 
cough in a post-hoc subgroup analysis of a phase III trial in Japan.8 Furthermore, pir-
fenidone inhibited cough reflex sensitivity in guinea pigs.9 To date, there are no studies 
prospectively investigating the effect of pirfenidone on cough in IPF. 
We aimed to objectively measure the effect of pirfenidone on cough in patients with 
IPF suffering from substantial cough. Additionally, we aimed to assess the effect of 
pirfenidone on subjective cough outcomes and QoL measures.
maTerIaLs anD meThODs 
study design and population
This study was an international, multicentre, prospective, observational study at four 
sites (Netherlands, Italy, France and UK) between December 2013 and June 2016. The 
study was approved by the ethics committees of all participating centers (e-Appendix 
1), and carried out according to the Declaration of Helsinki and good clinical practice. 
All patients provided written informed consent. An independent research organisation 
(Venn Life Science) monitored the study at all sites. The study was registered at clinical 
trials.gov, NCT02009293.
Treatment naïve IPF patients aged 40-85 years in whom pirfenidone therapy was about 
to be initiated according to regular practice, and who had daily cough related to IPF 
present for more than eight weeks with a cough score of ≥40 mm on a 0-100 mm visual 
analogue scale (VAS), were eligible for this study. Inclusion and exclusion criteria can be 
found in e-Table 1. 
outcomes
The primary outcome was the change in objective 24-h cough frequency at week 12 
compared to baseline. Secondary outcomes were: 1. change in cough frequency at 
baseline versus week 4; 2. change in subjective cough-related QoL and cough severity 
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and urge-to-cough at week 12 versus baseline; 3. the impact of cough on QoL, anxiety 
and depression at baseline, week 4 and week 12; 4. the change in cough frequency in 
relation to lung function; and 5. identification of clinical characteristics predictive of 
24-h cough.
Data collection
Leicester Cough Monitor (LCM) – objective measure
Patients underwent baseline 24-h ambulatory cough measurement with the LCM prior 
to starting with pirfenidone and after 4 weeks and 12 weeks of treatment. The LCM is 
a validated ambulatory cough monitoring system, which has been used in randomised 
controlled trials of therapy for patients with chronic cough.10-12 The LCM consists of an 
MP3 recording device and a small microphone attached to the patient’s clothes close to 
the neck. The cough monitor was set up in clinic and used by the patients at home for 
24 hours. Afterwards, the recordings were extracted from the recorders and centrally 
analysed with automated cough software as described previously.11
Questionnaires – subjective measures
On the days of cough recording, participants completed the Leicester Cough Question-
naire (LCQ), the VAS cough, VAS urge-to-cough, King’s Brief Interstitial Lung Disease 
health status questionnaire (K-BILD), the Hospital Anxiety and Depression Scale (HADS), 
the 7-item Generalized Anxiety Disorder screener (GAD-7) and Medical Research Coun-
cil questionnaire (MRC).13-17 
Physiological measures
Physical examination, symptom assessment, and pulmonary function tests were per-
formed at baseline, at week 4, and at week 12. 
statistical analysis
Parametric data are shown as mean (SD) and nonparametric data as median (range). 
Analyses were done on the intention-to-treat population. Objective cough frequency 
data were log transformed. To assess the effect of pirfenidone on cough over time we 
used a linear mixed model. This model imputes missing data.18,19 To determine the rela-
tionship between cough frequency, cough severity, cough-related QoL, QoL and pulmo-
nary function tests, Pearson’s correlation coefficients (r) were used. Sensitivity analyses 
were carried out on the per-protocol population with linear mixed models and paired 
t-tests. To identify clinical characteristics predictive of cough, a linear regression model 
was used. A two-sided p-value of less than 0.05 was considered statistically significant. 
SPSS Statistics version 21.0 and R version 3.2.2 were used for analysis. 
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resuLTs
Of 46 patients screened for the study, 43 patients were included (Figure 1). Thirty-
one patients completed the study with a mean follow-up of 92 days (range 77-104). 
Two cough recording errors occurred at baseline, two at week 4, and three at week 
12 (patients switched off recorder, incomplete recording, recording erased during 
transmission). Baseline patient characteristics are shown in Table 1. At baseline, 19% of 
participants reported having symptoms of gastroesophageal reflux disease (GERD). All 
of these patients were taking proton pump inhibitors (PPIs) for >4 weeks with no effect 
on their cough. Comorbidities and medications are shown in e-Table 2; none of the 
comorbidities were identified as causing the cough. 
5 drop-outs
3 stopped pirfenidone because of adverse event 
1 wished to con� nue treatment in local hospital
1 changed PPI a� er baseline visit
38 pa� ents completed week 4
3 pa� ents excluded
2 TLCOc < 30
1 TLCOc < 30 + VAS < 30
31 pa� ents completed week 12
46 pa� ents screened
43 pa� ents included
7 drop-outs
5 stopped pirfenidone because of adverse event 
1 stopped because of logis� c reasons
1 died because of pneumosepsis
figure 1. Flowchart cough study
table 1. Patients characteristics (n=43)
At baseline
(n=43)
Age (years) 72 (7)
Male 33 (77%)
Smoking status
Never 9 (21%)
Former 34 (79%)
FVC % predicted 78 (15)
TLCOc % predicted 51 (13)
Data are presented as mean (SD) or n (%). FVC, forced vital capacity; TLCOc, transfer capacity of the lung for carbon mon-
oxide, corrected for hemoglobin.
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At baseline, median 24-h cough counts were 520 (range 91-3394), with a higher median 
cough per hour during daytime (28; range 5-171) than at night (7.2; range 0.7-101) 
(Table 2). Patients also scored high on subjective cough scores, LCQ mean 12 (SD 4) and 
VAS cough 67 (SD 15) (Table 2). 
After 12 weeks of pirfenidone treatment, objective 24-h cough decreased by 34% (95% 
confidence interval (CI) -48% – -15%; p=0.002) (Table 3). Sensitivity analysis on the per-
protocol population showed similar improvements in 24-h cough; 35% decrease with 
the linear mixed model (p=0.002), and 36% decrease with the paired t-test (p=0.003) (e-
Table 3). At 12 weeks, 24-h cough frequency improved in 20/27 patients (74%), change 
per patient is shown in Figure 2. 
Subjective cough measures showed consistent outcomes. The LCQ improved after 12 
weeks by 2.0 points (CI 1.0-3.0, p<0.001) and the cough VAS by 19 points (CI -28 – -10, 
p<0.0001) (Table 3). No significant changes in disease-specific QoL measured with the 
K-BILD and anxiety, measured with the GAD-7 and HADS were found (Table 3). 
At 4 weeks, a decrease of 14% in 24-h cough frequency was found (95% CI -22% – -6%; 
p=0.002), with 24/35 patients (69%) showing an improvement. Lung function remained 
stable throughout the study; at 4 weeks mean FVC % predicted was 78% (SD 18) and at 
12 weeks FVC was 79% (SD 17). Also, TLCOc % predicted remained unchanged with a 
mean of 51% (SD 16) at 12 weeks. 
At baseline, objective cough scores correlated moderately with the MRC, LCQ and VAS 
cough and strongly with VAS urge-to-cough (Table 4). Cough frequencies did not corre-
table 2. Objective and subjective cough and health status measures
baseline
(n=43)
at 4 weeks
(n=38)
at 12 weeks
(n=31)
24-h cough 520 (91-3394) 511 (65-1947) 392 (75-1746)
Coughs per hour 23 (4-141) 22 (3-81) 17 (3-73)
Daytime 28 (5-171) 29 (4-106) 20 (4-121)
Nighttime 7.2 (0.7-101) 4.0 (0.3-45) 3.3 (0-54)
LCQ total 12 (4) 13 (3) 15 (4)
VAS cough 67 (15) 50 (20) 47 (27)
VAS urge-to-cough 68 (16) 53 (22) 49 (25)
MRC 3.1 (1) 2.9 (1) 2.8 (1)
K-BILD total 50 (22) 53 (22) 55 (23)
HADS anxiety 8.5 (4) 7.7 (4) 8.5 (4)
HADS depression 4.7 (3) 5.2 (3) 6.0 (3)
GAD-7 5.8 (6) 6.3 (6) 5.9 (6)
Data presented as median (range) or mean (SD). LCQ, Leicester Cough Questionnaire; VAS, visual analogue scale; MRC, 
Medical Research Council dyspnoea scale; K-BILD, King’s Brief Interstitial Lung Disease health status questionnaire; HADS, 
Hospital Anxiety and Depression Scale; GAD-7, Generalized Anxiety Disorder 7-item screener
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late with disease severity, measured with the FVC and TLCOc. There was no correlation 
between change in cough frequency and change in FVC (r=-0.03, p=0.897). 
To identify clinical characteristics predictive of cough, we used linear regression model 
with bootstrap (1000 samples) for coefficients as the residuals were not normally dis-
tributed. We found that gender (relative difference (RD) women 2.24 (CI 1.09-4.44), 
p=0.037) and smoking status (RD never-smoker 2.15 (CI 1.21-3.86), p=0.008) were 
significant predictors of 24-h cough in univariable analyses (e-Table 4). In a multivariable 
model both variables remained significant (RD women 2.09 (CI 1.02-3.88), p=0.029, and 
table 3. Effect of 12 weeks pirfenidone treatment on cough and health status measures, analyzed with a linear 
mixed model – intention-to-treat analyses (n=43)
Change 
(95% CI)
P-value
24-h cough, % -34% (-48% – -15%) 0.002
Coughs per hour, %
 Daytime -33% (-47% – -14%) 0.003
 Nighttime -34% (-54% – -5%) 0.029
LCQ, points 2.0 (1.0 – 3.0)* <0.001
VAS cough, mm -19 (-28 – -10) <0.0001
VAS urge-to-cough, mm -18 (-26 – -10) <0.0001
K-BILD, points 3.4 (-2.3 – 9.1) 0.245
HADS anxiety, points 0.7 (-0.6 – 1.9) 0.291
HADS depression, points 1.6 (0.5 – 2.6) 0.004
GAD-7, points 0.7 (-0.9 – 2.3) 0.396
* Minimal clinical important difference for chronic cough is 1.3
LCQ, Leicester Cough Questionnaire; VAS, visual analogue scale; K-BILD, King’s Brief Interstitial Lung Disease health status 
questionnaire; HADS, Hospital Anxiety and Depression Scale; GAD-7, Generalized Anxiety Disorder 7-item screener
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RD never-smoker 1.97 (CI 1.27-3.26), p=0.008), predicting 26% of the variation in 24-h 
cough (p=0.004) (e-Table 4). 
Adverse Events occurred in 30/43 patients (70%). Fatigue (23%), loss of appetite (19%), 
and nausea (16%) were the most frequent reported adverse events (e-Table 5). Two 
patients had a Serious Adverse Event; death because of pneumosepsis and an elective 
hospitalization (e-Table 5).
DIsCussIOn
In this observational study, pirfenidone treatment reduced objective 24-h cough counts, 
cough severity and cough-related quality of life in patients with IPF. The magnitude of 
these changes was clinically meaningful to patients. Furthermore, this study provides 
insights into impact of cough and different methods to assess cough in IPF. 
Cough is a major problem for patients with IPF, and their relatives.1,4,20 No good thera-
pies exist. This study is the first to show a significant improvement of a pharmacologic 
treatment both on objective as well as subjective measures of cough in patients with 
IPF.
As the study was not controlled, some placebo-effect should be questioned. When this 
study was designed, pirfenidone was just recently available and the only treatment pos-
sibility for patients with this deadly disease. This created high expectations for patients 
and physicians, and therefore patients, physicians and the ethics committee considered 
table 4. Correlation of objective cough frequencies with questionnaires and lung function
Cough per 24-h Cough/h daytime Cough/h nighttime
LCQ -0.34* -0.37* -0.14
VAS cough  0.42**  0.44**  0.37*
VAS urge-to-cough  0.55**  0.52**  0.54**
MRC  0.38*  0.38*  0.42**
K-BILD -0.19 -0.23 -0.05 
HADS anxiety <-0.01 -0.02  0.06
HADS depression  0.29  0.28  0.09
GAD-7 -0.22 -0.21 -0.28 
FVC % predicted -0.03 -0.03 -0.02 
TLCOc % predicted -0.20 -0.22 -0.41 
Data shown are Pearson’s correlation coefficients. All p≥0.05 except for *p<0.05 and ≥0.01, ** p<0.01
Cough data were not normally distributed and therefore log transformed.
LCQ, Leicester Cough Questionnaire; VAS, visual analogue scale; MRC, Medical Research Council dyspnoea scale; K-BILD, 
King’s Brief Interstitial Lung Disease health status questionnaire; HADS, Hospital Anxiety and Depression Scale; GAD-7, 
Generalized Anxiety Disorder 7-item screener; FVC; forced vital capacity; TLCOc, transfer capacity of the lung for carbon 
monoxide, corrected for hemoglobin level.
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it unethical to leave half the study population untreated for 12 weeks, a decision which 
might be viewed differently nowadays. Until now, there is only one placebo-controlled 
pharmacological study on cough in IPF completed that used objective cough as primary 
outcome. This recent phase 2 double-blind cross-over study, showed no placebo-effect 
at all in a similar group of IPF patients with chronic cough.21 We therefore believe that 
the outcomes of our study are not influenced by a placebo-effect, which is further 
supported by the already significant, though smaller, effect on cough after 4 weeks of 
treatment. 
Pirfenidone is an anti-fibrotic drug with pleiotropic effects. Its mechanisms of action are 
not completely understood, but in vitro studies have shown anti-fibrotic, anti-inflamma-
tory, and anti-oxidant properties.8 Given that the exact mechanism of chronic cough in 
IPF is also still unknown,22 we can only speculate on the mode of action of pirfenidone 
in reducing cough. In IPF cough reflex sensitivity is thought to be increased.6 Preliminary 
studies in guinea pigs show that pirfenidone decreases cough reflex sensitivity.9 Future 
investigations are needed to see if pirfenidone alters cough reflex sensitivity in patients 
with IPF. 
Recently, Froese et al. showed that mechanical tissue stretch activates TGF-beta1 and 
contributes to the development of pulmonary fibrosis in rodent and human.23 This in 
line with Leslie et al., who proposed that recurrent stretch injury caused by pressure 
changes during breathing promotes fibrosis.24 Cough might be an additional source of 
mechanical stress, and could theoretically contribute to a pro-fibrotic feedback loop. If 
this hypothesis is correct, this might explain why cough independently predicts disease 
progression.5 More research is needed to investigate the potential role of cough as a 
potential driver of disease progression in IPF, as this might have therapeutic implica-
tions. In the current 12-weeks study there was no correlation between change in cough 
and FVC.
In the present study patients had high baseline cough frequencies, with median 24-h 
cough counts of 23 per hour. Key et al reported lower cough frequencies in 19 patients 
with IPF (9.4 per hour).4 This is likely due to the selection of patients with a VAS cough 
score of ≥40 mm in the current study. The higher daytime cough frequencies we found 
corresponds with the diurnal pattern observed in patients with IPF and chronic cough.4,25 
Inhibition of cough by cortical pathways and higher thresholds of peripheral nerves at 
night might account for this pattern.25 Also, less exposure to stimuli that might induce 
cough, such as talking, exercise, and fumes might play a role.25
Comorbidities and co-medication use are frequent in IPF,26,27 and may cause cough. In 
our study we excluded patients with other reasons for cough. Patients with GERD had 
to be on PPI and remain on a stable dose, even though previous studies did not show a 
correlation with the presence of treatment for GERD and cough in IPF.5,28 As comorbid 
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conditions and co-medication remained unchanged during the study, we believe that 
these did not influence the study outcomes. 
Cough-related QoL, measured with the LCQ, also improved significantly after 12 weeks 
of pirfenidone treatment. The LCQs’ MCID in chronic cough is 1.3 points, so we consider 
the 2.0 point change found in our population as clinically meaningful to the patients.14 
There have been few studies evaluating anti-tussive treatment in IPF. A study by Horton 
et al. found that in patients with IPF thalidomide improved cough-specific QoL, though 
no objective cough measurements were done, and only 20% of the screened patients 
completed the trial.29 Thalidomide has a toxic side-effect profile including neuropathy 
and may increase risk for thrombotic diseases.30 Oral corticosteroids 40 to 60 mg/day 
for at least four weeks improved cough in six IPF patients in a non-randomized trial.6 Yet, 
they found no effect on cough-related QoL, and, furthermore, immunosuppression has 
been associated with deleterious effects in IPF.31 Currently, two medications are avail-
able for the treatment of IPF: nintedanib and pirfenidone. To date, there are no studies 
on the effect of nintedanib on cough. Our study results might imply that pirfenidone is 
preferable for treatment of IPF patients with severe cough; however, it would be valu-
able to compare the effects of both nintedanib and pirfenidone on cough prospectively. 
In line with previous findings, we found that objective cough counts correlated mod-
erately with subjective cough measures.4 In our study we newly included a VAS on 
urge-to-cough in IPF, which showed the best correlation with objective cough counts. 
This could be an interesting tool to easily assess cough in future IPF trials, and might 
be better related to the underlying cough reflex hypersensitivity described in patients 
with IPF. No correlations were found with measures of disease severity, such as FVC and 
TLCOc. This confirms that cough can be a troublesome symptom at all stages of disease, 
and is in line with previous findings.4
Gender and smoking status were the only predictors of cough in the current study. 
Women in the study had twice as many cough counts as men; this is in line with find-
ings in chronic cough patients, but not with other IPF studies.4,5,32 In contrast to chronic 
coughers and COPD patients, but in line with findings of Ryerson et al., we found that 
IPF patients who had no history of smoking coughed more than former smokers. It is 
unknown why some IPF patients cough more, but it might be connected to different IPF 
phenotypes.5
Our study has some limitations. Firstly, we included IPF patients with a VAS score of 
≥40 mm. Therefore, we do not know the effect of pirfenidone on IPF patients with mild 
cough. Nonetheless, patients with severe cough should benefit the most from reduction 
of their cough. Secondly, our study had a substantial drop-out rate, which is a known 
limitation of an observational study. By using the linear mixed model analyses we ac-
counted for these missing data.18 Moreover, the sensitivity analysis on the per-protocol 
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population showed similar results as the analysis on the intention-to-treat population. 
Lastly, our study had a short follow-up period of 12 weeks. The long-term effect of pir-
fenidone on cough in IPF patients is therefore unknown; however, our results suggest 
that the effect of treatment on IPF cough may be explored in 12-week trials.
COnCLusIOns
In patients with IPF, pirfenidone treatment significantly reduced objective 24-h cough 
counts by 34%, and improved subjective measures of cough. These results are clinically 
meaningful to patients. More research is warranted into the mechanisms and manage-
ment of cough in IPF and other fibrotic diseases. 
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e-appendix 1 Ethics approval
ethics approval
-  Medical Ethics Review Committee (METC) of the Erasmus Medical Center, Rotterdam, the Netherlands (METC-2013-
306). 
- Comité de protection des personnes sud-est IV, Lyon, France (number L13-155).
- Comitato Etico, Aziende Ospedaliero-Universitaria, Catania, Italy (n 698).
- National Research Ethics Service (NRES) committee London, United Kingdom (NL44729.078.13).
e-Table 1. Inclusion and exclusion criteria
inclusion criteria
- Diagnosis of definite or probable IPF according to ATS/ERS criteria1
- Daily cough related to IPF (exclusion of other causes) present more than eight weeks
- Cough score on the VAS of ≥40 mm
- FVC ≥50% and TLCOc ≥30%*
- Use of PPI more than four weeks, when patient had a history positive for GERD
exclusion criteria
-  Use of opiates, antitussive medication, antihistamines, steroids more than an equivalent of 10 mg 
prednisone or NAC within two weeks before the study
- Change in steroid dose if using <10 mg or inhalation steroids within two weeks before the study
- History of bronchial hyper responsiveness, asthma or relevant airway obstruction (FEV1/FVC <0.7)
-  Within six weeks of the start of the study signs of respiratory tract infection, change of sputum 
production and fever
1 Raghu G, Collard HR, Egan JJ, et al. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based 
guidelines for diagnosis and management. Am J Respir Crit Care Med. 2011;183(6):788-824.
* Except for Italy were a TLCOc ≥35% is required for treatment reimbursement 
IPF, idiopathic pulmonary fibrosis; ATS; American Thoracic Society; ERS, European Respiratory Society; VAS, visual analogue 
scale; FVC, forced vital capacity; TLCOc, transfer capacity of the lung for carbon monoxide, corrected for hemoglobin level; 
PPI, proton pump inhibitor; GERD, gastroesophageal reflux; NAC, N-acetylcysteine
e-Table 2. Comorbidities and medications
Comorbidities n (%)
GERD* 8 (19%)
Emphysema 3 (7%)
Pulmonary hypertension 1 (2%)
Cardio vascular disease 20 (47%)
Endocrine disease 8 (19%)
medications n (%)
PPI 34 (79%)
Antibiotics 0 (0%)
ACE-inhibitors 0 (0%)
Steroids** 9 (21%)
Statins 19 (44%)
Anticoagulants 2 (5%)
*Reported by patients 
** All patients had an equivalent dose ≤10 mg
There were no missing data. GERD, gastroesophageal reflux; PPI, proton pump inhibitor; ACE, angiotensin-converting-
enzyme
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e-Table 3. Sensitivity analyses
a. Effect of 12 weeks pirfenidone treatment on cough measures, analyzed with a linear mixed model – patient with data 
complete (n=27)
Change
(95% CI)
P-value
24-h cough, % -35% (-50% – -16%)* 0.002
Coughs per hour, %
Daytime -34% (-49% – -14%) 0.003
Nighttime -34% (-55% – -2%) 0.043
LCQ, points 1.9 (0.9 – 2.9)** <0.001
VAS cough, mm -16 (-26 – -6) 0.003
VAS urge-to-cough, mm -18 (-27 – -9) <0.001
K-BILD, points 3.0 (-2.8 – 8.8) 0.309
HADS anxiety, points 1.1 (-0.3 – 2.6) 0.124
HADS depression, points 1.5 (0.3 – 2.6) 0.016
GAD7, points 0.9 (-0.8 – 2.5) 0.291
* A decrease of 15% in 24-h cough was achieved at 4 weeks (95% CI -22% – -6%-; p=0.002)
** Minimal clinical important difference for chronic cough is 1.3
LCQ, Leicester Cough Questionnaire; VAS, visual analogue scale; MRC, Medical Research Council dyspnoea scale; K-BILD, 
King’s Brief Interstitial Lung Disease health status questionnaire; HADS, Hospital Anxiety and Depression Scale; GAD-7, 
Generalized Anxiety Disorder 7-item screener
b. Effect of 12 weeks pirfenidone treatment on cough measures, analyzed with a paired t-test (n=27)
baseline Week 12 Change P-value
24-h cough 758 (91-3394) 484 (75-1746) -36% 0.003
Coughs per hour
Daytime 41 (6-171) 26 (4-121) -36% 0.004
Nighttime 13 (1-101) 8 (0-54) -37% 0.039
LCQ, points 13 (3) 15 (4) 2.1 0.004
VAS cough, mm 66 (14) 49 (28) -18 0.002
VAS urge-to-cough, mm 68 (16) 49 (26) -19 <0.001
K-BILD, points 52 (22) 56 (24) 3.9 0.258
HADS anxiety, points 7.6 (4) 8.7 (4) 1.2 0.174
HADS depression, points 4.7 (3) 6.1 (3) 1.4 0.035
GAD7, points 4.9 (6) 5.8 (7) 0.8 0.386
Data are presented as mean (range) or (SD). LCQ, Leicester Cough Questionnaire; VAS, visual analogue scale; K-BILD, King’s 
Brief Interstitial Lung Disease health status questionnaire; HADS, Hospital Anxiety and Depression Scale; GAD-7, General-
ized Anxiety Disorder 7-item screener
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e-Table 4. Predictors of 24-h objective cough frequency (n=41)
Predictors of 24-h cough β relative difference (95% CI)# P-value#
univariable analysis 
Age (per year) 0.02 1.02 (0.98-1.06) 0.191
Gender (female) 0.81 2.24 (1.09-4.44) 0.037*
FVC % predicted (per 1%) <-0.01 1.00 (0.98-1.02) 0.824
TLCOc % predicted (per 1%) -0.01 0.99 (0.96-1.00) 0.195
Smoking status (never) 0.76 2.15 (1.21-3.86) 0.008*
Packyears (per year) 0.01 1.01 (1.00-1.04) 0.296
CT finding (possible UIP) 0.37 1.44 (0.78-2.68) 0.267
Clubbing (yes) 0.06 1.07 (0.59-2.08) 0.865
Reflux (yes) 0.16 1.17 (0.71-1.78) 0.515
Appetite (yes) 0.19 1.21 (0.45-3.22) 0.706
multivariable analysis
Model R2 = 26% 0.004*
Gender (female) 0.74 2.09 (1.02 – 3.88) 0.029*
Smoking status (never) 0.68 1.97 (1.27 – 3.26) 0.008*
# Linear regression on log-transformed number of coughs per 24 hours, bootstrapping (1.000 samples) was used to con-
struct 95% confidence intervals. Coefficients of the linear regression model were anti-logged to interpret the coefficients 
as relative difference 
* Statistically significant 
FVC, forced vital capacity; TLCOc, transfer capacity of the lung for carbon monoxide, corrected for hemoglobin level
e-Table 5. Adverse Events and Serious Adverse Events
Adverse events* n (%)
Fatigue 10 (23)
Loss of appetite 9 (19)
Nausea 8 (16)
Dizziness 6 (12)
Phototoxicity 4 (9)
Rash 4 (9)
Gastroesophageal reflux 4 (9)
Flu-like symptoms 4 (9)
Pneumonia 4 (5)
Change of mood/mood disturbance 3 (7)
Pruritus 3 (7)
Dyspepsia 3 (7)
Constipation 3 (7)
Diarrhea 2 (5)
Burning and dry eyes 2 (5)
serious Adverse events
Death because of pneumosepsis 1 (2)
Elective hospitalization 1 (2)
* Listed are all adverse events that were reported in at least 2 patients
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AbstrAct
Pulmonary fibrosis greatly impacts patients and their partners. Unmet needs of patients 
are increasingly acknowledged; the needs of partners often remain unnoticed. Little 
is known about the best way to educate patients and partners. We investigated pul-
monary fibrosis patients’ and partners’ perspectives and preferences in care, and the 
differences in these between the Netherlands and Germany. Additionally, we evaluated 
if interactive interviewing could be a novel education method in this population.
Patients and partners were interviewed during pulmonary fibrosis patient information 
meetings. In the Netherlands, voting boxes were used and results were projected di-
rectly. In Germany, questionnaires were used.
In the Netherlands, 278 patients and partners participated; in Germany, 51. Many 
participants experienced anxiety. Almost all experienced misunderstanding, because 
people do not know what pulmonary fibrosis is. All expressed a need for information, 
psychological support and care for partners. Use of interactive voting system is found to 
be pleasant (70%) and informative (94%).
This study improves the knowledge about care needs of patients with pulmonary fibro-
sis and their partners. There were no major differences between the Netherlands and 
Germany. Interactive interviewing could be an attractive method to acquire insights into 
the needs and preferences of patients and partners, while providing them information 
at the same time.
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InTrODuCTIOn
Pulmonary fibrosis is a respiratory disease characterised by scarring of the lungs, 
resulting in a reduced oxygen transport.1 Different forms of pulmonary fibrosis exist, 
with different disease courses and prognosis; however, in the majority of patients the 
disease is progressive. The main symptoms experienced by patients are cough, fatigue 
and breathlessness.2 Pulmonary fibrosis impacts the social and emotional wellbeing of 
patients, partners and other family caregivers, in addition to its physical impact.3-6
In recent years, several studies have been conducted to generate more information 
on the needs of patients with pulmonary fibrosis, especially in idiopathic pulmonary 
fibrosis (IPF).3-11 However, the needs of partners often remain unnoticed. Previous 
studies show the need for better disease related education, earlier diagnosis, support 
groups and better access to specialist centres and interstitial lung disease (ILD) specialist 
nurses. One of the crucial factors that empower patients to play a more active role in 
their care is education. However, the best way of educating pulmonary fibrosis patients 
and their partners needs to be established. 
A pulmonary fibrosis patient information meeting is organised annually in the Eras-
mus University Medical Center (Rotterdam, the Netherlands) and at the Thoraxklinik 
(Heidelberg, Germany) to provide additional information about pulmonary fibrosis. 
During these meetings we use an interactive voting system, which enables us to gather 
information about participants’ disease experiences and learn from their perspectives 
and preferences in care. These findings can be used to improve care for patients with 
fibrosis and their partners.
An interactive voting system, in addition, creates an environment where patients and 
partners can learn from each other’s experiences. Outcomes of surveys are not always 
shared with patients. However, information on problems that patients and partners 
encounter could be very informative and might generate a feeling of relief, as people 
learn that others are facing the same difficulties.
Studies on cultural differences in preferences and perspectives in care are limited in 
pulmonary fibrosis patients.9,12 By using the same survey at the pulmonary fibrosis 
patient information meetings in the Netherlands and in Germany, we could learn more 
about possible cultural differences.
The purpose of our study was to determine pulmonary fibrosis patients’ and their 
partners’ perspectives and preferences in care. In addition, we studied whether directly 
projecting survey answers, via an interactively voting system, is informative and wanted 
by pulmonary fibrosis patients and their partners. We also studied whether cultural 
differences exist in care needs between pulmonary fibrosis patients and their partners 
from the Netherlands and Germany.
Chapter 9
156
meThODs
Patients and partners were interviewed during pulmonary fibrosis information meetings 
at two tertiary ILD centres: the Erasmus University Medical Center and the Thoraxklinik, 
Heidelberg University Hospital. The three information meetings in the Netherlands took 
place in 2013, 2014 and 2015 and the meeting in Germany in 2014. The content of the 
programme is shown in online supplementary table S1. We use the terminology “part-
ners”, but this term also includes other family members or nearest and dearest when 
applicable. We avoided the word caregiver, as we think that a relationship between 
patient and partner (or other nearest and dearest) comprises more than caregiving 
alone. In the Netherlands, patients and partners answered questions anonymously 
via interactive voting boxes (TurningPoint 2008; Keepad Interactive, Sydney, Australia). 
The questions were projected on a wide screen. Questions and answers were first read 
aloud, then a clock countdown of 10 s was started. The system recorded the number of 
votes and results were projected directly. In Germany, questionnaires were handed out 
to all participants and questions were discussed afterwards. Questions were derived 
by literature search and input of patients, ILD physicians, ILD specialist nurses an ILD 
research nurses. The Generalised Anxiety Disorder-single item (GAD-SI) questionnaire 
was administered before the lectures started, to avoid the influence of information 
presented during the meeting.13 We asked participants 37 questions. In this article we 
present a selection of the questions asked. An overview of all questions is presented in 
online supplementary table S2.
Permission to use the data was obtained beforehand. All procedures followed were 
in accordance with the ethical standards of the responsible committee on human ex-
perimentation (institutional and national) and with the Helsinki Declaration of 1964, as 
revised in 2013. Patient permissions for data collection and usage were granted accord-
ing to specific local requirements of the medical ethical committee at each participating 
centre. Data were collected and analysed using Microsoft Excel 2010 (Redmond, WA, 
USA). All data are presented as % (n), as the number of responders could vary per ques-
tion.
resuLTs
278 patients and their partners participated in the Netherlands and 51 in Germany. 
Demographics are shown in table 1.
In Germany, 17% (8) of patients and partners attended the pulmonary fibrosis informa-
tion meeting the previous year. In the Netherlands, 24% (15) in 2014 and 18% (10) in 
2015 attended the previous meeting. 
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Figure 1 shows that approximately two-thirds of patients and partners experience anxi-
ety as assessed by the validated GAD-SI.13 The fast majority of participants experienced 
misunderstanding because people do not know what pulmonary fibrosis is (figure 2). 
Patients in the Netherlands prefer to talk about matters concerning end-of-life early in 
the course of the disease, while in Germany this is less explicit (figure 3). In all groups, 
there is great need for information on the disease (figure 4).
Other questions revealed that 88% (21) of the German and 61% (38) of the Dutch 
partners would like to have more care for partners. Psychological support was wanted 
by more than half of the German partners (55%, n=12). In addition, the majority of pa-
tients in the Netherlands and Germany would appreciate the possibility of psychological 
support: 80% (107) and 79% (19), respectively. Twenty-three percent (21) of patients 
think that psychological support is actually lacking in current care. 
Table 1. Demographics of patients and partners
The netherlands 
(2013+2014+2015)
Germany 
(2014)
Patients 134 [48] 27 [53]
Partners 144 [52] 24 [47]
Diagnoses*
IPF 88 [70] 20 [80]
CTD-PF 14 [11] 2 [8]
Exposure related 14 [11] 3 [12]
Unknown 10 [8] 0 [0]
Data are presented as n (%). IPF, idiopathic pulmonary fibrosis; CTD-PF, connective tissue disease-associated pulmonary 
fibrosis
* Based on survey question
In Germany, 17% (8) of patients and partners attended the pulmonary fibrosis information meeting the
previous year. In the Netherlands, 24% (15) in 2014 and 18% (10) in 2015 had attended the previous
meeting.
Figure 1 shows that approximately two-thirds of patients and partners experience anxiety as assessed by
the validated GAD-SI [13]. The vast m jority of participants had experienced misunderstanding because
people do not know what pulmonary fibrosis is (figure 2). Patients in the Netherlands prefer to talk about
matters concerning the end of life early in the course of the disease, while in Germany this is less explicit
(figure 3). In all groups, there is great need for information on the disease (figure 4).
Other questions revealed that 88% (21) of German and 61% (38) of Dutch partners would like to have
more care for partners. Psychological support was wanted by more than half of the German partners
(55%, n=12). In addition, the majority of patients in the Netherlands and Germany would appreciate the
possibility of psychological support: 80% (107) and 79% (19), respectively. 23% (21) of patients think that
psychological support is lacking in current care.
In the Netherlands, patient and partner priorities in care are information on their disease (47%, n=62);
access to an expertise centre (27%, n=35); and practical support (18%, n=23). Many Dutch patients desire
treatment and follow-up in a hospital with the most expertise (58%, n=67), but a third of the patients
(30%, n=34) prefer shared care between the expertise centre and a pulmonologist nearby. In Germany, the
same percentage of patients favour shared care between the expertise centre and a pulmonologist nearby
(29%, n=7), while only a third of pat ents prefer treatment only at an expertise centre (33%, n=8).
Additionally, a minority (17%, n=4) of German patients prefer a combination of care by their general
practitioner and pulmonologist nearby, whereas in the Netherlands only 4% (5) of patients prefer this
option. Specialised centres offer access to clinical trials. Many patients desire active involvement in the
development of clinical trials: 77% (20) of German and 68% (77) of Dutch patients.
TABLE 1 Demographics of patients and partners
The Netherlands (2013 + 2014 + 2015) Germany (2014)
Patients 134 (48) 27 (53)
Partners 144 (52) 24 (47)
Diagnoses#
IPF 88 (70) 20 (80)
CTD-PF 14 (11) 2 (8)
Exposure related 14 (11) 3 (12)
Unknown 10 (8) 0 (0)
Data are presented as n (%). IPF: idiopathic pulmonary fibrosis; CTD-PF: connective tissue disease-
associated pulmonary fibrosis. #: based on survey question.
FIGURE 1 Patients’ and partners’
experience of anxiety in the
Netherlands (NL) and Germany
(GE), based on the Generalised
Anxiety Disorder-single item
questionnaire [13]. Subject
responses to the question “How
often in the past 2 weeks did you
have problems relaxing?”
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figure 1. Patients’ and partners’ 
experience of anxiety in the Nether-
lands (NL) and Germany (GE), based 
on the Generalised Anxiety Disor-
der-single item questionnaire [13]. 
Subject responses to the question “How 
often in the past 2 weeks did you have 
problems relaxing?”
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At the Erasmus University Medical Center, ILD specialist nurses provide general care. They give additional
information about disease, care options, medication and oxygen supply and are easily accessible by phone
and email. Most (88%, n=36) Dutch patients think seeing an ILD specialist nurse is beneficial. At the time
of the survey, there was no ILD specialist nurse in Germany, although 55% (12) of patients asked for such
services. 21% (30) of patients and partners from both countries would like to see the ILD specialist nurse
every time they visit their doctor. However, the majority of patients prefer to see the ILD specialist nurse
only when asked for (67%, n=94).
The interactive voting system was well appreciated and considered informative by patients and partners
(figure 5). Patients and partners in both countries considered the meetings to be very useful and the
majority felt more secure after attending them (figures 6 and 7).
Discussion
This study improves the current knowledge of the needs of patients with pulmonary fibrosis and their
partners. It emphasises the major impact that pulmonary fibrosis has on the emotional wellbeing of
patients and partners and the need for better education on all aspects of disease and psychological and
practical support. Treatment is preferred in expertise centres with access to ILD specialist nurses, and
involvement in the development of clinical trials is wanted. Moreover, this study demonstrates a new way
of questioning and educating patients and partners, using an interactive voting system which projected
answers directly. Patients and partners found this method pleasant and informative. No major cultural
differences existed between the findings in in the Netherlands and Germany.
Anxiety
In our study, many patients and partners reported some level of anxiety. KREUTER et al. [14] showed that
depression and anxiety are common comorbidities in IPF. In another study of 502 IPF patients, anxiety
was found in 9.4% at baseline [15]. This is comparable with the number of patients and partners in our
group experiencing anxiety almost every day (11–16%). Multiple factors could contribute to the high
prevalence of anxiety in this population. Anxiety is a known emotional response in breathless patients, but
a background of anxiety can also increase the perception of breathlessness [16]. Partners feel helpless
because they cannot relieve the breathlessness [2, 17]. The relationship between breathlessness and anxiety
in patients and partners is also seen in chronic obstructive pulmonary disease (COPD) and chronic heart
failure [18, 19]. In COPD, anxiety is one of the comorbidities with the greatest influence on self-reported
health status [20]. The progressive nature of the disease, especially in IPF, could also cause anxiety.
Furthermore, the coughing attacks suffered by many pulmonary fibrosis patients increases anxiety of
partners, as they fear the next attack could be fatal [5]. Additionally, for certain patients, decisions about
screening and being on the waiting list for lung transplantation might play a role [7, 21].
Misunderstanding
Patients and their partners both feel misunderstood by society, as people often do not know what
pulmonary fibrosis is. This corresponds with the findings of the study of RUSSELL et al. [12], where IPF
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figure 2. Experience of misunderstanding by patients and partners in the Netherlands (NL) and Germany (GE). 
Subject responses to the question “How often do y u feel misunderstood becau e people d  not know what pulmonary fibrosis is?”
patients report feeling angry and frustrated because society has little knowledge of the disease. Moreover,
patients often do not look sick to start with, which makes it difficult for family and friends to understand
the devastating impact of the disease, troubling patients to talk about their condition [2, 7].
Psychological support
Many patients and partners in the Netherlands and Germany wish to receive psychological support,
consistent with the findings of previous studies [3, 4, 9, 12]. The progressive nature of the disease forces
patients to adapt to growing restrictions in things they love to do and limits them in the activities of
everyday life, impacting not only physical, but also emotional wellbeing. Patients become dependent on
their loved ones and relationships with friends and family change [2, 4]. Financial problems can occur
when patients have to stop working [22]. Additionally, psychological distress can increase when patients
start on supplemental oxygen. Besides loss of independence due to logistical difficulties, oxygen makes the
disease more visible [22]. For partners, the disease changes their lives and the relationship as well [17].
They become the main support in patients’ lives and often feel they have to be the “strong one”, allowing
themselves no time to deal with their own grief. The high number of requests for more care and
psychological support for partners found in our study illustrates the impact pulmonary fibrosis has on
partners and corresponds with previous findings [4, 17]. In both centres, the survey data helped to improve
the level of psychological care and the tailoring of this care to the needs of the patients and partners.
End of life
The majority of pulmonary fibrosis patients in our study prefer to talk about matters co cerning end of
life at an early stage of the disease, but cultural differences exist. The study by OVERGAARD et al. [5] shows
that reactional dyssynchrony can occur in coping with the disease. National Institute for Health and Care
FIGURE 3 Preference of talking
about matters concerning the end
of life in patients from the
Netherlands (NL) and Germany
(GE). Responses to the statement “I
would prefer to talk about matters
concerning end of life at an early
stage of my disease”.
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and partners from the Netherlands
(NL) and Germany (GE). Responses
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know everything about my disease
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figure 3. Preference of talking about 
matters concerning the end of life in 
patients from the Netherlands (NL) 
and Germany (GE).
Responses to the statement “I would pre-
fer to talk about matters concerning end 
of life at an early stage of my disease”.
patients report feeling angry and frustrated because society has little knowledge of the disease. Moreover,
patients often do not look sick to start with, which makes it difficult for family and friends to understand
the devastating impact of the disease, troubling patients to talk about their condition [2, 7].
Psychological support
Many patients and partners in the Netherlands and Germany wish to receive psychological support,
consistent with the findings of previous studies [3, 4, 9, 12]. The progressive nature of the disease forces
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themselves no time to deal with their own grief. The high number of requests for more care and
psychological support for partners found in our study illustrates the impact pulmonary fibrosis has on
partners and corresponds with previous findings [4, 17]. In both centres, the survey data helped to improve
the level of psy hological car and the tailoring of this care to the needs of the patients and partners.
End of life
The majority of pulmonary fibrosis patients in our study prefer to talk about matters concerning end of
life at an early stage of the disease, but cultural differences exist. The study by OVERGAARD et al. [5] shows
that reactional dyssynchrony can occur in coping with the disease. National Institute for Health and Care
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figure 4. Need for information on 
disease and prospects in patients 
and partners from the Netherlands 
(NL) and Germany (GE). 
Responses to the statement “I would like 
to know everything about my disease 
and its prospects”.
159
Patients and partners perspectives in pulmonary fibrosis
ch
ap
te
r 9
In the Netherlands, patients and partners priorities in care are information on their 
disease (47% , n=62); access to an expertise centre (27%, n=35); and practical support 
(18%, n=23). Many Dutch patients desire treatment and follow-up in a hospital with 
the most expertise (58%, n=67), but a third of the patients (30%, n=34) prefer shared 
care between the expertise centre and a pulmonologist nearby. In Germany, the same 
percentage of patients favour shared care between the expertise centre and a pulmon-
ologist nearby (29%, n=7), while only a third of patients prefer treatment only at an ex-
pertise centre (33%, n=8). Additionally, a minority (17%, n=4) of German patients prefer 
a combination of care at their general practitioner and pulmonologist nearby, whereas 
in the Netherlands only 4% (5) of patients prefer this option. Specialised centres offer 
access to clinical trials. Many patients desire active involvement in the development of 
clinical trials: 77% (20) of German and 68% (77) of Dutch patients.
At the Erasmus University Medical Center, ILD specialist nurses provide general care. 
They give additional information about disease, care options, medication and oxygen 
supply and are easily accessible by phone and email. Most (88%, n=36) Dutch patients 
think seeing an ILD specialist nurse is beneficial. At the time of the survey, there was 
no ILD specialist nurse in Germany, though 55% (12) of patients asked for such services. 
Twenty-one percent (30) of patients and partners from both countries would like to see 
the ILD specialist nurse every time when visiting their doctor. However, the majority of 
patients prefer to see the ILD specialist nurse only when asked for (67%, n=94).
The interactive voting system was well appreciated and considered informative by 
patients and partners (figure 5). Patients and partners in both countries considered 
the meetings to be very useful and the majority felt more secure after attending them 
(figure 6 and 7). 
Excellence (NICE) guidelines on IPF state that discussion about end-of-life issues should start at diagnosis,
and prior studies show patients’ need for information on end-of-life issues [23–25]. In addition, the
American Thoracic Society recommends advanced care planning for patients with severe lung disease [26].
However, it must be realised that these conversations could be distressing to patients and partners [27]. As
mentioned by THICKETT et al. [8], it is important to talk about disease progression and management so
patients can prepare for the future, but this process should be personalised and develop over time. This
corresponds with the wishes of patients and partners to receive paced information on disease and being
able to plan care in advance [5].
Education
Patients and partners have a consistent wish to receive more information on the disease and its prospects [3,
12, 25, 27–29]. Patients often consult the internet, but information found is frequently incomplete,
inaccurate and not up to date [11]. Although the need for information is well known in pulmonary fibrosis,
studies to improve education and care are scarce [27]. LINDELL et al. [27] studied whether a 6-week
disease-management programme would improve disease symptoms and health-related quality of life
(HRQoL) in patients with IPF. Strikingly, patients’ anxiety and HRQoL scores deteriorated, while the stress
levels of partners improved. Post-intervention interviews showed that the course was perceived to be
beneficial by all participants. In the current study, we used an interactive voting system with direct projection
to improve patients’ and partners’ knowledge of the disease. Although this method cannot be compared to a
disease-management programme, we found that after the meeting most patients felt more secure. The
majority of participants found the interactive voting system pleasant and informative. Studies on using
interactive response systems in teaching have been shown to improve learning, cognitive performance and
student test scores [30–32]. This method could therefore not only be a good and efficient way to inform
patients and partners, but also enhance the information patients and partners can absorb.
I find seeing the response of the other
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Do you find it informative to see the answers of 
the other participants on the screen?
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FIGURE 5 Feedback on interactive voting system in the Netherlands.
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figure 5. Feedback on interactive voting system in the Netherlands.
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DIsCussIOn
This study improves the current knowledge of the needs of patients with pulmonary 
fibrosis and their partners. It emphasises the major impact pulmonary fibrosis has on 
the emotional wellbeing of patients and partners and the need for better education on 
all aspects of disease and psychological and practical support. Treatment is preferred 
in expertise centres with access to ILD specialist nurses and involvement in the devel-
opment of clinical trials is wanted. Moreover, this study demonstrates a new way of 
questioning and educating patients and partners, by using an interactive voting system 
which projected answers directly. Patients and partners found this method pleasant 
and informative. No major cultural differences existed between the findings in the 
Netherlands and Germany. 
Excellence (NICE) guidelines on IPF state that discussion about end-of-life issues should start at diagnosis,
and prior studies show patients’ need for information on end-of-life issues [23–25]. In addition, the
American Thoracic Society recommends advanced care planning for patients with severe lung disease [26].
However, it must be realised that these conversations could be distressing to patients and partners [27]. As
mentioned by THICKETT et al. [8], it is important to talk about disease progression and management so
patients can prepare for the future, but this process should be personalised and develop over time. This
corresponds with the wishes of patients and partners to receive paced information on disease and being
able to plan care in advance [5].
Education
Patients and partners have a consistent wish to receive more information on the disease and its prospects [3,
12, 25, 27–29]. Patients often consult the internet, but information found is frequently incomplete,
inaccurate and not up to date [11]. Although the need for information is well known in pulmonary fibrosis,
studies to improve education and care are scarce [27]. LINDELL et al. [27] studied whether a 6-week
disease-management programme would improve disease symptoms and health-related quality of life
(HRQoL) in patients with IPF. Strikingly, patients’ anxiety and HRQoL scores deteriorated, while the stress
levels of partners improved. Post-intervention interviews showed that the course was perceived to be
beneficial by all participants. In the current study, we used an interactive voting system with direct projection
to improve patients’ and partners’ knowledge of the disease. Although this method cannot be compared to a
disease-management programme, we found that after the meeting most patients felt more secure. The
majority of participants found the interactive voting system pleasant and informative. Studies on using
interactive response systems in teaching have been shown to improve learning, cognitive performance and
student test scores [30–32]. This method could therefore not only be a good and efficient way to inform
patients and partners, but also enhance the information patients and partners can absorb.
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figure 6. Perception of patients and 
partners from the Netherlands (NL) 
and Germany (GE) of the usefulness 
of the information meeting.
Expertise centres
The majority of Dutch patients in this study wished to be treated and followed-up in a centre of expertise.
This result could be biased, because the pulmonary fibrosis information meetings were held in expertise
centers; however, similar findings were reported by SCHOENHEIT et al. [3]. They found that patients treated
in expertise centres were more satisfied on disease information and quality of care. Yet the German
patients in the present study preferred a co bination of treatment and follow-up at an expertise centre
and pulmonologist nearby in equal numbers those preferring treatment at an expertise centre only.
Geographical reasons may explain this difference, as in the Netherlands an expertise centre is usually
within <2 h range due to the small size of the country. The British Lung Foundation states that a
considerable amount of ongoing care must be available and provided at local hospitals. The current study
underlines the importance of this, as patients should be given the option of shared care, although in some
countries reimbursement rules may unfortunately complicate such collaborative care options.
Research
In expertise centres, patients generally get more access to information about and enrolment in clinical
trials. According to the British Lung Foundation, only 42% of patients currently receive information on
clinical trials [33]. A study of diabetic patients attending an ongoing trial shows that attending clinical
trials improves quality of care, patient interest and engagement in their overall health services and reduces
healthcare costs [34]. Moreover, patients were more motivated, informed and aware of their disease and
how to deal with their condition. Our study shows that patients not only want to receive information
about and participate in clinical trials, but also wish to be involved in the development of trials.
Involvement of patients in designing clinical trials could not only help identifying which outcomes are
most relevant to patients, but could also improve feasibility and patient participation in trials and tailored
dissemination of outcomes [12, 35].
ILD specialist nurses
ILD specialist nurses manage symptoms, treatment and possible side-effects, coordinate care and involve
other healthcare services where necessary. They also teach patients how to cope with their disease and
create a comfortable environment were patients can discuss their fears and problems [7, 8, 29]. In the
Netherlands, most patients find access to an ILD specialist nurse beneficial. The NICE guideline states that
all patients and their partners should have access to an ILD specialist nurse in all phases of the care
pathway [23]. Yet, currently, as seen in Germany, not all pulmonary fibrosis patients have access to ILD
specialist nurses, although the demand for such services is high [12, 33]. We agree with the NICE
guidelines that all patients and their partners should have access to ILD specialist nurses. However,
appointments with ILD specialist nurses should be individually tailored, as our study shows that patients
and partners prefer to see the ILD specialist nurse only when required.
Cultural differences
We found no major cultural differences between Germany and the Netherlands. This in line with previous
studies, showing that the emotional impact of disease is similar in different countries [9, 12, 28]. Practical
care preferences might vary due to differences in the organisation of care, geography, reimbursement
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anxiety
In our study, many patients and partners reported some level of anxiety. Kreuter et al.14 
showed that depression and anxiety are common comorbidities in IPF. In another study 
of 502 IPF patients, anxiety was found in 9.4% at baseline.15 This is comparable with 
the number of patients and partners in our group experiencing anxiety almost every 
day (11-16%). Multiple factors could contribute to the high prevalence of anxiety in this 
population. Anxiety is a known emotional response in breathless patients, but a back-
ground of anxiety can also increase the perception of breathlessness.16 Partners feel 
helpless because they cannot relief the breathlessness.2,17 The relationship between 
breathlessness and anxiety in patients and partners is also seen in chronic obstructive 
pulmonary disease (COPD) and chronic heart failure.18,19 In COPD, anxiety is one of the 
comorbidities with the greatest influence on self-reported health status.20 The progres-
sive nature of the disease, especially in IPF, could also cause anxiety. Furthermore, the 
coughing attacks, suffered by many pulmonary fibrosis patients increases anxiety of 
partners, as they fear the next attack could be fatal.5 Additionally, for certain patients, 
decisions about screening and being on the waiting list for lung transplantation might 
play a role.7,21
misunderstanding
Patients and their partners both feel misunderstood by society, as people often do not 
know what pulmonary fibrosis is. This corresponds with findings of the study of Russell 
et al.12, where IPF patients report feeling angry and frustrated because society has little 
knowledge of the disease. Moreover, patients often do not look sick to start with, which 
makes it difficult for family and friends to understand the devastating impact of the 
disease, troubling patients to talk about their condition.2,7 
Psychological support
Many patients and partners in the Netherlands and Germany wish to receive psycho-
logical support, consistent with the findings of previous studies.3,4,9,12 The progressive 
nature of the disease forces patients to adapt to growing restrictions in things they love 
to do and limits them in the activities of everyday life, impacting not only physical, but 
also emotional wellbeing. Patients become dependent on their loved ones and relation-
ships with friends and family change.2,4 Financial problems can occur when patients 
have to stop working.22 Additionally, psychological distress can increase when patients 
start on supplemental oxygen. Besides loss of independency due to logistical difficulties, 
oxygen also makes the disease more visible.22 For partners, the disease changes their 
lives and the relationship as well.17 They become the main support in patients’ lives and 
often feel they have to be the “strong one”, allowing themselves no time to deal with 
their own grief. The high number of requests for more care and psychological support 
for partners found in our study illustrates the impact pulmonary fibrosis has on partners 
and corresponds with previous findings.4,17 In both centres, the survey data helped to 
improve the level of psychological care and the tailoring this care to the needs of the 
patients and partners.
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end-of-life 
The majority of pulmonary fibrosis patients in our study prefer to talk about matters 
concerning end-of-life in an early stage of disease, but cultural differences exist. The 
study by Overgaard et al.5 shows that reactional dyssynchrony can occur in coping with 
the disease. National Institute for Health and Care Excellence (NICE) guidelines on 
IPF state that discussion about end-of-life should start at diagnosis, and prior studies 
show patients’ need for information on end-of-life issues.23-25 In addition, the American 
Thoracic Society recommends advances care planning for patient with severe lung 
diseases.26 However, it must be realised that these conversations could be distressing 
to patients and partners.27 As mentioned by Thickett et al.8, it is important to talk about 
disease progression and management so patients can prepare for the future, but this 
process should be personalised and develop over time. This corresponds with the 
wishes of patients and partners to receive paced information on disease and being able 
to plan care in advance.5 
education
Patients and partners, have a consistent wish to receive more information on the 
disease and its prospects.3,12,25,27-29 Patient often consult the internet, but information 
found is frequently incomplete, inaccurate and not up to date.11 Although the need for 
information is well known in pulmonary fibrosis, studies to improve education and care 
are scarce.27 Lindell et al.27 studied whether a 6-week disease-management programme 
would improve disease symptoms and health-related quality of life (HRQoL) in patients 
with IPF. Strikingly, patients’ anxiety and HRQoL scores deteriorated, while the stress 
levels of partners improved. Post-intervention interviews showed that the course was 
perceived to be beneficial by all participants. In the current study, we used an interac-
tive voting system with direct projection to improve patients’ and partners’ knowledge 
of the disease. Although this method cannot be compared to a disease-management 
program, we found that after the meeting most patients felt more secure. The majority 
of participants found the interactive voting system pleasant and informative. Studies 
on using interactive response systems in teaching have shown to improve learning, 
cognitive performance and student test scores.30-32 This method could therefore not 
only be a good and efficient way to inform patients and partners, but also enhance the 
information patients and partners can absorb. 
expertise centres
The majority of Dutch patients in this study wishes to be treated and followed-up 
in a centre of expertise. This result could be biased, because the pulmonary fibrosis 
information meetings were held in expertise centres; however, similar findings were re-
ported by Schoenheit et al.3 They found that patients treated in expertise centres were 
more satisfied on disease information and quality of care. Yet, the German patients in 
the present study preferred a combination of treatment and follow-up at an expertise 
centre and pulmonologist nearby in equal numbers those preferring treatment at 
an expertise centre only. Geographical reasons may explain this difference, as in the 
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Netherlands an expertise centre is usually within les <2 h range due to the small size of 
the country. The British Lung foundation states that a considerable amount of ongoing 
care must be available and provided at local hospitals. The current study underlines the 
importance of this, as patients should be given the option of shared care, although in 
some countries reimbursement rules may unfortunately complicate such collaborative 
care options. 
research
In expertise centres, patients generally get more access to information about and enrol-
ment in clinical trials. According to the British Lung Foundation, only 42% of patients 
currently receive information on clinical trials.33 A study of diabetic patients attending 
an ongoing trial shows that attending clinical trials improves quality of care, patients 
interest and engagement in their overall health services and reduces healthcare costs.34 
Moreover, patients were more motivated, informed and aware of their disease and how 
to deal with their condition. Our study shows that patients not only want to receive 
information about and participate in clinical trials, but also wish to be involved in the 
development of trials. Involvement of patients in designing clinical trials could not only 
help identifying which outcomes are most relevant to patients, but could also improve 
feasibility and patient participation in trials and tailored dissemination of outcomes.12,35
ILD specialist nurse
ILD specialist nurses manage symptoms, treatment and possible side effects, coordinate 
care and involve other healthcare services where necessary. They also teach patients 
how to cope with their disease and create a comfortable environment were patients 
can discuss their fears and problems.7,8,29 In the Netherlands, most patients find ac-
cess to an ILD specialist nurse beneficial. The NICE guideline states that all patients and 
their partners should have access to an ILD specialist nurse in all phases of the care 
pathway.23 Yet, currently, as seen in Germany, not all pulmonary fibrosis patients have 
access to ILD specialist nurses, although the demand for such services is high.12,33 We 
agree on the NICE guidelines that all patients and their partners should have access 
to ILD specialist nurses. However, appointments with ILD specialist nurses should be 
individually tailored, as our study shows that patients and partners prefer to see the ILD 
specialist nurse only when required. 
Cultural differences
We found no major cultural differences between Germany and the Netherlands. This 
in line with previous studies, showing that the emotional impact of disease is similar 
in different countries.9,12,28 Practical care preferences might vary due to differences in 
organisation of care, geography, reimbursement criteria and local habits.9,12,27,36 Cultural 
differences should be taken into consideration when trying to optimise guidelines for 
care. 
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Limitations
The interactive voting system used in the current study carries some limitations. Patients 
can potentially respond to questions aimed at partners and vice versa, resulting in higher 
numbers of answers and biased scores. In addition, participants might have responded 
too late or chosen not to respond, and a few participants left during the meeting for 
various reasons (fatigue, transport and unknown reasons), resulting in missing data. We 
therefore report in our results the absolute numbers of responders as well as percent-
ages. Furthermore, patients and partners attending the pulmonary fibrosis information 
meeting in the Netherlands could have attend previous meetings. However, we found 
that only 24% in 2014 and 18% in 2015 had attended the information meeting the previ-
ous year, indicating only a small overlap in the data. As the total number of participants 
(278 in the Netherlands and 51 in Germany) is high compared to other studies assessing 
preferences of pulmonary fibrosis patients and partners,3-5,12,17 this probably dilutes the 
potential voting errors and overlap in data. In the current study, questions were gener-
ated by healthcare providers of different backgrounds and patients. Although these 
questions were not validated (except for the GAD-SI), they were considered informative 
and useful by the participants and were used by the centres to improve care.
COnCLusIOn
This study in a large cohort of patients with pulmonary fibrosis and their partners con-
firms the major impact pulmonary fibrosis has on emotional wellbeing and improves 
the current knowledge of their needs. There is need for better education on all aspects 
of disease, psychological and practical support and the need for ILD specialist nurses. 
No major cultural differences were found between Germany and the Netherlands. The 
method of interactively educating and interviewing could be a good and efficient way 
to generate new insights into pulmonary fibrosis care and is informative for patients 
and their partners. However, further research into the best method of education and 
on tailored support programmes is needed, as these are essential to improve care for 
pulmonary fibrosis patients and their partners. 
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table s1. Content of pulmonary fibrosis patient information meetings in the Netherlands and Germany
The netherlands Germany 
Presentations
-  What is pulmonary fibrosis?
-  Types of pulmonary fibrosis
-  IPF - current state of affairs
-  Non-drug treatment for IPF
-  Role of ILD specialist nurse and research nurses
-  Additional problems in pulmonary fibrosis
-  What did we learn from you?
-  How to coop with pulmonary fibrosis?
-  Future treatments for pulmonary fibrosis
Presentations
-  Current therapy of different interstitial lung 
diseases
-  Clinical trials in interstitial lung diseases
-  Registries in interstitial lung diseases and role of 
ILD specialist nurses
-  Lung transplant
-  The role of patient support groups  - a patients´ 
perspective
Information market
-  Dutch pulmonary fibrosis patient association
-  Meet the researches
-  Physiotherapy
-  Oxygen supplier
-  Lung transplantation
-  Pulmonary function
IPF, Idiopathic Pulmonary Fibrosis; ILD, Interstitial Lung Disease.
In cooperation with the pulmonary fibrosis patient association.
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table s2. Questions asked during pulmonary fibrosis patient information meetings in the Netherlands and 
Germany
1 [Everyone] are you a patient or a partner? 
1.  I am patient 
2.  I am a partner
20 [Patients] I aspire active involvement in the 
development of clinical trials on pulmonary 
fibrosis
1.  Yes
2.  No
3.  Maybe
2 [Everyone] have you been to the patient 
information meeting in this center last year? 
1.  Yes
2.  No
21 [Patients] I would like to participate in medical 
trials because …
1.  I might get better of it
2.  It could help other people
3.  It gives my hope
4.  I do not want to participate in medical trials
5.  No opinion
3 [Patients] I mainly came for …
1.  More information
2.  To meet other people with pulmonary 
fibrosis
3.  The information market
4.  My nearest and dearest and/or partner
5.  Contact with the doctors and nurses 
outside the consultation room
22 [Patients] I find filling in questionnaires for 
research …
1.  Annoying
2.  Neutral
3.  Fine
4.  Nice
5.  I do not want to fill in questionnaires
4 [Partners] I mainly came for …
1.  More information
2.  To meet other people with pulmonary 
fibrosis
3.  The information market
4.  My nearest and dearest and/or partner
5.  Contact with the doctors and nurses 
outside the consultation room
23 [Patients] I would like to see and keep up with 
my own data online …
1.  Yes
2.  No
3.  Maybe
 
5 [Patients] how often do you feel 
misunderstood because people do not know 
what pulmonary fibrosis is?
1.  Never
2.  Now and then
3.  Regularly
4.  Often
5.  Most of the time
24 [Patients] I would find an ILD specialist nurse, 
who would take care of me during the whole 
course of my disease, very helpful in addition 
to the pulmonologist’s treatment …
1.  Yes
2.  No
3.  Unknown
6 [Partners] how often do you feel 
misunderstood because people do not know 
what pulmonary fibrosis is?
1.  Never
2.  Now and then
3.  Regularly
4.  Often
5.  Most of the time
25 [Partners] I find a visit to an ILD specialist nurse, 
who cares for me my through the who disease 
course, a good addition to the general visit by 
the pulmonologist …
1.  Yes
2.  No
3.  Unknown
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table s2. Questions asked during pulmonary fibrosis patient information meetings in the Netherlands and 
Germany (continued)
7 [Patients] how often in the past two weeks 
did you have problems to relax?
1.  Never
2.  Some days
3.  More than halve of the days
4.  Almost every day
26 [Patients] During the past period, I found seeing 
an ILD specialist nurse in addition to the out 
clinic visit to the pulmonologist beneficial …
1.  Agree
2.  Disagree
3.  Neutral 
8 [Partners] how often in the past two weeks 
did you have problems to relax?
1.  Never
2.  Some days
3.  More than halve of the days
4.  Almost every day
27 [Everyone] I see the ILD specialist nurse mainly 
as someone who …
1.  Is accessible for questions on my disease
2.  Helps me with my oxygen applies
3.  Gives support
4.  Does all the above mentioned
5.  No idea
9 [Everyone] What is pulmonary fibrosis?
1.  Inflammation of the lungs
2.  Celluloses
3.  Connective tissue
4.  Thrombosis
5.  It is unclear to me
28 [Everyone] I wish to see the ILD specialist nurse 
…
1.  Always when I visit the pulmonologist
2.  Only when asked for
3.  I only want to see the pulmonologist
10 [Everyone] What causes pulmonary fibrosis?
1.  Exposure to harmful dusts
2.  Underlying rheumatic diseases
3.  Certain medication
4.  Genetic predisposition
5.  Unknown cause
6.  All above mentioned causes
7.  I have no idea 
29 [Patients] next to support for my physical 
problems, I would like to have support for my 
psychological problems
1.  Yes
2.  Yes, I think that is lacking in current care 
3.  No
4.  I have no psychological problems, I do not 
need it
11 [Patients] What type of pulmonary fibrosis 
do you have?
1.  Idiopathic Pulmonary Fibrosis (IPF)
2.  Connective Tissue Disease associated 
Pulmonary Fibrosis (CTD-PF)
3.  Exposure related pulmonary fibrosis
4.  Lymphangioleiomyomatosis (LAM)
5.  Sarcoidosis 
6.  Unknown
30 [Partners] next to support for my physical 
problems, I would like to have support for my 
psychological problems
1.  Yes
2.  Yes, I think that is lacking in current care 
3.  No
4.  I have no psychological problems, I do not 
need it
12 [Patients] most occurring symptom …
1.  Breathlessness
2.  Cough
3.  Dullness
4.  Physical limitations
5.  Worries
6.  Other symptoms
31 [Patients] after this meeting I feel …
1.  More secure
2.  Less secure
3.  Nothing changed
4.  No opinion
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table s2. Questions asked during pulmonary fibrosis patient information meetings in the Netherlands and 
Germany (continued)
13 [Patients] I desire treatment and follow-up 
by …
1.  A pulmonologist nearby
2.  In an expertise center
3.  A pulmonologist nearby and in an 
expertise center combined
4.  A general practitioner and in an expertise 
center combined
5.  A general practitioner and pulmonologist 
combined
6.  No preference
32 [Partners] after this meeting I feel …
1.  More secure
2.  Less secure
3.  Nothing changed
4.  No opinion
14 [Patients] In the care for my lung fibrosis I 
mainly need …
1.  Access to an expertise center
2.  Information on my disease
3.  Contact with peers
4.  Practical support (e.g. medical devices)
5.  Emotional (psychological) support
33 [Patients] This meeting was …
1.  Very useful
2.  Partly useful
3.  Not useful
4.  No opinion
15 [Partners] In the care for my lung fibrosis I 
mainly need …
1.  Access to an expertise center
2.  Information on my disease
3.  Contact with peers
4.  Practical support (e.g. medical devices)
5.  Emotional (psychological) support
34 [Partners] This meeting was …
1.  Very useful
2.  Partly useful
3.  Not useful
4.  No opinion
16 [Patients] I would like to know everything 
about my disease and its prospects …
1.  Yes
2.  No
3.  No opinion
35 [Patients] I find current care …
1.  Excellent
2.  Good
3.  Sufficient
4.  moderate
5.  Poor
17 [Partners] I would like to know everything 
about the disease of my partner and its 
prospects …
1.  Yes
2.  No
3.  No opinion
36 [Everyone] I find seeing the response of the 
other participants …
1.  Pleasant
2.  Neutral
3.  Bothersome
4.  No opinion
18 [Patients] I would prefer talking about 
matters concerning end-of-life in an early 
stage of my disease
1.  Yes
2.  No
3.  No opinion
37 [Everyone] Do you find it informative to see 
the answers of the other participants on the 
screen?
1.  Yes
2.  No
3.  No opinion
19 [Partners] I would like to have more care for 
partners of patients with pulmonary fibrosis
1.  Yes
2.  No
3.  Maybe
ILD, Interstitial Lung Disease
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To the Editor:
Idiopathic pulmonary fibrosis (IPF) is a progressive, deadly disease with devastating 
impact on patients’ and their partners’ quality of life (QoL).1 Many studies have shown 
the need for support groups, better information resources and disease education in 
IPF.2-6 Although these needs have been identified, few studies currently exist concern-
ing interventions that can fulfill them and possibly improve QoL for patients and their 
partners.7 In our study, we determined the effect of a short multi-disciplinary empower-
ment programme on the QoL for patients with IPF and their partners.
In 2014 and 2015, consecutive IPF outpatients and their partners at the Erasmus 
MC, in Rotterdam, were asked to participate in a Patient and Partner Empowerment 
Programme for IPF, called PPEPP. “Partner” was broadly defined as spouse, partner, 
family member or close friend. PPEPP consisted of three afternoon meetings, divided 
over three consecutive weeks and focuses on coping with IPF. A psychologist who is 
experienced in group therapy leads PPEPP. A pulmonologist, specialized interstitial lung 
disease nurse, oxygen supplier, social worker and physiotherapists also contribute to 
the sessions. The protocol and content were designed by the participating disciplines. 
Moreover, two patients with IPF, a former physiotherapist and a vicar, gave their input 
on the protocol and content of the programme. A comprehensive description of the 
programme and contribution of each discipline can be found in the supplementary 
material. 
Patients and partners were included in three blocks: two intervention groups and one 
control group. Patients were included if they had been diagnosed with IPF according 
to the guidelines of 2011,8 had a life expectancy of ≥1 year, had a lung function with a 
forced vital capacity (FVC) ≥45% of predicted, and had a diffusion capacity for carbon 
monoxide (DLCO) ≥25% of predicted. Participants were asked to fill in questionnaires at 
baseline, after 3 weeks and after 3 months. All participants filled in the Hospital Anxiety 
and Depression Scale (HADS), Perceived Stress Scale (PSS) and a knowledge quiz about 
IPF.9 Furthermore, patients completed the King’s Brief Interstitial Lung Disease health 
status questionnaire (K-BILD), the Euroqol5D5L (EQ5D5L) and the Medical Research 
Council (MRC) dyspnoea scale, while their partners completed the Carer Quality of 
Life instrument (CarerQoL).10-12 We also asked participants to complete an evaluation 
form after PPEPP. The Wilcoxon signed rank test was used to compare baseline scores 
with follow-up scores, because the data were not normally distributed. Medical ethics 
committee approval was obtained, and all participants gave written informed consent.
In total, 46 participants were included, 15 couples in the intervention group (eight 
couples in the first, seven couples in the second) and eight in the control group. In 
the intervention group, two couples were excluded. One couple could not participate 
because of clinical worsening of IPF, and the other couple did not complete baseline 
questionnaires and missed the first meeting due to an influenza infection. In the control 
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group, one patient died of heart failure after 3 weeks, thereby excluding this couple 
from analysis. 
In the intervention group, most patients were men (10, 77%) and most partners were 
women (10, 77%); patients had a median age of 63 (range 54-74) years and partners 
of 64 (47-74) years; the median FVC in patients was 80% (50-100%) of predicted and 
DLCO was 46% (25-60%) of predicted. In the control group, all patients were men and 
all partners were women; patients had a median age of 76 (63-82) years and partners of 
74 (22-84) years; the median FVC in patients was 78% (53-96%) of predicted and DLCO 
was 48% (30-82%) of predicted.
Both groups matched on disease severity defined by pulmonary function. However, 
baseline questionnaire scores differed except for HADS depression, PSS and CarerQoL 
(table 1). Questionnaire scores significantly improved after 3 weeks of PPEPP (table 1) 
in the intervention group only.
After a 3-month follow-up, no significant changes in questionnaire scores compared 
with baseline were found in the intervention group. In the control group, QoL measures 
were lower at 3 months than at baseline: K-BILD total median of 72 (range 45-82) versus 
46 (31-86), p=0.03; K-BILD psychological domain 65 (38-73) versus 47 (15-72), p=0.03; 
EQ5D5L 0.9 (0.7-1.0) versus 0.8 (0.3-0.8), p=0.03; and HADS total 6 (0-22) versus 7 (1-
table 1. Wilcoxon signed rank test intervention and control group - baseline versus week 3
Questionnaires Intervention group (n=26) Control group (n=14)
Baseline Week 3 p-value Baseline Week 3 p-value
K-BILD total 43 (28-69) 46 (32-81) 0.06 72 (45-82) 61 (34-79) 0.17
K-BILD psych 49 (22-72) 52 (30-78) 0.03 65 (38-73) 63 (17-80) 0.87
EQ5D5L 0.6 (0.4-1.0) 0.7 (0.6-0.9) 0.07 0.9 (0.7-1.0) 0.9 (0.6-1.0) 0.40
MRC 3 (2-5) 3 (2-5) 0.32 2 (0-3) 2 (2-4) 0.18
HADS total 11 (3-26) 9 (0-27) 0.04 6 (0-22) 7 (1-23) 0.31
HADS anxiety 6 (1-15) 5 (0-14) 0.06 4 (0-13) 5 (0-12) 0.14
HADS depression 5 (0-15) 4 (0-13) 0.04 3 (0-10) 2 (1-12) 0.52
PSS total 20 (5-40) 21 (5-33) 0.94 23 (11-33) 23 (4-34) 0.48
CarerQoL 3 (0-10) 3 (0-6) 0.25 2 (0-3) 2 (0-3) 0.71
CarerQoL VAS 7 (5-9) 7 (5-10) 0.86 8 (7-9) 8 (6-9) 0.45
IPFquiz 6 (3-9) 7 (3-9) 0.27 4 (2-6) 4 (1-9) 0.86
Data are presented as median (range). K-BILD, King’s Brief Interstitial Lung Disease health status questionnaire; psych, 
psychological domain; EQ5D5L, Euroqol5D5L; MRC, Medical Research Council dyspnoea scale; HADS, Hospital Anxiety and 
Depression Scale; PSS, Perceived Stress Scale; CarerQoL, Carer Quality of Life instrument; VAS, visual analogue scale; IPF, 
Idiopathic Pulmonary Fibrosis
A higher score indicates better quality of life/ knowledge on disease
A higher score indicates worse breathlessness/ anxiety/ depression/ stress/ quality of life
Bold indicates statistically significant p-values.
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28), p=0.04. After 3 months, FVC deteriorated ≥5% in one patient of the control group 
and in none of the intervention groups.
All participants considered PPEPP useful and would recommend it to others, while 25 
participants (96%) found PPEPP fulfilled their expectations. The following quotes illus-
trate the participants’ experiences with PPEPP: “informative, useful and supportive”, 
“pleasant to share experience with and learn from peers”, “comforting to know that 
you’re not alone in your struggles”.
This study showed that a short multidisciplinary empowerment programme improved 
QoL for patients with IPF and their partners. To our knowledge, ours is the first study 
in which the effect of a support programme, co-developed with patients and multidis-
ciplinary experts, demonstrated a positive effect on the wellbeing of patients and their 
partners.
Currently, it is well acknowledged that there is a need for better information and support 
for patients with IPF and their partners. Many hospitals organize general IPF informa-
tion meetings and support groups; however, studies on effective ways of supporting 
and educating patients and partners are scarce. A previous study by Lindell et al.7 on 
the effect of a 6-week programme on disease management and symptom reduction 
showed, strikingly, a decline in patients’ QoL and increased anxiety levels. Nevertheless, 
in partners, stress levels decreased, and interviews showed that participants found 
attending the programme helpful. It is useful to realise that information can be distress-
ing to patients and should be tailored carefully. In our study, perceived stress scores 
showed no differences in stress levels. The co-development by two patient experts may 
have been a factor in helping to tailor our programme more effectively.
PPEPP consists of small groups, which stimulate personal interaction, and can be more 
patient-tailored than general information meetings, which are often made up of large 
groups. In our opinion, the experience of the psychologist with group therapy was cru-
cial in stimulating discussion and promoting balanced participation for all. The extensive 
experience with group counseling in the field of oncology could also prove useful. With 
IPF bearing similarities in both prognosis and treatment options with oncology, we think 
we could learn from their experience.13-15 
PPEPP improved short-term QoL but showed no effect long-term. Research into more 
chronic support is needed as different stages of disease often mandate adaptation of 
coping strategies for patients and partners.1 
This study has some limitations. First, it consists of small groups of patients from a single 
center, and though the results are encouraging, further studies are needed. Another 
limitation is the difference in baseline QoL scores between the intervention and control 
groups. We lack a good explanation for this, as no significant differences existed in 
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disease severity defined by pulmonary function (FVC and DLCO). Including patients in 
blocks (for practical reasons) instead of randomizing them may have influenced results. 
Still, participants were not allowed to choose between groups, and the control group 
was offered the opportunity to attend a future PPEPP. For future studies, it would be 
worth exploring the effect of matching participants based on their QoL scores instead 
of pulmonary function.
In conclusion, PPEPP, a concise multidisciplinary empowerment programme, improves 
short-term quality of life for patients with IPF and their partners. Patients and partners 
were very satisfied with PPEPP. More research, however, is needed to develop structural 
support programmes for patients and partners throughout the disease course.
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OnLIne suPPLemenT 
a. Overview of the PPePP program (chaired by psychologist)
Meeting 1 
· Introduction round and assessing patients’ and partners’ wishes and expectations of 
the program
· “What is idiopathic pulmonary fibrosis” by pulmonologist
· “Dealing with IPF – coping strategies” by psychologist
· “Physiotherapy and training” by physiotherapist
Meeting 2 
· “Dealing with IPF” by psychologist 
· “Dealing with IPF” patients (led by psychologist) and partners (led by social worker) 
separated
·  “Support by specialized ILD nurse and oxygen possibilities” by specialized ILD nurse
· Information market on oxygen devices, by oxygen supplier
· “Breathing, cough and limitations” by physiotherapist 
Meeting 3
· “Caring about, for and with each other” by psychologist
· “Practical problems at home” by social worker
· “Latest research developments and patient support groups” by pulmonologist
· Evaluation of the program and round-up
b. Content of PPePP program and contribution of each discipline 
Psychologist
The psychological content of the programme consists of three parts. In the first part, the 
psychologist explains theories concerning stress and coping. For stress, four domains 
are described and discussed with the participants; bodily, cognitive, emotional, and 
behavioural manifestations of stress. Coping is described in terms of emotion-focussed 
coping and problem-focussed coping. Stress and coping are discussed with the stress-
coping model of Lazarus and Folkman in mind.1 Another important topic is the different 
ways of setting goals, for this discussion the model of Problem Solving Therapy forms 
the basis.2 In this model, ample attention is paid to the definition of the problem at 
hand, because a change in problem formulation (e.g. from ‘I am too tired to do things’ 
to ‘I can no longer have long evenings with my friends because of my lack of energy’) 
will lead to a change in goals (e.g. from ‘getting more energy’ to ‘finding different ways 
to see my friends’). Patients are encouraged to formulate their problems more specifi-
cally, so that the goals they set are more specific and more attainable. 
The second part of the programme concerns the quality of the partner relation. For this 
part of the program patients and partners are separated, so that they can discuss more 
freely changes they experience in the partner-relationship. Subjects that are discussed 
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concern for instance feelings of dependency versus independence, changes in reciproc-
ity of the relationship and discussing complex emotions. After patients and partners 
have discussed separately, the subjects of the discussions are shared with the group 
in total, while the content of the separate discussions is not revealed. In this way, the 
confidentiality of the discussion remains intact, while both patients and partners know 
what subjects were discussed. The last part of the psychological intervention consists 
of a discussion of questions that arise within the groups. Important concerns were; the 
uncertainty regarding the future, dealing with diminished levels of energy and dealing 
with ignorance from bystanders regarding the nature of the disease. 
Physiotherapist
The physiotherapist’s contribution to the programme consists of two presentations. 
The first presentation is about physiotherapy and training. During this presentation, 
the physiotherapist explains the importance of exercise for patients with IPF. Exercise is 
necessary to maintain muscle strength and exercise capacity.3,4 The level of exercise can 
be adjusted according to the severity of patient’s disease, patient’s oxygen need, and 
should be adapted when disease progresses.5 Patients also get information on dyspnoea 
and desaturation, and the uses of pulse oximetry and Borg dyspnoea scales. Moreover, 
they receive tips and tricks on how to decrease their breathlessness by adapting their 
exercise and using tools. The physiotherapist also emphasizes, especially for partners, 
that dyspnoea is a subjective measure and that not all IPF patients experience the same 
severity of breathlessness.
The second presentation is about breathing techniques, cough and limitations. Breath-
ing techniques are often used in other lung diseases, such as COPD, and can help 
patients with lung fibrosis to control their breathing.5 Besides breathing difficulties, 
many patients with IPF experience a burdensome cough. Different types of cough are 
discussed and tips are shared as for instance on how to better cough up sputum or how 
to try to avoid the urge to cough sensation in the more dry type of cough, and how to 
deal with the dyspnoea caused by cough. Progressive lung function impairment and 
limitations in training abilities are discussed as well as the fact that oxygen therapy can 
be helpful for some patients to maintain their exercise capacity.4,5 It is important that 
patients inform their physiotherapist on IPF as many physiotherapists are not familiar 
with the disease. All participants received an information folder on how to exercise and 
to control your breathing, and contact information of the physiotherapist.
Social worker
The social worker’s contribution to the programme consists of a presentation explaining 
how they can provide practical and material support for patients. Questions regarding 
regulations and patient rights according to the national policy on disease are discussed. 
The social worker explains what patients can expect when they are not able to work, 
and called in sick or get disqualified for work. The impact of the patient’s medical situa-
tion on their partner and nearest and dearest is discussed, when patients and partners 
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are separated. Together with the psychologist subjects of the discussions are shared 
with the group in total, while the content of the separate discussions is not revealed to 
maintain confidentiality. 
Specialized ILD nurse / Oxygen supplier
The specialized ILD nurse is involved with the PPEPP program from the start and plays 
a vital role in the logistical part. The good relationship with the patients and their 
partners in the outpatient clinic enables her to contact patients for participation. She 
also organizes, together with the researcher, the room and catering, sends invitations 
and is a contact person for the participants. Moreover, the specialized ILD nurse gives 
a presentation on supplemental oxygen, and discusses the potential advantages and 
disadvantages with the group. One of the subjects discussed is the impact the use of 
supplemental oxygen may have on daily life by making the disease more visible and 
limiting freedom of being away from home.6 The need for supplemental oxygen is also a 
sign of disease progression,7 which can be frightening for patients. But also the benefits 
of oxygen use, for example during exercise and activities, are explained.5,8 Participants 
receive general information about supplemental oxygen; when to start with oxygen, 
what kind of devices exist, and what are the advantages and disadvantages of these 
devices. The specialized ILD nurse invites an oxygen supplier to show the different oxy-
gen devices during the ‘oxygen information market’. Participants get the opportunity to 
explore the use of different oxygen devices.
Pulmonologist
The pulmonologist also recruits patients for the PPEPP program and is available to answer 
disease-related questions. During the first meeting, the pulmonologist explains about 
IPF in an interactive way. Aetiology, risk factors, symptoms, diagnosis, heterogeneity in 
disease and prognosis are discussed with the group.9 The pulmonologist also discusses 
the current available anti-fibrotic treatments and supportive options as symptom relieve, 
quitting smoking, oxygen therapy, physiotherapy and psychological support. In the third 
meeting and update of the latest research developments is given. Furthermore, the 
concept of support groups lead by patients is explained. Experiences of support groups 
are discussed.10 Together with the psychologist, an evaluation round is done and a sum-
mary of the meetings and experiences is given. The meeting is concluded with drinks 
with the whole group.
183
Patient and partner empowerment programme for IPF
ch
ap
te
r 1
0
referenCes
 1. Lazarus RS, Folkman S. Stress, appraisal and coping. New York: Springer Publishing; 1984.
 2. Nezu AM, Nezu CM, D’Zurilla TJ. Problem Solving Therapy: a treatment manual. New York: Springer 
Publishing; 2012.
 3. Kagaya H, Takahashi H, Sugawara K, Kasai C, Kiyokawa N, Shioya T. Effective home-based pulmonary 
rehabilitation in patients with restrictive lung diseases. Tohoku J Exp Med. 2009;218(3):215-219.
 4. Gaunaurd IA, Gomez-Marin OW, Ramos CF, Sol CM, Cohen MI, Cahalin LP, Cardenas DD, Jackson 
RM. Physical activity and quality of life improvements of patients with idiopathic pulmonary fibrosis 
completing a pulmonary rehabilitation program. Respir Care. 2014;59(12):1872-1879.
 5. Garvey C. Interstitial lung disease and pulmonary rehabilitation. J Cardiopulm Rehabil Prev. 
2010;30(3):141-146.
 6. Wuyts WA, Peccatori FA, Russell AM. Patient-centred management in idiopathic pulmonary fibrosis: 
similar themes in three communication models. Eur Respir Rev. 2014;23(132):231-238.
 7. Vainshelboim B, Fox BD, Kramer MR, Izhakian S, Gershman E, Oliveira J. Short-Term Improvement 
in Physical Activity and Body Composition After Supervised Exercise Training Program in Idiopathic 
Pulmonary Fibrosis. Arch Phys Med Rehabil. 2016;97(5):788-797.
 8. Frank RC, Hicks S, Duck AM, Spencer L, Leonard CT, Barnett E. Ambulatory oxygen in idiopathic pulmo-
nary fibrosis: of what benefit? Eur Respir J. 2012;40(1):269-270.
 9. King TE, Jr., Pardo A, Selman M. Idiopathic pulmonary fibrosis. Lancet. 2011;378(9807):1949-1961.
 10. Pulmonary Fibrosis Foundation. Support group leader guide. http://pulmonaryfibrosis.org/docs/
default-source/support-group-leader/pff_sgl_guide_03-23-16.pdf?sfvrsn=0, 2016.

chapter 11
General discussion
“The good physician treats the disease; the great physician treats  
the patient who has the disease” 
William Osler
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GeneraL DIsCussIOn
Interstitial lung diseases (ILDs) contain a wide variety of diseases, usually affecting both 
lungs. The two most common ILDs are sarcoidosis and idiopathic pulmonary fibrosis 
(IPF), both known to negatively impact patients’ quality of life (QoL) (chapter 4, 6).1-4 In 
IPF, major drivers of QoL are decline in lung function, depression, cough and dyspnea.5 
In sarcoidosis, multiple organs can be involved, with diverse symptom burden, prognosis 
and effect on QoL.3,6 Furthermore, in sarcoidosis, medication can also have a negative 
impact on QoL3, while in IPF the effect of medication on QoL is less clear.
QoL is a defined by the World Health Organization (WHO) as “an individual’s perception 
of their position in life in the context of the culture and value systems in which they live 
and in relation to their goals, expectations, standards and concerns. It is a broad ranging 
concept affected in a complex way by the person’s physical health, psychological state, 
personal beliefs, social relationships and their relationship to salient features of their 
environment.”7 As QoL is a broad definition, studies often evaluate health-related QoL: 
the subset of QoL that is affected by health,8,9 or health status defined as: “the impact 
of disease on patients’ physical, psychological and social functioning.”10 Although these 
terms represent different concepts, they are often used exchangeably in research and 
daily care. In general, treatment of ILDs is focused on improving physiological outcomes, 
such as lung function parameters and 6-minute walk tests (6MWT). Some of these 
outcomes are also used as surrogate measures of survival.11,12 Physiological outcome 
measures often do not reflect patients’ QoL. In the recent years, it is increasingly ac-
knowledged that QoL should be part of treatment goals and that the patient’s “voice” 
should also be incorporated as an outcome measure in care and research.13-15 In ILD, 
there is a paucity of good patient-reported outcome measures (PROMs) and studies on 
interventions that may improve symptoms and QoL. 
The aim of the studies in this thesis was to measure and improve quality of life in inter-
stitial lung diseases by 1. generating better clinical outcome measures for quality of life; 
2. developing interventions focussed on improving quality of life.
Clinical outcome measures for quality of life
Patient-reported outcome measures
To improve patients’ QoL you first need to be able to measure it properly. PROMs are 
often used to measure QoL, but can also evaluate symptoms, such as cough, fatigue, 
and dyspnoea, that may impact QoL (chapter 2).14,16 PROMs are useful in research, but 
can also serve as outcome measure in daily clinical practise, to guide therapeutic deci-
sions, and for evaluating interventions and quality of care by healthcare policy makers 
(chapter 2). Chapter 2 shows that though PROMs have gained more attention over the 
last years, well-developed and validated PROMs for ILDs are still lacking. Ideally PROMs 
are developed according to a systematic approach14,15,17 and in collaboration with the 
target population. Subsequently, the PROM should be validated in this target popula-
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tion. Validation is an iterative process and the more an instrument is used in studies 
and real life, the more solid the validation will be. The risk of these comprehensive 
validations is that often less ideal PROMs are used, as choice of PROM will be based on 
familiarity and number of trials used before. This strategy may obstruct development 
and validation of new outcome measures. 
For the research in ILD in this thesis, we choose to primarily use PROMs that were de-
veloped in the target population, such as the King’s brief interstitial lung disease health 
status (K-BILD) questionnaire. The K-BILD is an ILD-specific PROM consisting of 15 ques-
tions, and has been developed and validated in an ILD population in 2012.18 Since then, 
the K-BILD has been translated and validated in Dutch, French, Italian, Swedish, and 
German.19,20 By developing these multi-linguistic versions, the questionnaire can now 
widely be used for international collaboration. Until now, the SGRQ has most often been 
used in ILD research and is the best validated questionnaire in patients with IPF.21 Yet, 
it failed to show an effect on QoL in drug trials that were positive.22,23 Disadvantages of 
the 50-item SGRQ are the original development in COPD and asthma, and the numerous 
questions, with many of them irrelevant to ILD patients. The SGRQ correlates well with 
the much shorter K-BILD,18 while the K-BILD is easier to use in daily practise. The K-BILD 
is currently used in several trials in ILDs,24-26 and registries are embracing the question-
naire,27,28 which will improve its validation. For IPF, other PROMs, as for example the 
Tool to Assess Quality of Life in IPF (ATAQ-IPF), and the COPD Assessment Test (CAT), 
are also being validated.29-32 Moreover, new questionnaires are now being developed 
for IPF, such as the IPF-PROM, IPF-PREM and patient experiences and satisfaction with 
medication (PESaM) questionnaire, that not only focus on patients perception regarding 
their health status and a given intervention, but also assess patient expectations and 
experiences with healthcare.33-35 
For sarcoidosis, we chose to use the King’s Sarcoidosis Questionnaire (KSQ) as it was 
developed in a sarcoidosis cohort, is simple to administer, and takes into account 
multiple organ involvement.36 In chapter 3 we translated and validated the KSQ in a 
Dutch cohort of sarcoidosis patients and thereby enabling use of the questionnaire in 
Dutch-speaking countries, and facilitating participation in international collaborations. 
The validation of the KSQ in Dutch has stimulated international collaborative projects, 
and the KSQ has been used in several international and Dutch clinical trials.37-41 These 
studies will prospectively follow up large cohorts in multiple countries and enable 
better validation of the KSQ. The minimal important difference (MID) for the KSQ Lung-
GHS domain has been determined, but no MID for the total list or separate modules 
exists.42 By correlating clinical data and outcomes to the different modules of the KSQ, 
future studies will help determining these MID using different anchors meaningful for 
patients. A study by Baughman et al. showed a significant improvement in KSQ scores 
after 24 weeks of additional treatment with repository corticotrophin in patients with 
sarcoidosis. Interestingly, they found no significant changes in SGRQ scores. This might 
be because the SGRQ was originally developed for COPD and asthma, and may contain 
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questions irrelevant to sarcoidosis patients.43 Moreover, the SGRQ is focussed on the 
lungs, while the KSQ contains multiple organ domains to capture the multi-systemic 
nature of sarcoidosis. At the time of the KSQ study, the SHQ was the only alternative 
sarcoidosis-specific QoL questionnaire.44 We chose to validate the KSQ, as the SHQ con-
tained only few organ-specific questions and was not validated in eye or skin disease. 
Another sarcoidosis-specific questionnaire, the Sarcoidosis Assessment Tool (SAT), was 
developed during our study.45 The SAT includes questions on multiple-organ involve-
ment, but is with its 51 items considerably longer than the KSQ.45 Both the SAT and SHQ 
have also shown to be able to capture effect of treatment.46,47
PROMs may serve a broader purpose than only as outcome measures; they might also 
be used as predictor for prognosis. As shown in a study in 182 Japanese patients with 
IPF, were the SGRQ showed to be an independent prognostic factor for mortality.48 
A score above 30 corresponded with significant higher mortality than a score below 
30. Interestingly, the study showed that both baseline forced vital capacity (FVC) and 
the SGRQ independently predicted mortality.48 The authors postulate that the SGRQ 
might capture another dimension and more comprehensive aspect of disease. This cor-
responds with our and previous findings that lung function parameters poorly correlate 
with QoL scores (chapter 3, 8),18,29,49 and underscores the importance of incorporating 
QoL PROMs as outcome measure in clinical trials. If more disease-specific PROMs as the 
K-BILD will even better relate to prognosis, still needs to be studied. The recent years it 
is increasingly acknowledged that comorbidities may affect prognosis and may also in-
fluence QoL.50,51 It seems reasonable to assume that comorbidities influence outcomes 
of disease-specific PROMs, however, to our knowledge no good research exist on the 
influences of comorbidities on PROM scores. 
One of the problems with PROMs is that they are often lengthy questionnaires. Com-
pleting of PROMs is not only time-consuming but can also yield recall bias. Furthermore, 
they often contain questions irrelevant to certain patients. One of the options to solve 
these problems, as described above, are shorter and more relevant questionnaires. 
Recall bias may be solved by enabling patient’s access to their data captured by serial 
measures, so that they can relate to their previous answers. The clinical meaningfulness 
and research implications of such methods need further evaluation. Another option 
might be the use of computer-adapted tests (CATs). CATs are based on an item response 
theory model, and try to establish the optimal test for each participant by adapting the 
test to their ability level or based on individual relevances.52,53 Items (questions) are 
derived from an item bank were they define a common domain.52,54 The first domain-
specific question a participant answers is believed to predict the domain score. The 
second question is selected based on the previous answer, and so one. After each ques-
tions the reliability of the predicted domain scores should become more convinced.44 
CATs have the advantage that they can be shortened and tailored-made, as irrelevant 
questions can be avoided.52 The KSQ with its multi-domains could potentially benefit 
from a CAT strategy. 
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Especially when studying orphan diseases, international collaboration is important to 
increase the number of patients that can be studied. Though the multilingual valida-
tions and new developments on ILDs PROMs are encouraging, more research is still 
needed to determine if disease-specific questionnaires, as the K-BILD and KSQ, can bet-
ter capture QoL and treatment effects than PROMs adapted from other lung diseases, 
such as the CAT and SGRQ. Also, many ILD PROMs still lack longitudinal data and need to 
be translated and validated in larger and prospective cohorts. Currently, registers pop-
up worldwide to study the clinical course of ILDs, possible biomarkers and PROMs.55-57 
Hopefully, these registers will provide the longitudinal data on PROMs we are waiting 
for. 
Patient-reported outcome measures as primary endpoint
PROMs are now increasingly used as secondary endpoint in clinical trials in ILDs, which 
raises the question if PROMs also could and should be used as primary endpoint. Clini-
cal trials in ILDs can broadly be divided into three groups: 1. trials aiming at disease-
modification, 2. trials aiming at improving symptoms, 3. trials aiming at improving QoL. 
In group one, FVC is commonly used as primary endpoint as it is reproducible, easy to 
test and associated with mortality.11,58 Other primary endpoints often used are transfer 
factor for carbon monoxide (TLCO), 6MWT, hospitalization and mortality.11,59 Currently, 
we do not have robust enough PROMs to serve as primary endpoint in trials aiming at 
disease-modification. Also, Food and Drug Administration (FDA) and European Medi-
cine Agency requirements should be taken into account, especially in drug registration 
trials.60,61 However, as PROMs seem to capture another aspect of disease they should at 
least be included as secondary endpoint. 
For group two, objective symptoms scores or measurements, or subjective symptom-
related QoL PROMs can be used as primary endpoint. Our and previous studies show 
that objective and subjective symptoms scores may vary in correlation from poor to 
good (chapter 8).62,63 For example, a patient’s cough frequency does not always defines 
how a patient experiences his or her cough. The effect of cough on a patients’ QoL might 
be influenced by work, social activities, and relationship status.64 In clinical trials aiming 
at improving symptoms, the main goal should be to improve patient’s experience of the 
symptom; ideally a symptom-related QoL PROM should therefore be used as primary 
endpoint. However, as objective symptom scores seem to capture another aspect of 
disease, and the relationship between objective and subjective is often only moderate 
(chapter 8), a novel strategy could be to use composite endpoints of subjective and 
objective outcomes. 
In the third group, a QoL PROM should be the primary endpoint. As shown by our 
“PPEPP study” in IPF patients, QoL-related PROMs scores are able to capture effects of 
interventions (chapter 10). Also, other studies in ILD/IPF have confirmed this.65,66 Better 
development and validation of PROMs together with patients, may improve the ability 
of the instruments to detect changes that are meaningful to patients. 
191
General discussion
ch
ap
te
r 1
1
Objective patient-reported outcome measures 
Current PROMs on QoL are subjective and sometimes of bothersome length for patients, 
and pose a burden on logistics in daily practise. An objective measure for QoL, that is 
easy to obtain and fit for longitudinal follow-up, may be an innovative step forward in 
outcome development. At first for use in clinical trials, but maybe in the future also in 
regular care. Previous studies showed that scalp hair cortisol could serve as an objective 
biological marker for chronic stress.67,68 Patients with ILDs may experience chronic stress, 
due to progressive respiratory symptoms, decreased QoL, and a sometimes chronic or 
even fatal disease course. We choose to first assess the feasibility of scalp hair steroid 
analyses in sarcoidosis, as patients with sarcoidosis often experience psychological dis-
tress and we also wondered if cortisol levels might be related to fatigue (chapter 4). Our 
study showed that scalp hair cortisol can be used to assess psychological distress, but 
that scalp hair steroids were not related to fatigue in patients with sarcoidosis. It also 
showed that cortisol and cortisone levels are much higher in sarcoidosis patients than 
in general population controls, which could be due to disease inflammation, or direct 
psychological distress. Further studies are needed to elucidate the increased chronic 
steroid levels, and to determine the precise role of scalp hair cortisol in monitoring 
patients with sarcoidosis. As many patients with other types of ILDs also experience 
psychological distress it is evident to evaluate scalp hair steroids level in these patients 
as well. Though research on biomarkers in ILDs is increasing, no biomarkers currently 
exist that can objectively measure QoL in ILDs. 
Clubbing as diagnostic feature
Clubbing is a diagnostic feature of fibrotic ILDs. It has shown to be an independent pre-
dictor of disease progression and might be used as objective measure for prognosis.69,70 
However, the predictive value of clubbing was based on physicians’ ratings and only 
assessed in IPF. To study if clubbing can be used as outcome measure in treatment or as 
predictor of prognosis in fibrotic ILDs, it is important to measure clubbing reliably and 
preferable quantify it. Clubbing can be measured subjectively on sight or objectively 
with several clubbing measuring methods (chapter 5).71-74 In chapter 5 we show that, 
in patients with fibrotic ILDs, assessment of clubbing by different measuring methods 
showed no to poor agreement. Also, PROM scores were not influenced by the presence 
or absence of clubbing. Yet, severity of disease, measured with TLCO, seemed worse in 
patients with clubbing than those without (chapter 5). Though the exact pathogenesis 
of clubbing is unclear, it has been proposed that platelet-derived growth factor (PDGF) 
and vascular endothelial growth factor play a central role in clubbing. Clubbing is known 
to disappear after lung transplantation or when underlying diseases are treated success-
fully.75-79 However, the effect of successful anti-fibrotic treatment on clubbing in ILD is 
unknown, though interesting as the anti-fibrotic drug nintedanib targets, among others, 
the PDGF receptor, that is thought to be involved in the pathogenesis of clubbing.23 Nor 
do we know if clubbing might be a marker of anti-fibrotic treatment response, and could 
even be associated with a certain phenotype of disease. Nevertheless, determination 
of a “gold standard” for clubbing should be established first, before longitudinal studies 
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can provide information on the predictive value of clubbing and its potential role as 
physical marker for treatment response.
Interventions focussed on improving quality of life
The interventions described in this thesis are mainly focussed on patients with IPF. Some 
of these might also be applicable for other ILDs, including sarcoidosis. In future research 
we not only wish to optimize the current interventions, but also include other ILDs. 
Holistic approach 
Disease modification is often the central focus of treatment in ILDs. However, modifica-
tion of disease behaviour will not always lead to improvement of symptoms and/or 
QoL. In IPF, the only curative option is lung transplantation, which is possible in only a 
small group of patients. Fortunately, there are now two drugs that slow down disease 
decline.22,23 In a deadly disease as IPF, most people want to live as long as possible, at 
the best possible quality. Treatment should therefore not only aim at slowing down 
lung function decline but also on improving patients’ symptoms and QoL. As inspir-
ingly formulated by a family caregiver and IPF patient “it’s really about what’s going to 
improve the quality versus the length of your life” and “if we can’t solve this problem 
today, let’s do something that improves patients symptoms, that improves their quality 
of life, that can help them to move forward, at least for a little bit of time with their 
families.”80,81 Chapter 6 focuses on how to optimize QoL in patients with IPF. We pro-
posed a new model for continuous care – the “ABCDE of IPF care”: Assessing patient’s 
and partner’s needs, backing patients by giving information and support, delivering 
comfort care by focusing on treating symptoms and taking into account comorbidities, 
striving to prolong life by Disease modification, and helping and preparing patients and 
their family for the end-of life (chapter 6). Reassessing the patient’s situation should be 
done during the different phases of the disease, as needs may change when the disease 
progresses. The ABCDE model tries to capture all aspects of disease management, and 
can function as guide for optimizing QoL in IPF patients. As with all models, the ABCDE 
model is not watertight and new insights or treatment options should lead to adapta-
tions in future. For example, many patients with IPF, like in other chronic respiratory 
diseases, lose weight.81,82 Though no studies have been done on the clinical significance 
of nutritional status in IPF, one could argue that dieticians, who can play an important 
role in maintaining patients’ weight, should be added to the ABCDE model as well. Also, 
new developments in disease modifying treatment and studies on genetics and differ-
ent phenotypes of patients with IPF will probably lead to alterations of the model. This 
model together with new approaches to managing IPF, underline the importance of a 
holistic approach when treating patients with IPF.83,84
Symptom intervention
As described in chapter 6, there is a paucity of interventions to improve QoL. In IPF, one 
of the main symptoms impacting patients’ QoL is cough.62,81 Patients with IPF often have 
a refractory and dry chronic cough (>8 weeks). Although cough in IPF can be related 
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to comorbidities, such as gastro-esophageal reflux disease, obstructive sleep apnea, 
and emphysema, its exact underlying mechanism is largely unknown (chapter 7).85 In 
chapter 7, we describe concepts that have been proposed as possible mechanism of 
cough in IPF. Cough in IPF is difficult to treat, no convincing studies on treatment in 
cough exist, and patients often do not respond to conventional anti-tussive therapies 
(chapter 7). A number of observations suggested that pirfenidone might decrease 
cough in IPF patients.86,87 In chapter 8, we therefore analysed the effect of pirfenidone 
on objective and subjective cough in patients with IPF, and found that both improved 
significantly after 12 weeks of treatment. These improvements were clinical meaningful 
for patients. Recently, a small placebo-controlled trial showed that 14-day inhalation of 
PA101, a highly concentrated cromolyn sodium formulation, has an beneficial effect on 
cough in patients with IPF.88 To our knowledge, this is the only other study on treatment 
for cough in IPF that used objective cough counts. No effect on cough was seen in the 
placebo group of the PA101 trial.88 In our study, no placebo group was studied, as at that 
time it was considered unethical to leave a group of patients untreated for 12 weeks. 
However, the results of the PA101 study suggest that no major placebo effect is present 
when treating IPF patients for their cough, and strengthens our results. Nevertheless, 
it remains unsatisfying that the exact mechanism of pirfenidone on fibrosis remains 
unknown and that we can only hypothesize what the possible mechanism on cough 
might be. In our study, pirfenidone significantly improved cough-related QoL measured 
by the LCQ, but showed no effect on K-BILD scores (chapter 8). This might be because 
the K-BILD contains no question on cough and possibly measures a different aspect of 
QoL. As shown by Lindell et al., cough not only impacts patients, but also their environ-
ment and relationships.89 A significant clinical meaningful improvement of cough can 
therefore have an enormous positive effect on both patients and family. We regret that 
we missed the opportunity in our study to also assess the families’ perception of cough 
and the impact of chronic cough and effect of cough changes on the patients’ nearest 
and dearest.
Cough is not only a major bothersome symptom, but also an independent predictor of 
disease progression in patients with IPF. IPF patients who cough might have a different 
phenotype of disease and could respond differently to therapy. To further explore this, 
cough should be included as outcome measure in clinical trials (chapter 7). Ideally in 
these trials both objective and subjective outcome measures are used, as is often the 
case in well-designed trials for chronic cough.90,91 However, it might not always be fea-
sible due to logistics and resource difficulties. In our study, we found that correlations 
between objective cough and subjective cough scores were moderate, with the urge-
to-cough VAS having the best correlation (r=0.55, p<0.01) (chapter 8). If objective cough 
counts cannot be used as primary endpoint, the urge-to-cough VAS, possibly in combi-
nation with the LCQ, would then be the way forward. Currently, clinical trials on new 
agents in IPF are already increasingly including cough as endpoint, and general chronic 
cough trials now often contain a subgroup of IPF patients.92-94 Most of these studies 
use subjective cough-specific QoL and severity scores as outcome measure, and some 
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also objective cough frequencies. Some of the chronic cough trials show encouraging 
results, such as the trial by Abdulqawi et al.95 They show that two weeks treatment with 
AF-219, a P2X3 receptor antagonist, reduced cough frequency by 75% in patients with 
refractory chronic cough.95 This agent is now studied in patients with IPF.92,96 
Cough is also a common symptom in sarcoidosis and other ILDs.97,98 The heterogeneity 
of ILDs complicates study design, but as cough is often also an unmet need in these 
diseases, they should not be forgotten. Hopefully positive developments in anti-tussive 
mediation in chronic cough and in IPF can be extrapolated to other diseases.88,95 Also, 
studies on the use of pirfenidone in other fibrotic ILDs are now emerging,84 and might 
show a beneficial effect on cough as well.99 If the anti-fibrotic drug nintedanib also has 
an effect of cough needs to be evaluated.
Quality of life intervention
In chapter 9, we asked pulmonary fibrosis patients and their partner’s questions 
regarding their needs and preferences in care. Consistent with previous studies, the 
study showed that pulmonary fibrosis has a major impact on patients’ and partners’ 
psychological wellbeing, and a need for comprehensive information, and psychological 
and practical support.2,100-103 An interactive voting system was used, which projected 
answers of participants directly on a screen. Participants found the system pleasant and 
informative, and felt more secure after the meeting (chapter 9). If this kind of educa-
tional methods will have a positive effect on QoL, through improvement of knowledge 
on disease and by showing patients and their partners that they are not alone in their 
struggles, is still unclear. Yet, we decided to continue using this interactive voting system 
at the patient meetings in our centre, to be able to continuously evaluate and improve 
our service and to catch potential changes in needs in future.
The unmet needs revealed during the patient information meetings, prompted us to 
develop an empowerment program for IPF patients and their partners, the “PPEPP pro-
gram” (chapter 10). The program focussed on disease education, psychological support 
and interaction with peers, and comprised multiple disciplines: a pulmonologist, ILD 
specialist nurse, oxygen supplier, social worker and physiotherapist. The “PPEPP pro-
gram” is the first IPF support program that shows to improve short-term QoL scores in 
both patients and partners (chapter 10). We currently implemented the PPEPP program 
in our general care and are now studying if follow-up meetings can prolong the QoL 
improvements found after 3 weeks.
There are several challenges in patient education and support. Practical challenges, 
as limited resources and time, demand new methods to be sought in addition to the 
consultation with doctor and specialist nurses. Group sessions as PPEPP could help, 
but are not (yet) reimbursed by insurance companies. Engaging patient associations 
is of great benefit, but not all patients wish or are able to travel to their meetings, 
and some prefer local setting and teams, and a more personalized approach. To more 
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actively involve patients in peer education, is difficult in a progressive disease as IPF 
were patients have limited energy. In the PPEPP program, we gave patients and partners 
information on how to continue the group and form a “self-organized” support group, 
based on the American Pulmonary Fibrosis Foundation support group leader guide.104 
Although they exchanged emails/addresses, none of them arranged a support group 
meeting. Another challenge is the content of the information, which should be carefully 
tailored as information may lead to more anxiety. Meeting peers with more advanced 
disease might also increase anxiety. In a 6-weeks support program in IPF of Lindell et al., 
patients’ QoL and anxiety scores deteriorated.105 By involving patient advisors from the 
start of the project we believe that this may be prevented. The effectiveness of different 
methods for delivering information to patients and family, through paper or online, is a 
subject for further studies. 
Role of partners in care process
Chapter 9 showed, in analogy with findings of other studies, that ILDs not only impacts 
QoL of patients, but also of their nearest and dearest.89,101,106,107 Patients with a life-
limiting, progressive disease as IPF do not have their disease alone, but “together” with 
their partners. In oncology, multiple support programs have been developed and incor-
porated in care,108-110 while in ILD there is little experience with this. With the “PPEPP 
program” we tried to fulfil this need, by letting the partner join the meetings (chapter 
10). They were pleased to be involved, so that they could support their loved-ones, 
learn more about the disease, and had the opportunity to talk with other partners of 
IPF patients. In both patients and their partners QoL improved after the PPEPP program 
(chapter 10). Partners play an important role in the care of IPF patients, especially in 
the end-stage of disease. Psychological support for partners can be beneficial for both, 
as it enables partners to continue caring for the patient, allowing the patient to stay at 
home till a later phase in the disease.101 In sarcoidosis, numerous studies assessed QoL, 
but none studied the impact of the disease on partners and other nearest and dearest. 
Unpublished data of interactive voting, during sarcoidosis patient meetings in the Eras-
mus MC in Rotterdam, showed that sarcoidosis patients have similar needs for care and 
psychological support as IPF patients. A PPEPP program adapted for sarcoidosis seems 
therefore desired. But, as QoL has shown to be decreased in almost all ILDs (chapter 4, 
5, 6, 9),18 the PPEPP program might need to be adapted for a more diverse group of ILDs.
Patient as partner in care and research 
Patients are, as shown in chapter 9, an important source of information. Much re-
search has been done on the preferences, perspectives and needs of patients with 
IPF,1,2,81,102,111,112 and patients are now increasingly becoming involved in the develop-
ment of outcome measures.18,31,33,44 Main topics of patients interests are obtained 
through focus groups and patient interviews during the translation process of PROMs 
(chapter 3).19,31,33 However, patients should also be involved in the start-up of clinical 
trials and care programs. As shown in chapter 9, the fast majority of patients wish to be 
involved in the development of clinical trials. Many problems could be overcome when 
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involving patients in an early stage. Knowledge on patients’ thresholds for participa-
tions, expected burden and therapy adherence beforehand might prevent delays in 
inclusion and disappointing drop-out rates. It is likely that one of the reason for success 
of the “PPEPP program” (chapter 10) was the fact that it was developed with input of 
patients, and was adapted after feedback of participants. In the one to one consultation, 
most doctors will strive to take treatment and care decisions together with patients. 
However, only patients that are well educated will be able to make realistic choices, and 
in daily practise discussion will be influenced by the doctors’ preferences. This may lead 
to, for instance, a different approach on when to start anti-fibrotic treatment, or differ-
ences in treatment limitations between doctors and centres. Besides better education 
also simple tools, such as the supportive and palliative care indicator tool (SPICT) that 
assesses patients at risk to progress or die,113 will stimulate more discussion on choices. 
Clinical implications 
ILDs will remain to have a high impact on patients’ QoL. In this thesis, most studies are 
focused on patients with IPF and sarcoidosis. In the future, we hope that our findings 
can be extrapolated to other ILDs.
This thesis generates new outcome measures for QoL in sarcoidosis and lung fibrosis 
(chapter 3, 4, 8). Clinical outcome measures can help with identifying subgroups of 
patients that benefit the most of treatment, and can also guide treatment decisions for 
the individual patients, both leading to more personalized medicine. Also, our studies 
show that simple interventions can improve QoL, and that anti-fibrotic drug, besides re-
ducing lung function decline, may improve the burdensome symptom cough (chapter 8, 
10). This fits in the ABCDE model of holistic and personalized care we propose (chapter 
6). The impact of wider implementation of this model on quality of care and on the QoL 
for patients and partners needs to be further explored.
Analysis of scalp hair steroids in a broader group of ILDs might provide new information 
on cortisol levels and the role of steroid levels in the psychological distress patients with 
ILDs experience. As prednisolone is a less common treatment for IPF and some other 
ILDs than for sarcoidosis, it will probably be easier to include larger groups of patients. 
For sarcoidosis, scalp hair cortisol could well serve as an objective outcome measure 
of an intervention (such as a patient and partner empowerment or pulmonary reha-
bilitation program) in patients that have no indication for steroid treatment. In patient 
needing steroid treatment, it would be interesting to look at scalp hair cortisol levels 
before start with prednisolone and after some months of treatment. As previous studies 
showed that exogenous corticosteroids, as inhalation and systemic corticosteroids, can 
suppress cortisol production,114,115 scalp hair cortisol might have a role for the monitor-
ing of compliance and dosing of corticosteroid treatment in sarcoidosis.
For clubbing, it should be sorted out first which measure is most reliable. As in daily clini-
cal practice clubbing is often rated by physicians, it would be interesting to look at the 
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intra- and interobserver agreement on clubbing of several ILD physicians. Longitudinal 
studies are needed to unravel the possible effect of anti-fibrotic treatment on clubbing, 
its prognostic value, and if clubbing could be a feature in personalized medicine.
future perspectives 
PROMs
Validation of existing non-ILD and ILD-specific PROMs, and development of new ILD 
PROMs, together with CATs might result in an overgrowth of questionnaires, with a risk 
of fragmented use and validation, with negative effect on quality. In future, international 
collaboration between countries with different backgrounds, systems and religions is 
required to filter out the best PROMs for ILD. We see a role for international networks, 
such as the European Reference Network to coordinate and fund collaborative efforts 
to promote more universal PROM development.
Expectation management
Besides PROMs, also patient-reported experienced measures (PREMs), that focus on 
patients expectations and experience with medications and care, are gaining more at-
tention. In England, a IPF-PREM is developed which focuses on the quality of services 
during the different stages of the disease.34 In the Netherlands, the PESaM, a ques-
tionnaire that focuses on patients’ experiences and satisfaction with medication, for 
patients with IPF has been developed.35 Better expectation management and education 
could influence patients’ experiences with medications, and potentially improve medi-
cation adherence and handling of side-effects, which could positively contribute to QoL. 
Moreover, understanding patients’ experiences with medication and care generates 
insights in how to improve quality of care and treatment perception. Well-validated 
PREMs may possibly complement PROMs in a structural approach to improve care for 
IPF, and hopefully in future also for other ILDs.
E-health
E-health is an emerging field in medicine. A broad range of definitions of e-health ex-
ists116, with the WHO defining e-health as: “the use of information and communication 
technologies (ICT) for health.”117 We developed an e-health self-management tool for 
patients with IPF in our centre: IPF online.118 IPF online is a secured personal platform 
which provides information about IPF, lung function parameters, PROMs on symptoms 
and QoL, and has an e-consult possibility.118 IPF online and other e-health tools could 
give patients a more active role in care and research and might optimize care by provid-
ing high quality information, increasing efficiency of care, and overcome geographic 
distances difficulties in (international) research and care services.119 E-health has the 
potential to bring care from the hospitals to the patients’ homes by even adding home-
based spirometry to e-health platforms.120 In future, home-spirometry may be used to 
prevent unnecessary hospital visits and can help to monitor treatment response.120,121 
Further studies are needed to discover the exact role of e-health and home-spirometry 
in precision medicine and care of patients with ILDs.
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Personalized medicine
While in this thesis we have tried to personalize care by focusing on clinical needs and 
outcomes, for true personalized or precision medicine these data should be integrated 
with more basic data such as genomics and biomarkers.122,123 The last decades, research 
on genetics in ILDs has been evolving.124-127 For IPF, numerous gene mutations and 
polymorphisms have been found associated with the disease.123,124,128 Some of them 
are associated with survival in IPF.124,128,129 Differences in genotypes might also influence 
treatment decision. A first example of this in IPF is that patients with an rs3750920 TT 
genotype might have a favourable effect of N-acetylcysteine (NAC) therapy while for pa-
tients with an rs3750920 CC genotype NAC treatment seems harmful.130 In the coming 
years, more genetic mutations and polymorphisms will probably be discovered in ILDs, 
enabling differentiation of the various types of IPF and other ILDs. Also, biomarkers may 
play a role in predicting therapy response and disease behaviour. Only by integrating 
data from biomedical research, clinical outcomes and patient-reported outcomes, we 
will be able to improve diagnosis, treatment and care for the individual patient with ILD.
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summary
Interstitial lung diseases (ILDs) contain a wide variety of disorders, usually affecting both 
lungs diffusely. The name is actually incorrect, as the interstitium is the space between 
the alveoli and blood vessels, but ILDs also affect alveoli, respiratory tract, pleura, and 
blood vessels. There are more than 200 diverse ILDs, with the most common idiopathic 
pulmonary fibrosis (IPF) and sarcoidosis. 
IPF is a progressive fibrotic lung disease of unknown cause, with a median survival of 
3-5 years without treatment. Besides lung transplantation, which is only available for a 
small group of patients, no curative treatment exists. Recently two anti-fibrotic drugs 
became available that slow down lung function decline and improve life expectancy; 
pirfenidone and nintedanib. IPF has a high symptom burden, with progressive dyspnea, 
fatigue and cough having the most impact on patients’ quality of life (QoL). 
Sarcoidosis is a granulomatous multisystem disease of unknown cause. It can affect 
every organ but is mostly seen in the lungs, skin, eyes, liver and peripheral lymph nodes. 
Sarcoidosis has multiple manifestations, ranging from asymptomatic to life-threatening 
pulmonary fibrosis or cardiac disease. Symptoms can vary and depend on organ involve-
ment, but most frequent symptoms seen are cough, dyspnea, pain and fatigue, with 
fatigue having the most impact on patients’ QoL. 
Although it is well-known that QoL is impaired in ILDs, treatment is often mainly focused 
on improving physiological outcome measures, such as lung function parameters and 
six minute walking tests. These physiological outcomes often do not reflect the impact 
ILDs have on a patient’s QoL. Patient-reported outcome measures (PROMs), mostly 
questionnaires, can be used for measuring QoL and symptom burden. Unfortunately, 
there is lack of well-developed and validated ILD-specific PROMs and other measures to 
assess these important aspects of disease. Also, interventions on improving QoL in ILDs 
are scarce and of poor benefit.
The aim of this thesis was to measure and improve QoL in ILDs by generating better 
clinical outcome measures for QoL (part 1) and developing interventions focussed on 
improving QoL (part 2).
Part 1: Outcome measures in interstitial lung diseases
chapter 2 describes the recent advances in research on PROMs in IPF. PROMs can be 
used for multiple purposes: as outcome measure for daily care or for driving therapeutic 
decisions, as efficacy endpoints in clinical trials, or as tools to collect data for healthcare 
policy makers in order to improve access and quality of care. They hold great potential 
to reveal new aspects of IPF, which can help understanding the variable response to 
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treatment and reduce interpretation biases in clinical trials. Unfortunately, well-validat-
ed IPF-specific PROMs are still lacking and past IPF trials showed that generic PROMs 
correlate poor with established endpoints of treatment response, such as the forced 
vital capacity (FVC). Nonetheless, promising IPF-specific PROMs have been developed 
and are currently being validated in large cohorts. The next years are likely to bring new 
well-validated instruments, which will provide useful data for researchers, healthcare 
providers, patients and policy makers to improve quality and access to IPF care.
In chapter 3, we translated and validated a sarcoidosis PROM, as no sarcoidosis-specific 
questionnaire existed yet in Dutch. This sarcoidosis-specific questionnaire, the King’s 
Sarcoidosis Questionnaire (KSQ), was developed in 2012 in the UK. The KSQ is a brief 
self-administered PROM, which assesses health status using five modules; General 
health status, Lung, Medication, Skin and Eye. We translated and validated the KSQ in 
a Dutch population. The KSQ was translated according to an international multi-step 
forward-backward procedure, and tested on its relevance and applicability in ten struc-
tured patient interviews. Subsequently, 98 consecutive outpatients (85 lung, 22 skin and 
24 eye involvement) completed multiple PROMs twice, two weeks apart. Psychometric 
validation showed good construct validity between KSQ modules and corresponding 
questionnaires, except for the medication module. Internal consistency was good for 
all KSQ modules (Cronbach’s α 0.70-0.90), and intraclass correlation coefficients and 
Bland-Altman plots showed good repeatability. The Dutch KSQ was shown to be a valid 
and reliable PROM for assessing health status in Dutch patients with sarcoidosis and 
facilitates international collaboration in clinical trials in sarcoidosis. 
Patients with sarcoidosis often experience fatigue and psychological distress, but little is 
known about the etiology of these conditions. Factors that might play a role are stress, 
systemic inflammation, hypocortisolism and hypogonadism, which can influence corti-
sol and testosterone levels. While serum and saliva cortisol levels are used to monitor 
acute stress, scalp hair analysis is a new method that measures long-term steroid levels. 
In chapter 4 we investigated whether scalp hair cortisol, cortisone, and testosterone 
levels differ between sarcoidosis patients both with and without fatigue and general 
population controls. Additionally, we studied if these hormones could serve as objective 
biomarkers for psychological distress in sarcoidosis. Hair steroid levels were measured 
using liquid chromatography-tandem mass spectrometry in glucocorticoid naïve sar-
coidosis patients. Hair steroid levels from 293 participants of the Lifelines cohort study 
served as controls. We included 32 sarcoidosis patients; of them 23 were fatigued (FAS 
score ≥22). Strikingly, we found that scalp hair cortisol and cortisone levels were signifi-
cantly higher in sarcoidosis patients than in general population controls. No significant 
differences in hair testosterone levels were found between male sarcoidosis patients 
and controls, and in hair steroid levels between fatigued and non-fatigued sarcoidosis 
patients. Increased hair cortisol levels of sarcoidosis patients were significantly associ-
ated with increased anxiety and depression, and decreased mental health, but not with 
fatigue. Our study is the first to assess scalp hair steroids in sarcoidosis, and to show 
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that scalp hair cortisol is a promising non-invasive biomarker for psychological distress 
in patients with sarcoidosis.
Digital clubbing is considered typical in IPF and has been associated with poor prognosis 
of disease. Clubbing is also seen in other fibrotic ILDs, but little is known about the 
prevalence and clinical meaning of clubbing, and the best method to assess clubbing in 
these ILDs. In chapter 5 we aimed to evaluate agreement between different clubbing 
assessment methods in patients with fibrotic ILDs. Additionally, we assessed the preva-
lence of clubbing in these ILDs, and the relationship between clubbing, disease severity 
and QoL. We included 153 consecutive outpatients with fibrotic ILDs (68 IPF patients) 
of two tertiary referral centers. Clubbing was assessed with the phalangeal depth ratio, 
the digital index, the Schamroth sign test, and by the treating physicians and investiga-
tor. Additionally, patients completed PROMs on QoL, capability, frailty and symptoms. 
We found no to weak agreement on the presence of clubbing between the different 
clubbing measuring methods. Strikingly, the assessment of clubbing by the physician 
and investigator showed a much better agreement. Prevalence of clubbing ranged from 
7-42% in the total group and 7-52% in IPF, depending on assessment method used. 
Clubbing did not correlate with disease severity (FVC and transfer capacity for carbon 
monoxide corrected for hemoglobin (TLCOc): p>0.2) or with QoL.
Part 2: Improving quality of life in interstitial lung diseases
chapter 6 summarizes the most recent insights into improving QoL in patients with IPF 
and discusses challenges in the management of this devastating disease. In a relent-
less disease such as IPF, striving to optimize QoL should complement the endeavor to 
prolong life. Unfortunately, there is a paucity of interventions and research focusing on 
symptom improvement and optimizing (heath-related) QoL. As symptoms, perceptions 
and reactions interact, and may change over time, a synchronized comprehensive man-
agement strategy is vital to match patients’ needs throughout the disease course. We, 
therefore, proposed a new model for continuous care in IPF – ‘the ABCDE of IPF care’: 
Assessing patients’ needs; Backing patients by giving information and support; deliver-
ing Comfort care by focusing on treating symptoms and taking into account Comorbidi-
ties; striving to prolong life by Disease modification; helping and preparing patients and 
their caregivers for the End-of-life. To optimize QoL for patients with IPF, we need to 
provide patient-centered care that is comprehensive and not mainly focused on disease 
modification therapies. 
chapters 7 describes the latest insights into chronic cough in IPF. Chronic cough is a 
frequent, distressing and disabling symptom in IPF, with a major impact on QoL. It has 
also shown to be an independent predictor of disease progression in IPF. The pathogen-
esis of cough is most likely “multifactorial” and influenced by mechanical, biochemical 
and neurosensory changes. Increased cough reflex sensitivity, due to increased levels of 
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neurotrophins or alteration of nerve fibers by mechanical distortion, might play a role 
in the pathogenesis of IPF-related cough. Also, pressure changes might cause recurrent 
stretch injury leading to sheer stress and activation of pro-fibrotic mechanisms. This 
hypothesis could explain why cough is an independent predictor of disease progres-
sion in IPF and corresponds with the finding that mechanical ventilation is a risk factor 
for acute exacerbations in pulmonary fibrosis. Comorbidities also have an important 
role, in particular gastro-esophageal reflux disease. While insight into the pathogenesis 
of cough in IPF is increasing, more research to find effective therapies is still needed. 
Currently, treatment of IPF-related cough is a major challenge for both the patient and 
treating physician, as the cough is often refractory. Clinical trials of cough treatment in 
IPF have only recently started, with either compounds developed for “general” chronic 
cough or new compounds in development for IPF that also evaluate a potential effect on 
cough. It is crucial that both objective and subjective validated cough measurements are 
included in these trials. Hopefully, these new studies will ultimately lead to adequate 
treatment of cough, thereby improving QoL in patients with IPF.
The anti-fibrotic drug pirfenidone may contribute to adequate treatment of cough in 
IPF, as several observations suggested that it might decrease cough. In chapter 8 we, 
therefore, aimed to objectively measure the effect of pirfenidone on cough in patients 
with IPF suffering from substantial cough. Additionally, we assessed the effect of 
pirfenidone on subjective cough and QoL measures. In this multicenter, prospective, 
observational study, patients with IPF and a cough visual analogue scale (VAS) score ≥40 
mm, about to start on pirfenidone, were recruited from four European centers (Italy, 
France, United Kingdom and the Netherlands). The primary endpoint was change in 
24-h objective cough counts at 12 weeks compared to baseline, measured with the 
validated ambulatory Leicester Cough Monitor. Secondary endpoints included changes 
in subjective cough-related QoL measured with the Leicester Cough Questionnaire 
(LCQ), cough severity with the VAS, and QoL measures. Of the 46 patients screened for 
the study, 43 were included. Pirfenidone significantly decreased objective 24-h cough 
by 34%. Importantly, this was also sensed by the patients, as the subjective PROMs 
on cough also significantly improved. Cough frequencies did not correlate with disease 
severity, measured with the FVC and TLCOc. Our study is the first to show a significant 
improvement of a pharmacologic treatment both on objective as well as subjective 
measures of cough in patients with IPF. The magnitude of these changes was clinically 
meaningful to patients. 
In recent years, unmet needs of pulmonary fibrosis patients have increasingly been 
acknowledged, however, needs of partners often remain unnoticed. Also, little is 
known about the best way to educate pulmonary fibrosis patients and their partners. 
In chapter 9 we investigated pulmonary fibrosis patients’ and partners’ perspectives 
and preferences in care. Additionally, we evaluated whether interactive interviewing 
could be a novel education method in this population, and if cultural differences in 
care needs existed between the Netherlands and Germany. Patients and partners were 
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interviewed during pulmonary fibrosis information meetings at two tertiary ILD cen-
ters. In the Netherlands, patients and partners answered questions anonymously via 
interactive voting boxes and results were projected directly. In Germany, questionnaires 
were handed out to all participants. In total, 278 patients and partners participated in 
the Netherlands and 51 in Germany. Our study confirms the major impact pulmonary 
fibrosis has on patients’ and their partners’ emotional wellbeing, and improves the cur-
rent knowledge of their care needs. Participants expressed a need for better education, 
psychological and practical support, and care for partners. Treatment was preferred in 
expertise centers with access to ILD specialist nurses. The new method of interactively 
educating and interviewing could be a good and efficient way to acquire new insights 
into pulmonary fibrosis care and to educate patient and partners. Participants found 
the interactive voting system pleasant (70%) and informative (94%). No major cultural 
differences existed between the Netherlands and Germany.
Few studies currently exist that try to improve QoL of patients with IPF and their part-
ners. In chapter 10 we, therefore, studied the effect of a short multidisciplinary Patient 
and Partner Empowerment Program for IPF (PPEPP) on QoL. PPEPP consists of three 
afternoon meetings, divided over three consecutive weeks, and focuses on coping with 
IPF. The program is led by a psychologist experienced in group therapy, and a pulmon-
ologist, specialized ILD nurse, oxygen supplier, social worker and physiotherapists also 
contribute to the sessions. Consecutive IPF outpatients and their partners were included 
in three blocks: two intervention groups and one control group. Participants completed 
QoL-related PROMs at baseline, after 3 weeks, and after 3 months. In total, thirteen 
couples were included in the two intervention groups and seven in the control group. 
PROM scores on anxiety, depression and ILD-specific QoL significantly improved after 3 
weeks of PPEPP in the intervention group only. After 3 months, PROM scores did not 
significantly change in the intervention group, while in the control group QoL measures 
inexplicably declined. All participants considered PPEPP useful and would recommend 
it to others, and 25 participants (96%) found that PPEPP fulfilled their expectations. To 
our knowledge, PPEPP is the first support program demonstrating a positive short-term 
effect on the wellbeing of IPF patients and their partners. 
chapter 11 contains a general discussion on the findings described in this thesis.
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Interstitiële longziekten (ILDs) is een verzamelnaam voor een heterogene groep aandoe-
ningen die over het algemeen beide longen diffuus aantasten. Eigenlijk is de naam niet 
helemaal juist, want het interstitium is de ruimte tussen de alveoli en de bloedvaten, 
maar ILDs beperken zich niet alleen tot deze ruimte. Ook de alveoli, luchtwegen, pleura 
en bloedvaten kunnen zijn aangetast. Er zijn meer dan 200 verschillende ILDs. De meest 
voorkomende zijn idiopathisch pulmonale fibrose (IPF) en sarcoïdose. 
Bij IPF is er sprake van progressieve verlittekening (fibrose) van de long. De oorzaak 
van IPF is onbekend en zonder behandeling kent de ziekte een gemiddelde overleving 
van 3-5 jaar. De enige curatieve optie is longtransplantatie. Helaas is longtransplantatie 
alleen maar geschikt voor een kleine groep patiënten. Gelukkig zijn er sinds kort twee 
anti-fibrotische medicijnen verkrijgbaar die de achteruitgang van de longfunctie vertra-
gen en de levensverwachting verbeteren; pirfenidone en nintedanib. IPF patiënten heb-
ben veel belastende klachten zoals dyspneu, vermoeidheid en hoesten. Deze klachten 
nemen toe naarmate de ziekte vordert en hebben een grote impact op kwaliteit van 
leven (KvL). 
Sarcoïdose is een granulomateuze multisysteem ziekte met een onbekende oorzaak. De 
ziekte kan in elk orgaan voorkomen, maar wordt het meest gezien in de longen, huid, 
ogen, lever en perifere lymfeklieren. Sarcoïdosis kan zich op meerdere manieren mani-
festeren, variërend van asymptomatisch tot levensbedreigende pulmonale fibrose of 
cardiale ziekte. Klachten kunnen variëren en zijn afhankelijk van het orgaan dat betrok-
ken is. De meest voorkomende klachten zijn hoesten, dyspneu, pijn en vermoeidheid. 
Vermoeidheid heeft van deze klachten de grootste impact op de KvL van patiënten. 
Hoewel het bekend is dat KvL verminderd is in ILDs, richt de huidige behandeling zich 
vaak voornamelijk op het verbeteren van fysiologische uitkomstmaten, zoals longfunc-
tie parameters en de zes minuten looptest. Deze fysiologische uitkomstmaten geven 
vaak niet goed weer wat voor impact ILDs hebben op de KvL van een patiënt. Patiënt-ge-
rapporteerde uitkomstmaten (PROMs), meestal vragenlijsten, kunnen worden gebruikt 
om KvL en klachten te meten. Helaas is er gebrek aan goed ontwikkelde en gevalideerde 
ILD-specifieke PROMs en andere uitkomstmaten voor deze belangrijke aspecten van de 
ziekte. Tevens zijn er nauwelijks interventies die zich richten op het verbeteren van KvL 
in ILDs, of deze zijn weinig effectief.
Het doel van dit proefschrift was het meten en verbeteren van KvL in ILDs, door het 
genereren van betere klinische uitkomstmaten voor KvL (deel 1) en het ontwikkelen van 
interventies die zich richten op de verbetering van KvL (deel 2).
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Deel 1: uitkomstmaten in interstitiële longziekten
hoofdstuk 2 beschrijft recente ontwikkelingen op het gebied van PROMs in IPF. PROMs 
kunnen voor meerdere doeleinden worden gebruikt. Ze kunnen dienen als uitkomst-
maat voor de dagelijkse zorg en helpen bij beslissingen over de behandeling. PROMs 
kunnen ook worden gebruikt als uitkomstmaat in klinisch onderzoek, bijvoorbeeld om 
te kijken naar de werking van nieuwe medicatie. Tevens kunnen zij dienen als hulpmid-
del bij het verzamelen van gegevens voor beleidsmakers in de gezondheidszorg, zodat 
zij de toegang tot zorg en kwaliteit van zorg kunnen verbeteren. Door PROMs kunnen 
nieuwe kenmerken van IPF aan het licht komen, dit kan bijvoorbeeld helpen bij het ver-
klaren van verschillende reacties op behandeling. Helaas ontbreken er nog steeds goed 
gevalideerde IPF-specifieke PROMs. De eerdere IPF onderzoeken hebben daarnaast 
laten zien dat generieke PROMs slecht correleren met de gevestigde uitkomstmaten 
van behandeling, zoals de geforceerde vitale capaciteit (FVC). Gelukkig zijn er veelbe-
lovende IPF-specifieke PROMs ontwikkeld die momenteel worden gevalideerd in grote 
cohorten. Naar verwachting zullen er in de komende jaren nieuwe gevalideerde PROMs 
beschikbaar komen. Zij zullen hopelijk nuttige data gaan leveren aan onderzoekers, 
zorgverleners, patiënten en beleidsmakers, waarmee de kwaliteit van en toegang tot 
IPF zorg geoptimaliseerd kan worden.
In hoofdstuk 3 is een sarcoïdose PROM vertaald en gevalideerd, omdat er nog geen 
sarcoïdose-specifieke vragenlijst bestond in het Nederlands. Deze sarcoïdose-specifieke 
vragenlijst, de King’s Sarcoidosis Questionnaire (KSQ) is ontwikkeld in 2012 in Engeland. 
De KSQ is een korte PROM die de gezondheidstoestand van sarcoïdose patiënten meet 
door middel van vijf modules; Algemene gezondheidstoestand, Long, Medicatie, Huid 
en Ogen. We vertaalden de KSQ volgens internationale richtlijnen en valideerden deze 
in een Nederlandse populatie. De KSQ werd getest op relevantie en toepasbaarheid in 
10 gestructureerde patiënten interviews. Vervolgens vulden 98 poliklinische patiënten 
(85 long, 22 huid en 24 oog betrokkenheid) meerdere PROMs tweemaal in, met een tus-
senpoos van twee weken. Psychometrische validatie liet een goede construct validiteit 
zien tussen de KSQ modules en bijhorende vragenlijsten, behalve voor de Medicatie 
module. Interne consistentie was goed voor alle KSQ modules (Cronbach’s α 0.70-0.90) 
en de intraclass correlatie coëfficiënten en Bland-Altman plots toonden een goede her-
haalbaarheid van de KSQ. De Nederlandse KSQ bleek een valide en betrouwbare PROM 
voor het meten van de KvL van Nederlandse patiënten met sarcoïdose en vergemak-
kelijkt internationale samenwerking in klinische onderzoeken naar sarcoïdose. 
De KvL van sarcoïdose patiënten wordt vaak beperkt door klachten als vermoeidheid 
en stress. Er is echter weinig bekend over de etiologie van deze klachten. Factoren die 
mogelijk een rol spelen, zijn spanningen, systemische inflammatie, hypocortisolisme en 
hypogonadisme. Deze factoren kunnen cortisol en testosteron waarden beïnvloeden. 
Voor het monitoren van acute stress worden vaak serum en speeksel cortisol concentra-
ties gebruikt. Chronische concentraties van cortisol en andere steroïden kunnen worden 
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gemeten met een nieuwe methode, waarbij gebruikt wordt gemaakt van hoofdhaar 
analyse. In hoofdstuk 4 onderzochten wij of er een verschil was in hoofdhaar cortisol, 
cortison en testosteron waarden tussen vermoeide en niet-vermoeide sarcoïdose 
patiënten, en tussen sarcoïdose patiënten en een controlegroep uit de algemene bevol-
king. Tevens analyseerden wij of deze steroïd hormonen konden dienen als objectieve 
biomarker voor stress in sarcoïdosis. Hoofdhaar steroïd concentraties werden gemeten 
met vloeistof chromatografie-tandem massa spectrometrie in glucocorticoïd naïeve 
sarcoïdose patiënten. Haar steroïd concentraties van 293 deelnemers van de Lifelines 
cohort studie dienden als controlegroep. In totaal werden er 32 sarcoïdose patiënten 
geïncludeerd, waarvan 23 vermoeide (Fatigue Assessment Scale score ≥22). Opvallend 
genoeg waren hoofdhaar cortisol en cortison waarden significant hoger in sarcoïdose 
patiënten dan in de controlegroep. Er werden geen significante verschillen gevonden in 
haar testosteron waarden tussen mannelijke sarcoïdose patiënten en controles, en in 
haar steroïd waarden van vermoeide en niet-vermoeide sarcoïdose patiënten. Toename 
in haar cortisol waarden van sarcoïdose patiënten correleerde significant met toename 
in angst, depressie en verminderde mentale gezondheid, maar was niet geassocieerd 
met vermoeidheid. Onze studie is de eerste studie die hoofdhaar steroïden onderzoekt 
in sarcoïdose, en laat zien dat hoofdhaar cortisol een potentieel veelbelovende objec-
tieve biomarker is voor stress in patiënten met sarcoïdose.
Clubbing van de vingers wordt beschouwd als kenmerkend voor IPF en is geassocieerd 
met een slechte prognose. Hoewel clubbing ook wordt gezien in andere fibrotische 
ILDs, is er maar weinig bekend over de prevalentie en klinische betekenis van club-
bing, en de beste methode om clubbing te meten. In hoofdstuk 5 onderzochten wij 
de overeenstemming tussen verschillende meetmethodes voor clubbing bij patiënten 
met fibrotische ILDs. Daarnaast onderzochten wij de prevalentie van clubbing in deze 
ziektebeelden en de relatie tussen clubbing, de ernst van de ziekte en KvL. Er werden in 
totaal 153 poliklinische patiënten met fibrotische ILDs (68 IPF patiënten) geïncludeerd 
in twee tertiaire verwijzingscentra. Clubbing werd gemeten met de phalangeal depth 
ratio, de digital index, de Schamroth sign test en vastgesteld door de behandelende arts 
en onderzoeker. Deelnemers vulden daarnaast verscheidende PROMs in. We vonden 
geen tot een zwakke overeenstemming betreffende de aanwezigheid van clubbing 
tussen de verschillende meetmethodes. Opvallend genoeg kwam de beoordeling van 
clubbing door de arts en onderzoeker veel beter overeen. Prevalentie van clubbing 
varieerde van 7-42% in de totale groep patiënten en 7-52% in IPF, afhankelijk van welke 
meetmethode was gebruikt. Clubbing correleerde niet met de ernst van ziekte (FVC 
en transfer capaciteit voor carbon monoxide gecorrigeerd voor hemoglobine (TLCOc): 
p>0.02) of met KvL. 
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Deel 2: verbeteren van kwaliteit van leven in interstitiële longziekten
hoofdstuk 6 vat de meest recente inzichten in het verbeteren van KvL van patiënten met 
IPF samen en behandelt uitdagingen in de zorg voor patiënten met deze ziekte. In een 
ongenadige ziekte als IPF moeten we trachten te streven naar een verbetering van KvL 
in aanvulling op levensverlenging. Helaas is er een tekort aan interventies en onderzoek 
dat zich richt op het verbeteren van klachten en optimaliseren van KvL. Symptomen, 
percepties en reacties hebben een onderlinge wisselwerking en kunnen veranderen 
gedurende de ziekteperiode. Een flexibel en veelomvattend behandelplan is cruciaal, 
zodat er kan worden voorzien in de wisselende behoeften van patiënten gedurende het 
ziekteverloop. Vandaar dat wij een nieuw model voor continue zorg in IPF voorstellen 
‘de ABCDE van IPF zorg’: Assessing (vaststellen) van de behoeften van de patiënten; 
Backing (bijstaan) van patiënten door ze te informeren en te ondersteunen; het geven 
van Comfort care (klachten verlichting) door het gericht behandelen van symptomen, 
rekening houdend met Comorbidities (bijkomende ziekten); streven naar levensverlen-
ging door Disease modification (fibrose remming); en het helpen en voorbereiden van 
patiënten en hun naasten op het End-of-life (fase rondom het overlijden). Om KvL van 
IPF patiënten te optimaliseren is er een patiëntgerichte zorg nodig die breder is dan het 
remmen van de longfibrose met medicijnen.
hoofdstuk 7 beschrijft de laatste inzichten op het gebied van chronische hoest in IPF. 
Chronische hoest is een frequente, zeer belastende klacht in IPF en heeft een enorme 
impact op KvL. Het is tevens een onafhankelijke voorspeller van ziekte progressie. De 
pathogenese van hoest is waarschijnlijk “multifactorieel” waarbij mechanische, bio-
chemische en neurosensorische veranderingen een rol spelen. Zo speelt toename van 
de hoest reflex sensitiviteit, door toename van neurotrofine concentraties of door de 
aantasting van zenuwvezels door mechanische vervormingen, mogelijk een rol in de 
pathogenese van IPF-gerelateerde hoest. Daarnaast kunnen drukveranderingen zorgen 
voor herhaaldelijke rekschade en leiden tot activatie van pro-fibrotische mechanismen. 
Deze hypothese zou kunnen verklaren waarom hoest een onafhankelijke voorspeller is 
van ziekte progressie in IPF en sluit aan bij de bevinding dat mechanische beademing 
een risico factor kan zijn voor een acute exacerbatie van longfibrose. Comorbiditeiten, 
in het bijzonder gastro-oesofageale reflux, spelen ook een belangrijke rol. Hoewel er 
veel vooruitgang is geboekt in onderzoek naar de pathogenese van hoest in IPF, is 
onderzoek naar effectieve behandelingen nog steeds beperkt. Behandeling van IPF-
gerelateerde hoest is op dit moment een enorme uitdaging voor zowel de patiënt als de 
behandelende arts, omdat de hoest vaak therapie resistent is. Klinisch onderzoek naar 
hoest medicatie in IPF is pas recent gestart en richt zich op nieuwe middelen voor chro-
nische hoest in het algemeen. Bovendien wordt bij nieuwe middelen, die getest worden 
voor IPF, steeds vaker gekeken naar een potentieel effect op hoest. Het is belangrijk dat 
zowel objectieve als subjectieve gevalideerde hoest metingen worden gebruikt in deze 
studies. Hopelijk zullen nieuwe studies uiteindelijk leiden tot succesvolle behandeling 
van hoest in IPF en hiermee de KvL van IPF patiënten verbeteren.
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Het anti-fibrotische middel pirfenidone zou kunnen bijdragen aan de behandeling van 
hoest in IPF. Verscheidene observaties suggereerden dat het middel mogelijk hoest-
klachten vermindert. In hoofdstuk 8 hebben we daarom het effect van pirfenidone 
op hoest objectief gemeten in patiënten met IPF met hoestklachten. Tevens werd het 
effect van pirfenidone op subjectieve hoest en KvL uitkomstmaten onderzocht. In deze 
internationale, multicenter, prospectieve, observationele studie werden patiënten ge-
includeerd met IPF die op het punt stonden om te starten met pirfenidone en een hoest 
visueel analoge schaal (VAS) score hadden van ≥40 mm. De primaire uitkomstmaat 
was de verandering in 24-uur objectieve hoest frequentie na 12 weken pirfenidone ten 
opzichte van baseline zonder behandeling, gemeten met de gevalideerde ambulante 
Leicester hoest monitor. Secundaire uitkomstmaten waren verandering in subjectieve 
hoest-gerelateerde KvL, gemeten met de Leicester Cough Questionnaire (LCQ), de 
ernst van hoest gemeten met de VAS en KvL gemeten met de King’s Brief Interstitial 
Lung Disease vragenlijst. Van de 46 gescreende patiënten werden er 43 geïncludeerd. 
Pirfenidone verminderde objectieve 24-uur hoest frequentie significant met 34%. Be-
langrijker is dat dit ook door de patiënten werd ervaren, want de subjectieve uitkomst-
maten verbeterden ook significant. Hoest frequenties correleerde niet met de ernst 
van de ziekte, gemeten met FVC en TLCOc. Onze studie is de eerste die een significante 
verbetering van een farmacologische behandeling op zowel objectieve als subjectieve 
hoest uitkomsten laat zien in IPF patiënten. Deze verandering was klinisch relevant voor 
patiënten.
In de afgelopen jaren zijn de zorg behoeften van patiënten met longfibrose steeds meer 
erkend. Echter de naasten van patiënten werden hier vaak niet bij betrokken. Ook is er 
weinig bekend over de beste manier om patiënten en hun naasten te informeren over 
longfibrose. In hoofdstuk 9 onderzochten wij de opvattingen en voorkeuren van longfi-
brose patiënten en hun naasten over de zorg. Daarnaast evalueerden wij of interactief 
interviewen een nieuwe onderwijsmethode kan zijn voor deze populatie. Een deel van 
dit onderzoek werd ook gedaan in Duitsland, zodat we konden bekijken of er culturele 
verschillen in zorg behoeften waren. Patiënten en naasten werden geïnterviewd tijdens 
longfibrose informatie bijeenkomsten in twee tertiaire ILD centra. In Nederland beant-
woorden patiënten en naasten vragen anoniem via interactieve stemboxen en werden 
de resultaten direct geprojecteerd. In Duitsland werden vragenlijsten uitgedeeld aan 
alle deelnemers. In totaal deden 278 patiënten en naasten mee in Nederland en 51 
in Duitsland. Onze studie bevestigt de enorme impact die longfibrose heeft op het 
emotionele welzijn van patiënten en hun naasten en verbetert de huidige kennis van 
hun zorgbehoeften. Deelnemers hadden behoefte aan beter onderwijs, psychologische 
en praktische support en zorg voor naasten. Patiënten werden bij voorkeur behandeld 
in expertise centra met toegang tot gespecialiseerde ILD verpleegkundigen. De nieuwe 
methode van interactief lesgeven en interviewen kan een goede en efficiënte manier 
zijn om longfibrose zorg te optimaliseren en om patiënten en naasten te informeren. 
Deelnemers vonden het interactieve stemsysteem prettig (70%) en informatief (94%). 
Er bestonden geen grote culturele verschillen tussen Nederland en Duitsland.
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Er zijn op dit moment weinig studies die proberen de KvL van patiënten met IPF en hun 
naasten te verbeteren. In hoofdstuk 10, onderzochten wij daarom het effect van een 
kort multidisciplinair Patiënt en Partner Empowerment Programma voor IPF (PPEPP) 
op KvL. PPEPP bestaat uit drie middag bijeenkomsten, verdeeld over drie opeenvol-
gende weken, en richt zich op het omgaan met IPF. Het programma wordt geleid door 
een psycholoog met ervaring in groepstherapie. Een longarts, gespecialiseerd ILD 
verpleegkundige, zuurstofleverancier, maatschappelijk werker en fysiotherapeuten 
dragen tevens bij aan de sessies. Poliklinische IPF patiënten en hun partners werden 
achtereenvolgend geïncludeerd in drie blokken: twee interventiegroepen en één con-
trolegroep. Deelnemers vulden KvL-gerelateerde PROMs in op baseline, na 3 weken en 
na 3 maanden. In totaal werden er dertien koppels in de twee interventiegroepen en 
zeven in de controlegroep geïncludeerd. Angst, depressie en ILD-specifieke KvL PROM 
scores verbeterden alleen in de interventie groep significant na 3 weken PPEPP. Na 3 
maanden veranderden PROM scores niet significant in de interventie groep, terwijl de 
KvL uitkomsten in de controle groep verslechterden. Alle deelnemers vonden PPEPP 
nuttig en zouden het aan anderen aanbevelen. Vijfentwintig deelnemers (96%) vonden 
dat PPEPP aan hun verwachtingen voldeed. Voor zover ons bekend is PPEPP het eerste 
support programma dat een positief effect laat zien op het welzijn van IPF patiënten en 
hun partners. 
hoofdstuk 11 bevat een algemene discussie over de bevindingen beschreven in dit 
proefschrift.
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DGP conference – Stuttgart, Germany (poster discussion) 2017 1.0
Lung days – Ermelo, the Netherlands (oral presentation) 2017 1.0
Text, reviews and committee
Interview Sarcoscoop 2014 0.1
Article ild care website – King’s Sarcoidosis Questionnaire 2014 0.1
Interview Lung days public price – IPF online 2016 0.1
Promotion movie Lung days public price – IPF online 2016 0.3
Article ild care today – IPF online 2016 0.3
Interview PICASSO newsletter – IPF online 2016 0.1
Interview lung fibrosis patient association – PPEPP study 2016 0.1
Review article for Health and Quality of Life 2016 0.4
Review article for Sarcoidosis Vasculitis and Diffuse Lung Disease 2016 0.3
Review article for European Respiratory Journal 2017 0.2
Junior member of ERS Taskforce on Cough guidelines 2017 0.1
2. Teaching
Lecture lung specialists (in training) – ‘Cough in idiopathic pulmonary fibrosis’ 2016 0.4
Lecture lung function analysts – ‘Clinical lesson on cough in idiopathic pulmonary 
fibrosis’
2016 0.2
Lecture research nurses – ‘Update cough study in idiopathic pulmonary fibrosis’ 2016 0.1
Supervising master’s thesis R. Vrijenhoeff, Medicine, Erasmus University, 
Rotterdam
2016 5.0
Supervising master students J. Berendsen, W. Botterman and T. Janssen, course 
Medical Device Prototyping, University of Technology, Delft
2016 1.0
3. awards
Jan Gerrit Mulder abstract Scholarschip – WASOG conference, Kusadasi 2014
Sarcoïdose belangen vereniging Nederland (SBN) persoonlijke 
onderzoeksondersteuning 2015 for the ‘KSQ study’
2015
Trust fonds scholarschip – PFF summit, Washington 2015
Longfonds Public price 2016 for ‘IPF online’ 2016
NRS young investigator travel grant – ATS conference, San Francisco 2016
Förderung des wissenschaftlichen Nachwuches preis 2017 award for the ‘cough 
study’
2017
Total ECTS 34.9
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DanKWOOrD
Veel van mijn presentaties eindigden met de zin: “onderzoek doe je niet alleen”. Daarom 
wil ik graag de volgende mensen bedanken die direct of indirect een bijdrage hebben 
geleverd aan dit proefschrift.
De patiënten en naasten die hebben meegedaan aan mijn studies. Zonder hun deel-
name, inzet en feedback was dit proefschrift nooit tot stand gekomen. Eindeloze reek-
sen vragenlijsten hebben zij zonder morren voor mij ingevuld. Het was heel inspirerend 
om te zien dat velen, ook als ze zelf geen baat hadden bij het onderzoek, zich wilden 
inzetten voor de toekomstige patiënt. In het bijzonder wil ik dhr. Hentzen bedanken, zijn 
deelname aan verschillende studies en adviezen voor de onderzoeken waren heel waar-
devol. Mede dankzij zijn bijdrage heb ik de Longfonds Publieksprijs mogen ontvangen. 
Prof. dr. H.C. Hoogsteden, mijn promotor. Ik wil u bedanken voor de kans die ik heb 
gekregen om te promoveren op de afdeling Longziekten. U hebt het mogelijk gemaakt 
dat ik verscheidende congressen in het buitenland kon bezoeken en zelfs een maand 
stage kon lopen bij een gerenommeerde hoestkliniek in Engeland, een hele mooie en 
leerzame ervaring.
Dr. M.S. Wijsenbeek, mijn copromotor. Beste Marlies, bedankt voor een geweldige 
samenwerking de afgelopen jaren. Ik had me geen betere copromotor kunnen wensen! 
Jouw enthousiasme voor onderzoek is ontzettend aanstekelijk en motiverend. Ondanks 
jouw steeds drukkere planning maakte je altijd tijd vrij om kritisch naar mijn artikelen te 
kijken en gezamenlijk de opzet en analyses van studies door te nemen. Je hebt mij ook 
wegwijs gemaakt in de internationale onderzoekswereld en laten zien dat samenwerken 
de sleutel is tot succes. Ik heb vele congressen samen met jou mogen bezoeken, waar 
naast (poster) presentaties en verbetering van kennis, ook netwerken, uiteten, borrelen 
en feesten centraal stond. Zeker Turkije zal ik niet snel vergeten! Ik kreeg daarnaast de 
kans om diverse cursussen te volgen, naar het buitenland te gaan en mij zo te ontwik-
kelen tot de onderzoeker die ik nu ben. Je wilde dat ik alles uit mijn promotie zou halen, 
en dat is zeker gelukt. Dankjewel!
Overige leden van de kleine commissie. Prof. dr. J.G.J.V. Aerts, bedankt voor het kritisch 
lezen van mijn proefschrift en zitting nemen in de commissie. Prof. dr. E.F.C. van Rossum, 
beste Liesbeth, bedankt voor je hulp bij de “haren studie”. Ik heb onze samenwerking 
altijd als zeer prettig ervaren. Tevens bedankt voor het beoordelen van mijn proefschrift 
en dat je, ondanks je drukke programma, zitting zal nemen in de commissie. Prof. dr. C. 
Vancheri, I would like to thank you for joining my reading committee and your valuable 
input on the cough manuscripts.
Overige leden van de grote commissie. Prof. dr. A.H. Morice. Dear Alyn, thank you for the 
lovely time in Hull. I learnt so much during my stay, not only about cough, but also about 
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various lung diseases and a broad range of other subjects. Thank you for taking time to 
show me around the beautiful city of York and to have some nice drinks together. I am 
really honoured that you are taking place in the opposition of my PhD defence. Prof. dr. 
S.S. Birring. Dear Surinder, thank you for all your help with, and valuable comments on, 
the KSQ and cough manuscripts. It was really nice meeting you during the conferences. 
Your explanation about cough monitors and other cough-related subjects was very 
helpful. I am really privileged that you want to join the opposition of my PhD defence, 
and looking forward to work with you and Prof. Morice on the cough ERS taskforce. Prof. 
dr. J.C. Grutters. Ik wil u bedanken voor uw waardevolle commentaar op het clubbing 
manuscript en voor het zitting nemen in de commissie.
Co-auteurs. Ik wil jullie ontzettend bedanken voor de fijne samenwerking en kritische 
en waardevolle feedback op mijn manuscripten. In het bijzonder wil ik Vincent Wester 
bedanken voor de hulp bij de opzet, analyses en het schrijven van het “haren artikel”, 
Marjolein Drent voor de samenwerking bij de validatie van de KSQ en Adriaan van ‘t 
Spijker voor zijn bijdrage aan de PPEPP studie. Het succes van dit programma is mede te 
danken aan jouw inzet en sturing van de groepen.
Co-authors. I wish to thank you for the pleasant collaboration and your valuable feed-
back and help with preparing the manuscripts. Special thanks to Prof. dr. Cottin for his 
valuable input on the cough articles and Prof. dr. Kreuter for his support of my research 
and help with the manuscript on the “patient information meeting survey”.
Sarcoïdose Belangen vereniging Nederland (SBN). Dank voor jullie aanmoediging en 
vertrouwen in mijn onderzoek. Longfibrose patiëntenvereniging, bedankt voor de 
interesse in mijn onderzoek en de prettige samenwerking bij de patiëntendagen. Het 
Longfonds wil ik bedanken voor de Publieksprijs, dit heeft mij zeer gesteund in mijn 
onderzoek. Lungenfibrose e.V., thank you for your encouragement award on my cough 
research.
Jitske Kraan, ik ben jou een bijzondere dank verschuldigd. Je hebt verscheidene studies 
helpen opzetten en uitvoeren, dankjewel!
Peter Heukels en Caroline Broos, bedankt voor jullie gezelligheid tijdens de congressen 
en het mij wegwijs maken in het PhD traject. Caroline, bedankt voor je hulp bij de voor-
bereiding van het manuscript voor de leescommissie. Peter, je was tevens een gezellige 
kamergenoot en mede wielerfan, succes nog met de laatste loodjes van je promotie!
Arts-assistenten. Bedankt voor jullie interesse in mijn onderzoek, bezorgdheid als ik tot 
laat doorwerkte, en dat ik als “vreemde eend in de bijt” kon aansluiten bij congressen 
en uitjes. Ik zal de repetities en optreden van onze “dansact” tijdens het afdelingsfeest 
niet snel vergeten. Speciaal dank ook aan mijn gezellige kamergenoten; Bas, Marthe en 
Joyce. Ik kon met mijn klinische vragen altijd bij jullie terecht en jullie hebben enthou-
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siast vele patiënten casussen toegelicht, waardoor ik een klein beetje inzicht kreeg in 
hopelijk mijn “toekomstige” beroep. Ook bedankt voor jullie advies en uitleg over mijn 
proefschrift en de verdediging.
ILD longartsen. Zonder jullie hulp bij de inclusie van patiënten was het voor mij niet 
mogelijk geweest om dit onderzoek te doen. Veel dank hiervoor en tevens voor de 
feedback op mijn studies en artikelen. Maar vooral ook dank voor de aanmoediging 
tijdens mijn (poster) presentaties en de ontspannen en leuke sfeer tijdens congressen. 
Dank natuurlijk ook aan alle andere longartsen, voor de interesse in mijn promotie en 
support gedurende het schrijven van mijn proefschrift.
Longfunctie. Bij jullie is het allemaal begonnen. Ik werd in een warm bad ontvangen 
en kom nog met plezier bij jullie koffie drinken, helaas wat minder vaak dan voorheen. 
Bedankt voor alle hulp bij het opzetten van de “KSQ studie”, maar vooral ook voor de 
gezelligheid. Ik kijk met plezier terug naar de kerst- en Sinterklaasdiners, het uitje naar 
Brouwersdam en onze pinguïn act tijdens het afdelingsfeest. Maar ik zal natuurlijk ook 
de heerlijke taarten missen die altijd spontaan verschijnen als ik bij jullie kom buurten.
Beste Monique, als mede begeleidster van mijn keuze-onderzoek heb ik je leren kennen 
als een positief, enthousiast en energiek persoon, die het belangrijk vindt om goed en 
nauwkeurig onderzoek te doen. Bedankt voor het beantwoorden van mijn vragen en 
de hulp bij de statistiek en analyses tijdens mijn onderzoek. Maar zeker ook voor de 
theetjes, etentjes en dansjes daarbuiten.
Beste Femke, jij hebt mij vanaf het begin geholpen met invoeren, databasen bouwen 
en was altijd bereid om mee te denken over studies. Bedankt voor je hulp en interesse, 
maar ook voor de gezellige gesprekken tussendoor.
Research verpleegkundigen. Bedankt voor het oplossen van mijn vele vragen over on-
derzoek. In het bijzonder wil ik Marjolein bedanken voor haar hulp bij het opzetten, de 
inclusie en de monitor visites van de hoeststudie en Anne-Marie die mij wegwijs maakte 
in de wereld van METC aanvragen, monitor visites en investigator site files.
Specialistisch ILD verpleegkundigen. Dank voor alle hulp bij het benaderen van patiën-
ten voor studies en het uitdelen en verzamelen van vragenlijsten. Speciale dank aan 
Nelleke, die een sleutelrol vervulde in het contact met patiënten. Je weet altijd precies 
wat er bij hen speelt en verliest het belang van de patiënt nooit uit het oog. Daarnaast 
was je voor mij een gezellige kamergenoot tijdens de ERS en een waardevolle en en-
thousiaste gesprekspartner.
Secretariaat. Dank voor jullie hulp bij praktische zaken en de gezellige praatjes tussen-
door.
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Robin Vrijenhoeff. Ik mocht je begeleiden bij je master onderzoek, waar je voor mij de 
clubbing studie hebt opgezet. Je ging snel en nauwkeurig te werk, wat resulteerde in 
een monster inclusie van 90 patiënten in minder dan 3 maanden. Heel erg bedankt! 
Marcel Veltkamp, Laura Vermeer, en Nadine Teunissen, ook jullie wil ik ontzettend 
bedanken voor jullie hulp bij de clubbing studie.
Beste Karen, dankjewel voor je hulp bij het doorlezen van mijn proefschrift en de gezel-
ligheid tijdens het werk en de congressen. Ik vind het super dat jij als mijn “opvolgster” 
het onderzoek naar clubbing en IPF online zal doorzetten en dat we samen nog de 
“fan studie” hebben kunnen opstarten. Ik heb er alle vertrouwen in dat jij met jouw 
enthousiasme, gedrevenheid en inzet deze en alle toekomstige onderzoeken tot een 
goed einde zal brengen. Nog heel veel succes en plezier met je promotie!
Lieve vrienden en vriendinnen, bedankt voor de interesse in mijn onderzoek en alle bij-
horende verhalen. Maar zeker ook bedankt voor de gezellige weekendjes weg, etentjes, 
borrels en mooie party’s. Een heerlijke afleiding van mijn promotie!
Lieve Marietje, Mariëlle, Jan-Willem en Malin, ik had geen betere schoonfamilie kunnen 
wensen! Marietje, bedankt voor de weekendjes Archem, de mooie wandelingen, de 
heerlijke Hollandse kost, maar ook jouw gezellige bezoekjes aan Rotterdam, waarna 
onze koelkast vaak weer rijkelijk gevuld was. Mariëlle, bedankt voor de leuke etentjes, 
lunchen, borrels en feestjes in Rotterdam, je bent een top schoonzus! Jan-Willem en 
Malin, bedankt dat we in Singapore, Kuala Lumpur en Heby bij jullie mochten crashen, 
maar ook voor de gezelligheid tijdens jullie bezoekjes in Nederland. Een weekendje 
Herman en Mette in huis en promoveren lijkt opeens de “easiest” job in de world.
Lieve opa, ooit was het jouw droom om te promoveren. Nu mag ik als eerste kleinkind 
die droom in vervulling brengen. En ook al zijn jouw herinneringen soms vluchtig, weet 
ik dat je ontzettend trots op mij bent. Hopelijk kan je er tijdens mijn verdediging bij zijn.
Lieve Anke en Judith, lieve zussen, ondanks dat wij elkaar niet dagelijks spreken en Ju-
dith naar het “einde van de wereld” is verhuisd, hebben we een ontzettend sterke band. 
Jullie zijn er altijd voor mij geweest en super geïnteresseerd in waar ik mee bezig ben, 
zeker nu “het kleine zusje” gaat promoveren. Ik ben dan ook enorm trots dat jullie mijn 
paranimfen willen zijn. En ik heb er alle vertrouwen in dat jullie het daarbij behorende 
uurtje op hoge hakken goed zullen doorstaan, en mocht ik flauwvallen, alle vragen met 
verve zullen beantwoorden. 
Lieve papa en mama, jullie hebben mij altijd gesteund in alles wat ik deed. Of dat nou 
betekende zwetend in een zaaltje naar mijn danskunsten kijken, mij aanmoedigen en 
coachen tijdens hockeywedstrijden, als “rust oord” dienen tijdens het studeren of met 
de boot een weekendje je dochter in Hull komen bezoeken. Bedankt voor jullie kritische 
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vragen, enthousiasme over mijn onderzoek en het bieden van een luisterend oor voor al 
mijn verhalen over congressen, ontmoetingen, onderzoeken, submissie van artikelen en 
het “boekje”. Papa, geweldig hoe jij je stiekem als patiënt inschreef voor de Longdagen, 
zodat je mij “in actie” kon zien en we later die dag samen de prijs in ontvangst mochten 
nemen. Mama, de heerlijke dagjes shoppen, uit eten, naar de film en bijkletsen waren 
een geweldige afleiding en zullen hopelijk nog heel vaak voorkomen. Bedankt dat jullie 
zulke fantastische ouders voor mij zijn!
Lieve Gerjan, opgegroeid op de boerderij vond je het heel normaal als mijn werk soms 
in de weekenden en avonduren doorging. Je hebt er nooit over geklaagd en zorgde er 
vaak voor dat zelfs in de late uren er nog wat eten klaarstond. Je hebt me tijdens mijn 
hele promotie gesteund, niet alleen door kritisch te zijn op mijn studies, stellingen en 
quotes, maar ook door me op het juiste moment mee te slepen naar de film of een res-
taurant. Ook onze mooie reizen waren altijd een heerlijke afleiding. Gerjan, dankjewel 
dat je er altijd voor me bent, en zoals ze in het “oosten” zeggen: “Ik bin zo gek met oe!”.
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Interstitial lung diseases (ILDs) contain a 
wide variety of disorders, usually affecting 
both lungs diffusely. The most common 
ILDs are idiopathic pulmonary fibrosis and 
sarcoidosis. ILDs have a major impact on 
quality of life. Although it is well-known 
that quality of life is impaired in ILDs, treat-
ment is often mainly focused on improv-
ing physiological outcome measures, such 
as pulmonary function parameters. These 
physiological outcome measures frequently do not reflect the 
impact ILDs have on a patient’s quality of life. Patient-reported 
outcome measures (PROMs) can be used for measuring quality 
of life and symptom burden. Unfortunately, there is lack of well-
developed and validated ILD-specific PROMs and other measures 
to assess quality of life and symptoms. Also, interventions on 
improving quality of life in ILDs are scarce. The aim of this thesis 
was to measure and improve quality of life in ILDs by generating 
better clinical outcome measures for quality of life and developing 
interventions focused on improving quality of life.
